FDP Foreign Cost Reimbursement Subaward			
Federal Awarding Agency: National Institutes of Health (NIH)			
Pass-Through Entity (PTE):	Subrecipient:		
Alfred I. duPont Hospital for Children of The Nemours Foundation	KLE Society's Jawaharlal Nehru Medical College		
PTE PI: Zubair Aghai, MD	Sub Pl: Sangappa M Dhaded		
PTE Federal Award No: 1R01HD102967-01A1	Subaward No: RSUB1233529		
Project Title: A Cluster Randomized Clinical Trial of Umbilical Cord Milking to I	mprove Short and Long-term Outcomes in Neonates Who are Non-Vigorous at Birth		
Subaward Budget Period: Start: 08/01/2021 End: 07/31/2022	Amount Funded This Action (USD): \$ 331,141.00		
Estimated Period of Performance Start: End:	Incrementally Estimated Total (USD): \$		
	d Conditions		
this Subaward are as shown in Attachment 5. In its performance employee or agent of PTE. No Party has the authority to bind any other Party, and no Party (including an employee or other represe	ed by 2 CFR 200.331), to Subrecipient. The Statement of Work and budget for of Subaward work, Subrecipient shall be an independent entity and not an other Party in contract or to incur any debts or obligations on behalf of any entative of such Party) shall take any action that attempts or purports to bind what of any other Party, without the affected party's prior written approval.		
2. Subrecipient shall submit invoices Monthly for allowable costs incurred. All invoices shall be submitted using PTE's standard invoice shown in Attachment 6, and shall include current and cumulative costs (including cost sharing information if applicable), breakdown by major cost category, Subaward number, and certification, as required in 2 CFR 200.415 (a). Invoices that do not reference PTE Subaward number shall be returned to Subrecipient. Invoices and questions concerning invoice receipt or payments shall be directed to the party's Financial Contact, shown in Attachment 3A. Expenditures of Subrecipient shall conform to budget in Attachment 5. All payments will be in U.S. Dollars.			
3. A final statement of cumulative costs incurred, including cost sharing, marked "FINAL" must be submitted to PTE's Principal Investigator Contact, as shown in Attachment 3A, NO LATER THAN 30 Days after Subaward end date. The final statement of costs shall constitue Subrecipient's final financial report.			
4. All payments shall be considered provisional and subject to adjustment within the total estimated cost, in the event such adjustment is necessary as a result of an adverse audit finding against the Subrecipient. Upon the receipt of proper invoices, the PTE agrees to process payments in accordance with this Subaward and 2 CFR 200.305.			
5. Matters concerning the technical performance of this Subaward Agreement shall be directed to the appropriate party's Principal Investigator as shown in Attachments 3A and 3B. Technical reports are required as shown in Attachment 4 "Reporting Requirements".			
6. Matters concerning the request or negotiation of any changes in the terms conditions or amounts cited in this Subaward Agreement and any changes requiring prior approval, shall be directed to the PTE's Administrative Contact, and the Subrecipient's Principal Investigator Contact as shown in Attachments 3A and 3B. Any such change made to this Subaward requires the written approval of each party's Authorized Official, as shown in Attachments 3A and 3B.			
7. The PTE may issue non-substantive changes (defined as: documentation of prior approvals, addition of non-competing continuation budget periods/funds and no cost extensions) to the Budget Period(s) and Budget Unilaterally . Unilateral modifications shall be considered valid 14 days after receipt, unless otherwise indicated by Subrecipient. Requests for No Cost Extensions are as shown in Attachment 2.			
8. Each Party shall be responsible for its negligent acts or omissions, and the negligent acts or omissions of its employees, officers, or directors, to the extent allowed by law.			
9. Either party may terminate this Subaward with 30 days written notice. Notwithstanding, if the Awarding Agency terminates the Federal Award, PTE will terminate in accordance with the Awarding Agency requirements. PTE notice shall be directed to the PTE's Administrative Contact and the Subrecipient's notice directed to the Authorized Official Contact, as shown in Attachments 3A and 3B. PTE shall pay Subrecipient for termination costs as allowable under Uniform Guidance, 2 CFR 200, or 45 CFR Part 75 Appendix IX, as applicable.			
10. No Party shall be in default by reason of any failure in performance of this Subaward if such failure arises, directly or indirectly, out of causes reasonably beyond the direct control or foreseeability of such Party, including but not limited to, acts of God or of the public enemy, U.S. or foreign governmental acts in either a sovereign or contractual capacity, labor, fire, flood, epidemic and strikes.			
11. By signing this Subaward, including the attachments hereto which are hereby incorporated by reference, Subrecipient certifies that it will perform the Statement of Work in accordance with the terms and conditions of this Subaward and the applicable terms of the Federal Award, including the appropriate Research Terms and Conditions ("RTCs") of the Federal Awarding Agency, as referenced in Attachment 2. The parties further agree that they intend this Subaward to comply with all applicable laws, regulations and requirements.			
By ap Authonized Official of Pass-through Entity:	By an Authorized Official of Subrecipient:		
Vicky L. Funanage, PhD February 14,	2022 09/02/2022		
Name: Vicky L.Funanage, PhD Date	Name: Dr(Mrs) Niranjana S Mahantashetti Date		
Title: Executive Director, Research	Title: Principal		

Attachment 1

Certifications and Assurances

Subaward Number:

RSUB1233529

By signing the Subaward, the Authorized Official of Subrecipient certifies, to the best of his/her knowledge and belief, that:

Certification Regarding Lobbying (2 CFR 200.450)

No U.S. Federal appropriated funds have been paid or will be paid, by or on behalf of the Subrecipient, to any person for influencing or attempting to influence an officer or employee of any agency, a Member of Congress, an officer or employee of Congress, or an employee of a Member of Congress in connection with the awarding of any U.S. Federal contract, the making of any U.S. Federal grant, the making of any U.S. Federal loan, the entering into of any cooperative agreement, and the extension, continuation, renewal, amendment, or modification of any U.S. Federal contract, grant, loan, or cooperative agreement.

If any funds other than Federal appropriated funds have been paid or will be paid to any person for influencing or intending to influence an officer or employee of any agency, a Member of Congress, an officer or employee of Congress, or an employee of a Member of Congress in connection with this Federal contract, grant, loan, or cooperative agreement, the Subrecipient shall complete and submit Standard Form -LLL, "Disclosure Form to Report Lobbying," to the PTE.

This certification is a material representation of fact upon which reliance was placed when this transaction was made or entered into. Submission of this certification is a prerequisite for making or entering into this transaction imposed by 31 U.S.C. 1352. Any person who fails to file the required certification shall be subject to a civil penalty of not less than \$10,000 and not more than \$100,000 for each such failure.

Debarment, Suspension, and Other Responsibility Matters (2 CFR 200.214 and 2 CFR 180)

All foreign institutions and international organizations, except for foreign governments or governmental entities, public international organizations, or foreign-government-owned or -controlled entities (in whole or in part) are subject to the Debarment, Suspension and Other Responsibility Matters.



Subrecipient certifies by signing this Subaward that neither it, nor its principals, are presently debarred, suspended, proposed for debarment, declared ineligible or voluntarily excluded from participation in this transaction by any U.S. Federal Department or Agency.

Or

Subrecipient is either a foreign government or governmental entity, public international organization, or foreign-government-owned or -controlled entity (in whole or in part); and it IS NOT subject to the debarment or suspension certification requirement or to debarment or suspension under 45 CFR Part 75.

Audit and Access to Records

Subrecipient certifies by signing this Subaward that it complies with the Uniform Guidance, will provide PTE notice of the completion of required audits and any adverse findings which impact this Subaward Agreement as required by parts 200.501- 200.521, and will provide access to records as required by parts 200.337 and 200.338 as applicable.

All financial and related documentation, including but not limited to financial reports, invoices, financial audits, or receipts, shall be provided to PTE in English at Subrecipient's expense.

RESERVED

Use of Name

Neither party shall use the other party's name, trademarks, or other logos in any publicity, advertising, or news release without the prior written approval of an authorized representative of that party. The parties agree that each party may use factual information regarding the existence and purpose of the relationship that is the subject of this Subaward for legitimate business purposes, to satisfy any reporting and funding obligations, or as required by applicable law or regulation without written permission from the other party. In any such statement, the relationship of the parties shall be accurately and appropriately described.

Foreign Corrupt Practices

Subrecipient agrees to use funds in compliance with (1) the U.S. Foreign Corrupt Practices Act; (2) Subrecipient agrees that, under this Subaward, it will not offer, promise, or provide (or authorize the offer, promise, or provision of), directly or indirectly, anything of value to any government official, political party official, political candidate, or employee thereof, or to any other third party, for the purpose of obtaining or retaining business or obtaining any illegal benefit or advantage.

Export Controls

Each Party is responsible for determining whether its performance is subject to, and in compliance with, U.S. export control laws and regulations ("U.S. Export Controls"), including but not limited to the Export Administration Regulations - EAR (Department of Commerce), the International Traffic in Arms Regulations - ITAR (Department of State), the sanctions programs embodied in regulations administered by the Department of the Treasury's Office of Foreign Assets Control (OFAC), the U.S. anti-boycott laws and regulations (EAA) and U.S. anti-terrorism financing laws and regulations.

Attachment 8 of this Subaward includes additional applicable terms related to Export Controls.

Prohibition on Certain Telecommunication and Video Surveillance Services or Equipment

Pursuant to 2 CFR 200.216, Subrecipient will not obligate or expend funds received under this Subaward to: (1) procure or obtain; (2) extend or renew a contract to procure or obtain; or (3) enter into a contract (or extend or renew a contract) to procure or obtain equipment, services, or systems that uses covered telecommunications equipment or services (as described in Public Law 115-232, section 889) as a substantial or essential component of any system, or as a critical technology as part of any system.

The Subrecipient shall require that the language of the certifications above in this Attachment 1 be included in the award documents for all subawards at all tiers (including subcontracts, subgrants, and contracts under grants, loans, and cooperative agreements) and that all subrecipients shall certify and disclose accordingly.

	Attachment	2	Subaward Number	
	Federal Award Terms and Conditions		RSUB1233529	
Required Data Elements		Awarding A	gency Institute (If Applicable)	
		EUNICE KENNEDY SHRIVER	ATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT	
The data elements required by Unit		Federal Award Issue	Date FAIN Assistance Listing No.	
Guidance are incorporated in the a	allached Federal Award.	10/14/21	R01HD102967 93.865	
This Subaward Is:			e Listing Program Title (ALPT)	
	Subject to FFATA		man Development Extramural Research	
Research & Development	Subject to FFATA		y Personnel Per NOA	
		Zubair Aghai		
General Terms and Conditions				
By signing this Subaward, Subrecipient ag	grees to the following:			
 To abide by the conditions on activiti applicable to this Subaward to the ex Awarding Agency's website: 	es and restrictions on expenditure of			
http://grants.nih.gov/grants/policy/awardco	nditions.htm		(
2. 2 CFR 200				
3. The Federal Awarding Agency's gran performance or as amended found at		a in effect as of the b	eginning date of the period of	
https://grants.nih.gov/policy/nihgps/index.h	ntm			
4. Research Terms and Conditions, inc		's Specific Requireme		
http://grants.nih.gov/grants/policy/awardcon			except for the following :	
a. <u>No-cost extensions require</u> the wr Administrative change.			nsion shall be directed to the the desired effective date of the requested	
 b. Any payment mechanisms and fin Conditions and Agency-Specific Required. c. Any prior approvals are to be sourd. d. Title to equipment as defined in 2 funds, as direct costs of the project or e. Prior approval must be sought for 5. Treatment of program income: Additional context of the program income of the progr	irements are replaced with Terms ar ght from the PTE and not the Federal CFR 200.1 that is purchased or fabri program, shall vest in the Subrecipie a change in Subrecipient PI or change	nd Conditions (1) throu Awarding Agency. cated with research fu ent subject to the cond	igh (4) of this Subaward; and inds or Subrecipient cost sharing litions specified in 2 CFR 200.313.	
Special Terms and Conditions:				
Data Sharing and Access: Subrecipient agrees to comply with the or the Federal Awarding Agency's star No additional requirements	e Federal Awarding Agency's data sh ndard terms and conditions as refere	naring and/or access ro nced in General Term	equirements as reflected in the NOA s and Conditions 1-4 above.	
	Data Rights: Subrecipient grants to PTE the right to use data created in the performance of this Subaward solely for the purpose of and only to the extent required to meet PTE's obligations to the Federal Government under its PTE Federal Award.			
Copyrights:				
Subrecipient Grants to PTE a reproduce, make derivative works, dis software and its documentation and/or only to the extent required to meet PT	databases) first developed and deliv	ghts or copyrighted ma rered under this Subay	aterial (including any computer ward solely for the purpose of and	
Subrecipient grants to PTE the right to purpose of and only to the extent requi				
Promoting Objectivity in Research (Subrecipient must designate herein wh	COI): hich entity's Financial Conflicts of Inte	rest policy (COI) will a	apply: PTE	
If applying its own COI policy, by exect the relevant Federal Awarding Agency	ution of this Subaward, Subrecipient			
Attachment 3A. Any financial conflicts	Subrecipient shall report any financial conflict of interest to PTE's Administrative Representative or COI contact, as designated on Attachment 3A. Any financial conflicts of interest identified shall, when applicable, subsequently be reported to Federal Awarding Agency. Such report shall be made before expenditure of funds authorized in this Subaward and within 45 days of any subsequently identified COI.			

Governing Language:

In the event that a translation of this Subaward is prepared and signed by the parties, and a conflict arises between the English version and other language version, this English language version shall be the official version and shall govern and control.

Governing Law:

The Parties acknowledge that PTE is subject to the laws of the United States. The parties hereby agree that nothing in this Subaward or any of its attachments or references shall be deemed to require either Party to breach any mandatory statutory law under which each Party is operating.

Patents:

Pursuant to Public Law 96-517, as amended by Public law 98-620, title to any invention or discovery made or conceived under this Subaward shall vest in the Subrecipient. Subrecipient shall promptly notify PTE as shown in Attachment 4 hereto.

Subrecipient hereby grants to PTE a royalty-free, non-exclusive license for research purposes to any Subrecipient invention or discovery under this Subaward.

Second Tier Subawards:

Subrecipient may not issue any subawards under this Subaward without the express prior written consent of PTE. In the event that such consent is granted, all assurances, certifications, and terms included in this Subaward shall be flowed down to the second tier subaward.

Disputes:

The Parties shall attempt to resolve disputes through good faith negotiations. Any dispute arising under, or related to, this Subaward shall be resolved to the maximum possible extent through informal dispute resolution. Unresolved issues shall be arbitrated in accordance with the International Arbitration Rules of the American Arbitration Association. Arbitration Association.

Additional Terms

Work Involving Human or Vertebrate Animals (Select	t Applicable Op	otions)
No Human or Vertebrate Animals	IRB	Upon Request
Human Subjects		
Vertebrate Animals The PTE requires verification of IRB and/or IACUC approval be	e sent to the Ad	ministrative Contact as required above:
approved by its Institutional Review Board (IRB) and/or its Insti maintain current and duly approved research protocols for all p Subrecipient certifies that its IRB and/or IACUC are in full comp that any submitted IRB / IACUC approval represents a valid, ap	itutional Animal (periods of the Sul pliance with appli pproved protocol	baward involving human and/or vertebrate animal research. cable state and federal laws and regulations. The Subrecipient certifies
Human Subjects Data (Select One) Applicable		
Human Subjects Data will be exchanged under this	The PTE will	set forth the terms of the exchange of
Subaward (check all that apply):	Human Subje	cts Data (Select One):
From Subrecipient to PTE From PTE to Subrecipient		In Attachment 9.

This section left intentionally blank

Attachment 3A
Pass-Through Entity (PTE) Contacts

Subaward Number:

RSUB1233529

	-			
PTE Information				
Entity DUNS Name: Alfred I. duPont Hospital for Children of The Nemours Foundation				
Legal Address: 1600 Rockland Road, Wilmington, DE 19803-3607				
Website:	www.nemc	ours.org		
PTE Contacts				
Central Email	:	SponsoredProjectsDV@nemours	s.org	
Principal Investiga	stigator Name: Zubair Aghai, MD			
Email:	Zubair.Agh	ai@nemours.org	Telephone Number:	(215) 955-6523
Administrative Cor	ntact Name:	Shawkita K. Wilder		
Email:	Shawkita.V	Vilder@nemours.org	Telephone Number:	(302) 651-6832
COI Contact email	(if different	to above):		
Financial Contact	Name:	Alana Conover		
Email:	Email: Alana.Conover@nemours.org Telephone Number: (904) 697-5923			
Email invoices? Yes No Invoice email (if different): subaward_invoices@nemours.org				
Authorized Official	Name:	Vicky L. Funanage, PhD		
Email:	vfunanag@	nemours.org	Telephone Number:	(302) 651-6819
PI Address:				
1600 Rockland Road, Wilmington, DE19803-3607				
Administrative Address:				
1600 Rockland Road, Wilmington, DE 19803-3607				

Invoice Address:

10140 Centurion Pkwy N., Jacksonville, FL 32256

Attachment 3B

Subaward Number:

RSUB1233529

	Subrecipient Contacts			
Subrecipient Information for FFATA reporting				
Entity's DUNS Name: KLE SOCIETY'S JAWAHARLAL NEHRU MEDICAL COLLEGE				
EIN No.: Institution Type: Non-Domestic (non-US) Entity				
DUNS: 650251213	Currently registered in SAM.gov: Yes No			
Parent DUNS:	Exempt from reporting executive		<u> </u>	
	This section for U.S. Entities: Congressional District:	Zip Code Look-L Zip Code+4:		
Place of Performance Address			L	
KLE Society's Jawaharlal Nehru Medical College Women's and Children's Health Research Unit Nehru Nagar Belagavi 590010, Karmataka India				
Subrecipient Contacts				
Central Email:				
Website: https:/	/www.jnmc.edu			
Principal Investigator Name: Sanga	ppa M Dhaded			
Email: drdhadedsm@gmail.com Telephone Number: +91 98442 32586				
Administrative Contact Name: Shivaprasad S Goudar				
Email: sgoudar@jnmc.edu Telephone Number: +91 94481 26371				
Financial Contact Name: Virupaxi Gombi				
Email: virupaxi.gombi@g	virupaxi.gombi@gmail.com Telephone Number: +91 99643 93988			
Invoice Email: bkilled	nvoice Email: bkilledar@jnmc.edu			
Authorized Official Name: Niranja	ficial Name: Niranjana Mahantashetti Principal (of JNMC)			
Email: principal@jnmc.edu, niranjanasn@yahoo.com Telephone Number: +91 0831 2471350				
Legal Address:				
KLE Society's Jawaharlal Nehru Medical College Nehru Nagar Belagavi 590010, Karmataka India				
Administrative Address:				
KLE Society's Jawaharlal Nehru Medical College Nehru Nagar				

India
Payment Address:

Belagavi 590010, Karrnataka

Beneficiary Account Name: KLE ACADEMY OF DEEMED UNIVERSITY Bank Name: STATE BANK OF INDIA Bank Address: FCRA CELL, 4TH FLOOR, STATE BANK OF INDIA, NEW DELHI MAIN BRANCH, 11, SANSAD MARG, NEW DELHI, PIN 110001 BRANCH CODE: 00691 Account Number: 4023005648 (FCRA SAVINGS ACCOUNT) IFSC: SBIN0000601 Swift Code: SBININBB104 Currency: INR **Attachment 3B-2**

Subaward Number:

RSUB1233529

Highest Compensated Officers

Subrecipient:

Institution Name:	KLE Society's Jawaharlal Nehru Medical College
PI Name:	Sangappa M Dhaded

Highest Compensated Officers

The names and total compensation of the five most highly compensated officers of the entity(ies) must be listed if the entity in the preceding fiscal year received 80 percent or more of its annual gross revenues in Federal awards; and \$25,000,000 or more in annual gross revenues from Federal awards; and the public does not have access to this information about the compensation of the senior executives of the entity through periodic reports filed under section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. §§ 78m(a), 78o(d)) or section 6104 of the Internal Revenue Code of 1986. See FFATA § 2(b)(1) Internal Revenue Code of 1986.

Officer 1 Name:
Officer 1 Compensation:
Officer 2 Name:
Officer 2 Compensation:
Officer 3 Name:
Officer 3 Compensation:
Officer 4 Name:
Officer 4 Compensation:
Officer 5 Name:
Officer 5 Compensation:

Attachment 4

I

Subaward Number:

İ

 \mathbf{F}

	Reporting and Prior Approval Terms	RSUB1233529
Subrecipient agrees to subm	it the following reports (PTE contacts are identified in Atta	chment 3A):
Technical Reports:		
Monthly technical/progr of the end of the month	ess reports will be submitted to the <u>PTE's</u> Principal Investigat	tor within 15 days of
Quarterly technical/prog to the PTE Administrative	ress reports will be submitted within 30 days after the end	of each project quarter
to the PTE's Administra		•
research of any new key	y personnel, and annual IRB or IACUC approval, if applica	ble.
	ss report will be submitted to the PTE's Administrative Cont d or after termination of this award, whichever comes first.	
	orts on the project as may be required by PTE's Administrat bligations to the Federal Awarding Agency.	ive Contact in order for the PTE
Prior Approvals:		
Carryover:		Carryover instructions and requirements are as
Carryover is restricted for	this subaward by the: Pass-Through Entity	stated by the Federal Awarding Agency guidance or as shown below.
Submit carryover requ	ests to the Administrative Contact	
Other Reports:		
PTE's Administrative Cor Subrecipient's personne Federal Awarding Agen Project Period to be incl A negative repo	el responsible for patent <u>matters. The Subrecipient will sub</u> cy specific forms to the PTE's <u>Administrative Contact</u> wit uded as part of the PTE's final invention report to the Fede rt is required:	ees invention(s) in writing to mit a final invention report using thin 60 days of the end of the eral Awarding Agency.
Property Inventory Repo	ort (only when required by Federal Awarding Agency), spec	cific requirements below.
date(s) of performance I name of the PTE Princip include both current cos signature, that costs are supported by a general may request supporting Supporting documentati supplies, or time records	ccompanied by a brief technical report, and: (i) be sequenti by the Subrecipient; (iii) state the Purchase Order number, bal Investigator; (iv) itemize costs in detail, in accordance w ts and cumulative costs; (vi) include the Subrecipient certif e appropriate and accurate and that payment has not yet be ledger report originating directly from the Subrecipient's fin documentation in certain categories prior to or subsequent on includes, but is not limited to, travel receipts, purchase s, Property Inventory Report; frequency, type, and submiss quired by PTE Federal Award.	the title of the project and the with the Subaward budget; (v) fication, with authorized official's een received; and (vii)) be ancial record keeping system. PTE t to approving the invoice. orders, invoices for services or

Other Special Reporting Requirements:

INVOICING: The invoices shown in Attachment 6 shall be e-mailed to subaward_invoices@nemours.org for processing. An excel version of the invoice template will be emailed once the agreement is fully executed with additional details.

Invoices to PTE must include a detailed report of the personnel, effort, fringe, and other expenses that occurred during the billing period.

In addition to the invoicing terms and conditions identified on face-page of the Subaward, the following also applies:

-Subaward Number and RSUB PO# -- must be placed on each invoice

-A/U Number - 10148072 must be placed on each invoice

-Amount actually expended according to each budget/cost category. Sufficient details must be provided within each invoice.

Invoice period: The period for which the expenditures apply

Subaward Number: RSUB1233529

Attachment 5

Statement of Work, Cost Sharing, Indirects & Budget

Statement of Work

Below Attached, 5 pages If award is FFATA eligible and SOW exceeds 4000 characters, include a Subrecipient Federal Award Project Description

Budget Information

	Cost Sharing No
Budget Details Below Attached, 9 pages	Budget Totals Direct Costs \$ 306,612.00 Indirect Costs \$ 24,529. Total Costs \$ 331,141.00 All amounts are in United States Dollars

A Cluster Randomized Clinical Trial of Umbilical Cord Milking versus Early Cord Clamping on Short and Long-term Outcomes in Neonates Who are Non-Vigorous at Birth (CORDMILK Study)

Statement of Work

The goal of the CORDMILK trial is to determine if umbilical cord milking compared to early cord clamping will improve short and long-term outcomes in neonates who are non-vigorous at birth. The JNMC site will serve as the collaborating center in India and will:

1. Overall supervising site for all centers in India

The study will be conducted at the following seven sites in India. The JNMC will be the overall supervising site and coordinating center. The following sites and investigators will participate in the study.

Site	Study Investigators
KLE Academy of Higher Education and Research	Pediatrician:Dr. Bhavana Koppad
(Deemed-to-be-University)'s	Obstetrician: Dr. Yeshita Pujar
Jawaharlal Nehru Medical College (JNMC)	Radiologist:Dr. Santosh Patil
Nehru Nagar, Belagavi, 590010, India	Developmental Specialist: Dr. Deepa
	Metgud
Government Medical College,	
Hanuman Nagar, Medical Chowk, Ajni, Nagpur,	Pediatrician: Dr. Manoj Bhatnagar, MD
Maharashtra, 440003, India	Obstetrician: Dr. Manjushri Waikar
	Radiologist: Dr. Amit Disawal, MD
Daga Memorial Maternity and Children's Hospital,	Pediatrician: Dr. Vineeta Jain, MD
Gandhibagh, Nagpur, Maharashtra 440002, India	Obstetrician: Dr. Seema Parvekar
Pravara Institute of Medical Sciences/The Rural	Pediatrician: Dr. Sujit Mulay, MD
Medical College and Hospital,	Obstetrician: Dr Parikshit Jondhale
Loni Tal: Rahata, District Ahmednagar, Maharashtra	Radiologist: Dr. Ganesh Vikhe
413736, India	Developmental Specialist: Dr. Bhushan
	Deo
Mahatma Gandhi Institute of Medical Sciences/	Pediatrician: Dr. Manish Jain, MD
Kasturba Hospital,	Obstetrician: Dr. Shuchi Jain
Sevagram, Wardha , Maharashtra 442102, India	Radiologist: Dr. Sushil Kale
	Developmental Specialist: Dr. Anurag
	Chandel
Karnataka Institute of Medical Sciences, PB Road,	Pediatrician: Dr. Prakash Wari
Vidya Nagar, Hubbali Karnataka, 580022, India	Obstetrician: Dr. Kasturi Dominath

	Radiologist: Dr. GC Patil Developmental Specialist: Dr. Sahithya B R
Indira Gandhi Medical College, Nagpur, India	Pediatrician: Milind Suryawanshi Obstetrician: Dr. Alka Patankar
All India Institute of Medical Science Plot No. 2 Section 20, MIHAN, Nagpur Maharashtra 441108, India	Pediatrician: Dr. Meenakshi Girish Developmental Specialist: Dr Akash Bang, Dr. Urmila Chauhan

The "Women's and Children's Health Unit" (WCRU) at JNMC will assist in conducting the CORDMILK trail. The WCRU was established in 2001 when JNMC was designated as a site for the National Institute of Child Health and Human Development (NICHD) Global Network for Women's and Children's Health Research. The goal of the Global Network was to implement community based research studies to improve maternal, neonatal, infant and early childhood health and accelerate the achievement of Millennium Development Goals 4 and 5 (of reducing maternal and neonatal mortality) in LMICs across Asia, Africa and Latin America. The establishment of WCRU at JNMC has been supplemented by essentials like setting up five regional data centers, training dedicated research faculty and strengthening Institutional Review Board mechanisms in order to accomplish building research capacity and infrastructure development. The WCRU has developed a Study Management System, comprising of electronic data entry and management, for monitoring the process evaluation. The facilities at WCRU includes staff offices, meeting facilities, the primary data center, secure storage areas for records, study materials and supplies, and many additional features supportive of the WCRU's mission. There are adequate computers, printers, copiers and data center equipment and supplies for those working with the WCRU. The Ethics Committee at JNMC operates under the federal-wide assurance (FWA) on human subject research.

S M Dhaded, Principal Investigator will be responsible for ensuring the proper conduct of the trial, including recruitment of participants, accurate collection of data, oversight of all study personnel, approval from IRBs and other regulatory bodies, monitoring for protocol violations and occurrence of any unanticipated events, ongoing reporting, and preparation of publications. (1) confirming proper IRB approval; (2) observing the delivery of the study intervention; (3) assessing and evaluating the quality of the trial's conduct; (4) comparing the quality with preset standards and ensuring compliance with the intervention; (5) evaluating accuracy, precision, and completeness of data collected, entered, and transmitted; (6) discussing the results of the monitoring with the local investigators; (7) ensuring that all personnel are fulfilling their obligations; (8) maintaining morale and enthusiasm of the staff; (9) handling ad hoc problems and maintaining communication; (10) ensuring between site consistency; and (11) proposing improvements to the monitoring activities.

Shivaprasad Goudar, MD, Co-Investigator will help Site Principal Investigator in monitoring responsibilities. He will be responsible for the day-to-day implementation of the study including establishing liaisons between the Hospital and Government establishments. He will also be responsible for coordination between the Indian and other research teams at all stages of the study with respect to study protocol. Along with the PI, he will be responsible for generating study progress.

Site Co-Investigator OBGYN - will help Site Principal Investigator in monitoring and responsibilities. He/She will be responsible for training local staff for recognizing non-vigorous infants, performing umbilical cord milking and the day-to-day implementation of the study. He/she will also be responsible for coordination between the Indian and other research teams at all stages of the study with respect to study protocol. Along with the PI, he/she will be responsible for generating study progress and collaborate with the Principal Investigator on data interpretation and manuscript preparation.

Site Co-Investigator Pediatrician - will help Site Principal Investigator in monitoring and responsibilities. He/She will be responsible for the training of supporting staff on neurological examination and classification of HIE and day-to-day implementation of the study. He/she will also be responsible for coordination between the Indian and other research teams at all stages of the study with respect to study protocol. He/she will be responsible for managing stafff and generating study progress. Collaborate with the Principal Investigator on data interpretation and manuscript preparation.

Co-Investigator Radiology - will help Site Principal Investigator for performing and scoring MRI on infants with moderate to severe HIEs. He/ She will be responsible for the day-to-day implementation of the study including training supporting staff on performing MRI.

Co-Investigator Developmental Follow Up: Will be responsible for the developmental follow-up at 12 months using DAASI and 24 months using BSID-IV. Collaborate with the Principal Investigator on data interpretation and manuscript preparation.

Research Assistants/coordinators will be to assist the investigators on the study in enrolment of participants. She/he will be responsible for screening and enrollment of the study participant. They will be responsible for checking all the study documentation of the participant for correctness and completion. They will prepare the CRF for data entry. She/ He will be responsible for reviewing the forms that have been submitted before data entry and resolve any discrepancies. Dedicated research coordinators/research assistants will be hired at each site, and they will be trained to get informed consent, enroll babies, and collect data.

2. Site visits and training

In preparation for the study implementation central study team will visit each site and interact with site investigators with focus on the following

- Dissemination of study objectives to stakeholders.
- Identification and hiring of study staff.
- Developing procedures for safety monitoring.
- Methods of monitoring and improving follow-up visit compliance.
- Identifying potential implementation challenges and developing appropriate solutions.
- Training of study staff in implementation of study procedures and follow-up activities

The JNMC will conduct a training session at Belagavi for all site OB and Pediatric PIs before initiating trial. Each site PI will conduct training for site investigator and supporting staff using a variety of teaching methods and a video certification process. Each site PI (obstetrician and pediatrician) will orient their site study staff to the study and protocol. Prior to study enrollment simulation videos will be shared (developed and available at trail website) to ensure that all sites use the same technique for cord milking. Video recordings of UCM for 5 patients per site will be reviewed by the steering committee to ensure the milking technique is properly performed before study subjects can be enrolled. Additional videos will be developed if variation is noted. In addition, time to cord clamping and the number of times the cord is milked will allow identification of situations where UCM is not performed correctly. A 2-month audit period will be implemented to ensure that sites have complied with the protocol and have correctly logged non-vigorous infants using study criteria (tone, color, or breathing). In addition, sites will also have a similar 2-month crossover period before beginning the second epoch with the same audit process. The paediatricians will be trained to perform Sarnat staging on neonates with HIE via an initial webinar and subsequent videos of five subjects. Similar training will be performed for performing brain MRI and scoring and developmental follow-up at 12 and 24 months.

3. ICMR and regulatory approval

Any study performed in India with foreign collaboration require an approval from the Indian Council of Medical Research (ICMR) before initiating the study. The JNMC teamwill prepare and submit all required documents for the ICMR approval. Few centers will also need approval from the State Governments. The JNMC team will help centers for preparing documents and getting approval from the State Government as needed.

4. IRB Approvals

The study will be approved by the Institutional Ethics Committee (IEC) from each site. The JNMC team will assist in preparing documents including translating consent forms in local languages for the IEC approval.

5. Preparing the documents CRF, MOO, training materials

The JNMC team along with the investigators from USA will prepare the documents related to the trial including Case Report Form (CRF), Manual of Operations (MOO) and training materials.

6. Data Coordinating Center/ Data Storage and Security

Information Systems and data management and security will be managed by the **Data Coordinating Center (DCoC)** at JNMC Women and Children's Health Research Unit, a WHO designated collaborating center for research in Maternal and Perinatal Health. Data Management will be conducted under the direction of **Amit Revankar (Data Coordinator and Network Manager)** and will include case report form design, management and entry, data quality assurance, and reporting. Amit Revankar is experienced in coordinating large multicenter and single center studies, and he was the lead coordinator for several multi-center clinical trials sponsored by the NICHD, Bill & Melinda Gates Foundation and the World Health Organization. As the overall study Data Manager, he will coordinate the trial, provide technical expertise for equipment and data collection, oversee the completion of study forms, and prepare data for statistical analyses. The study will be closely monitored for issues of data quality, study conduct, and adverse events. These analyses will be presented to the DSMB. Data will be entered into a secure, backed up, 24 hour, web-based database using electronic forms developed by the DCoC staff with the assistance of investigators and statisticians.

REDCap (Research Electronic Data Capture): All case report forms for the trial will be captured using a secure web-based data capture system REDCap. REDCap under the direction of the JLNH Data Management Center offers and manages REDCap. The JNMC Data Management team will maintain and provide full administration and support for REDCap. The REDCap application supports many data collection and analysis projects. Data collection projects rely on a thorough study-specific data dictionary defined in an iterative self-documenting process by all members of the research team with planning and analytic assistance from biostatisticians. The iterative development and testing process results in a wellplanned data collection strategy for individual studies. The REDCap Survey tool is used for building and managing online surveys. The research team can create and design surveys in a web browser and engage potential respondents using a variety of notification methods. Both REDCap and REDCap Survey systems provide secure, web-based applications that are flexible enough to be used for a variety of types of research, provide an intuitive interface for users to enter data and have real time validation rules (with automated data type and range checks) at the time of entry. These systems offer easy data manipulation with audit trails and reporting, monitoring and querying patient records, and an automated export mechanism to common statistical packages (SPSS, SAS, Stata, R/S-Plus). The system has been deployed using a highly secure, HIPAA-compliant network design and is housed in a physically secure data center. Back up of data is performed nightly and archived off-site for two years for Disaster Recovery purposes. Principal investigators may opt to archive the data for up to seven (7) years offsite to AWS Glacier.

Expected overall target enrollment for all centers in India is 3824 subjects over one year period and follow them till the age of 2 years. The total duration of study is 4 years.

Proj	ect Budget: UCM							
	Title of Project			UCM		Í		
	Host Institution							
	Country			India				
	Local currency			Rupees				
	Exchange Rate Rupees (local	currency) per USD		70.0000				
							Preparation	Recruitmen
Line	Budget item						Preparation a	ind enrollment
							12 m	onths
1. Pe	rsonnel						1-Aug-21	1-Jul-22
	Last name, First Name	Functional Title	Already receives salary from institution?	Monthly payroll cost Rupees (local currency)	% of full-time devoted to this project	h	Rupees	US Dollar
	S M Dhaded	Principal Investigator	Yes	228,170	20%	12	547,608	7,823
	Shivaprasad Goudar	Co-Principal Investigator	Yes	318,030	5%	12	190,818	2,726
	Meenakshi	Site Principal Investigator- Nagpur	Yes	180,000	10%	7	126,000	1,800
	Sunil Vernekar	Project Coordinator	Yes	171,600	20%	12	411,840	5,883
	Yogesh Kumar	Project Coordinator	Yes	171,600	20%	12	411,840	5,883
	Revankar, Amit	Data Management & IT Support	No	190,000	5%	12	114,000	1,629
	Bhim rao	Logistics Admin.	No	41,000	50%	6	123,000	1,757
	Shweta	Clerk	No	41,000	50%	6	123,000	1,757
	Shivanand	Budget Admin	No	41,000	50%	6	123,000	1,757
	Belgaum - KLESH							

TBD		Site Co-Investigator -OBGYN	Yes	141,036	10%	7	98,725	1,410
TBD		Site Co-Investigator - Pediatrician	Yes	141,036	10%	7	98,725	1,410
∨ijay	yalaxmi Hasaraddi	ResearchOfficer	No	90,000.00	50%	7	315,000	4,500
TBD	•	Research Nurse	No	18,000.00	100%	7	126,000	1,800
TBD		Research Nurse	No	18,000.00	100%	7	126,000	1,800
TBD		Research Nurse	No	18,000.00	100%	7	126,000	1,800
TBD		Research Nurse	No	18,000.00	100%	7	126,000	1,800
Nag	pur - DAGA Hospital							
Тога	ıt	Site Co-Investigator -OBGYN	Yes	141,036	10%	7	98,725	1,410
Vine	eta Jain	Site Co-Investigator - Pediatrician	Yes	141,036	10%	7	98,725	1,410
Seer	ma Parvekar	Administrative Coordinator	Yes	141,036	4%	7	39,490	564
TBD		Reseach Officer	No	40,000	100%	7	280,000	4,000
TBD		Reseach Officer	No	40,000	100%	7	280,000	4,000
T.BD)	Data Management /Logistics	No	20,000	100%	7	140,000	2,000
TBD)	Research Nurse	No	18,000.00	100%	7	126,000	1,800
TBD		Research Nurse	No	18,000.00	100%	7	126,000	1,800
TBD		Research Nurse	No	18,000.00	100%	7	126,000	1,800
TBD)	Research Nurse	No	18,000.00	100%	7	126,000	1,800
TBD)	Research Nurse	No	18,000.00	100%	7	126,000	1,800
Nag	pur- GMC Hospital							
Man	ijushri Waikar	Site Co-Investigator -OBGYN	Yes	141,036	10%	7	98,725	1,410
Man	oj Bhatnagar	Site Co-Investigator - Pediatrician	Yes	141,036	15%	7	148,088	2,116

	TBD	Administrative Coordinator - OBGYI	Yes	141,036	4%	7	39,490	564
	TBD	Administrative Coordinator - Pediatr	Yes	141,036	4%	7	39,490	564
	TBD	Research Officer	No	40,000	100%	7	280,000	4,000
	TBD	Research Officer	No	40,000	100%	7	280,000	4,000
	TBD	Data Management /Logistics	No	20,000	100%	7	140,000	2,000
-	TBD	Research Nurse	No	18,000.00	100%	7	126,000	1,800
	TBD	Research Nurse	No	18,000.00	100%	7	126,000	1,800
	TBD	Research Nurse	No	18,000.00	100%	7	126,000	1,800
	TBD	Research Nurse	No	18,000.00	100%	7	126,000	1,800
	TBD	Research Nurse	No	18,000.00	100%	7	126,000	1,800
	Nagpur- IGG Medical College							
	TBD	Site Co-Investigator -OBGYN	Yes	141,036	10%	7	98,725	1,410
	Milind Suryawanshi	Site Co-Investigator - Pediatrician	Yes	141,036	10%	7	98,725	1,410
	TBD	Administrative Coordinator - OBGYI	Yes	141,036	4%	7	39,490	564
	TBD	Administrative Coordinator - Pediatr	Yes	141,036	4%	7	39,490	564
	TBD	Research Officer	No	40,000	100%	7	280,000	4,000
	TBD	Research Officer	No	40,000	100%	7	280,000	4,000
	TBD	Data Management /Logistics	No	20,000	100%	7	140,000	2,00
	TBD	Research Nurse	No	18,000.00	100%	7	126,000	1,80
	TBD	Research Nurse	No	18,000.00	100%	7	126,000	1,80
	TBD	Research Nurse	No	18,000.00	100%	7	126,000	1,80

TBD		Research Nurse	No	18,000.00	100%	7	126,000	1,800
TBD		Research Nurse	No	18,000.00	100%	7	126,000	1,800
MGIN	/IS, Wardha							
Such	i Jain	Site Co-Investigator -OBGYN	Yes	141,036	10%	7	98,725	1,410
Mani	sh Jain	Site Co-Investigator - Pediatrician	Yes	141,036	10%	7	98,725	1,410
TBD		Administrative Coordinator - OBGY	Yes	141,036	4%	7	39,490	564
TBD		Administrative Coordinator - Pediatr	Yes	141,036	4%	7	39,490	564
TBD		Research Officer	No	40,000	100%	7	280,000	4,000
TBD		Research Officer	No	40,000	100%	7	280,000	4,000
TBD		Data Management /Logistics	No	20,000	100%	7	140,000	2,000
TBD		Research Nurse	No	18,000.00	100%	7	126,000	1,800
TBD		Research Nurse	No	18,000.00	100%	7	126,000	1,800
TBD		Research Nurse	No	18,000.00	100%	7	126,000	1,800
TBD		Research Nurse	No	18,000.00	100%	7	126,000	1,800
TBD		Research Nurse	No	18,000.00	100%	7	126,000	1,800
KIMS	s, Hubbali							
Praka	ash Wari	Site Co-Investigator - Pediatrician	Yes	141,036	10%	7	98,725	1,410
TBD		Site Co-Investigator -OBGYN	Yes	141,036	10%	7	98,725	1,410
TBD		Administrative Coordinator - OBGYI	Yes	141,036	4%	7	39,490	564

Scanners Printers Computers Cost Developmental Assessment Scales for Indian Infants (DASII) Operating System With Msoffice Utility expenses	5 Scanner @ \$582.86 each6 Printer @ \$388.57 each6 Computers @ 940.71 each6 @ 14000 each5 User licensesAt 6 Centers \$97.14 per month	40800 27200 65850 14000 113070 6800	5 6 6 1 6		12	204,000 163,200 395,100 84,000 113,070 489,600	2,9 2,3 5,6 1,2 1,615. 6,9
Scanners Printers Computers Cost Developmental Assessment Scales for Indian Infants (DASII) Operating System With Msoffice	6 Printer @ \$388.57 each 6 Computers @ 940.71 each 6 @ 14000 each 5 User licenses	27200 65850 14000 113070	6 6 6 1		12	163,200 395,100 84,000 113,070	2,9 2,3 5,6 1,2 1,615.
Scanners Printers Computers Cost Developmental Assessment Scales for Indian Infants (DASII)	6 Printer @ \$388.57 each 6 Computers @ 940.71 each 6 @ 14000 each	27200 65850 14000	6 6 6			163,200 395,100 84,000	2,9 2,3 5,6 1,2
Scanners Printers Computers Cost	6 Printer @ \$388.57 each 6 Computers @ 940.71 each	27200 65850	6			163,200 395,100	2,9 2,3 5,6
Scanners Printers	6 Printer @ \$388.57 each	27200	6			163,200	2,9
Scanners							2,9
· · · · · · · · · · · · · · · · · · ·	5 Scanner @ \$582.86 each	40800	5			204,000	
							-,-
Communications expenses	Rs 2000 per month per center for 6 centers Approximately	2000	6		12	144,000	2,
Computer supplies (see also majo	r eAt 6 Centers at Rs 2000 Per month	2000	6		12	144,000	2,
Printing and stationery supplies	At 6 Centers at Rs 5000 Per month	5000	6		12	360,000	5,
Internet connections	At 6 Centers at Rs 2000 Per month	2000	6		12	144,000	2,057
rvices and small supplies						Rupees	US D
Subtotal						11,103,582	158,0
TBD	Research Nurse	No	18,000.00	100%	7	126,000	1,
TBD	Research Nurse	No	18,000.00	100%	7	126,000	1,
TBD	Research Nurse	No	18,000.00	100%	7	126,000	1,
TBD	Research Nurse	No	18,000.00	100%	7	126,000	1,
TBD	Data Management /Logistics	No	20,000	100%	7	140,000	2,
TBD	Research Officer	No	40,000	100%	7	280,000	4,
	Research Officer	No	40,000	100%	7	280,000	4,
TBD						39,490	

Item	Unit cost	Number of participants			Rupees	US Dolla
Screening at >=35 weeks						
Initial Screening Cost	100	31250	18	9	1,562,500	22,321
MRI Brain	4,800	1071	18	9	2,570,400	36,720
ABG	300	1912	18	9	286,800	4,097
CBC	300	1912	18	9	286,800	4,097
Dasi Evaluation	2,000	1071		0	-	-
Bayley III Evaluation of Babies	3,000	1071	Ì	0	-	-
Subtotal					4,706,500	67,236
Subtotal Or Equipment (Items costing over US\$ 1, Item, including packing, freight, insurance cost Bayley Kit @ \$1360Per kit	000) 95200	8			4,706,500 Rupees	
or Equipment (Items costing over US\$ 1, Item, including packing, freight, insurance cost		8				67,236
or Equipment (Items costing over US\$ 1, Item, including packing, freight, insurance cost		8				
or Equipment (Items costing over US\$ 1,	000)					
or Equipment (Items costing over US\$ 1, Item, including packing, freight, insurance cost Bayley Kit @ \$1360Per kit	95200	8			Rupees - -	

_							
	Dr Dhaded	1 trips to Delhi & Bangalore for Regulatory Approvals including Accommodation, Per Diem, Local Transportation etc.	35,000	5		35,000	500
	Central Team Travel to Nagpur & other sites or preparatory	2 persons 3 trips 3 days Accommodation, Per Diem etc	56,000	4	2	224,000	3,200.00
	Central Team Travel to Nagpur & other Sites	2 persons every 3 month 2 days Accommodation, Per Diem etc, total 4 trips	56,000	1	4	224,000	3,200
	Monitoring Trips to the field	3900 per trip for 6 trips per week	3,900	6	7	163,800	2,340
	Transport and Loss to wages for Mother to get Baby for evaluations	3900 per trip	3,900	2,142			-
-	Subtotal					646,800	9,240
Dth	er Costs						
	Item					Rupees	US Dolla
_	Translation of forms					15,000.00	21
	Training: Study Protocol with Site st	20 members X 7,500 -3 days: aincludes Travel, Accommodation, Food and Training Material cost				150,000.00	2,142.8

Subtotal					2,765,000	39,500
incentive for mothers for follow up		610	1071			
DMS Development and Management	nt & Support for 4 years				1,800,000	25,714.2
Study Insurance	\$10294 per year Clinical Research insurance				700,000.00	10,00
Cost of Setting Up evaluation Center	1 Cupbord +I Cabinate with drawers + 1 table + 4 Chairs + Steps + Matting for centers		99600	6		
Training workshop: at each site for Study Proceedure 1 day	100 participants (Birth Attendants) x2 sites plus trainers for 1day includes Travel, Food & Refreshment and Training Material Cost @ Rs.1000 per person				100,000.00	1,428.5

BUD	GET SUMMARY		
		Rupees US	Doll
1	Personnel	11,103,582 15	58,623
2	Services and small supplies	2,240,970 3	32,01
3	Participant costs	4,706,500 6	67,236
4	Major equipment	-	-
5	Local travel and fieldwork	646,800	9,240
6	Other costs	2,765,000 3	89,500
ΤΟΤΑ	L BUDGET	21,462,852 30)6,612
8% in	direct	1,717,028 2	24,529
ΤΟΤΑ	AL INSTITUTION BUDGET	23,179,880 33	31,141

Budget Justification

S M Dhaded, Site Principal Investigator will be responsible for ensuring the proper conduct of the trial, including recruitment of participants, accurate collection of data, oversight of all study personnel, approval from IRBs and other regulatory bodies, monitoring for protocol violations and occurrence of any unanticipated events, ongoing reporting, and preparation of publications. (1) confirming proper IRB approval; (2) observing the delivery of the study intervention; (3) assessing and evaluating the quality of the trial's conduct; (4) comparing the quality with preset standards and ensuring compliance with the intervention; (5) evaluating accuracy, precision, and completeness of data collected, entered, and transmitted (along with the DCC); (6) discussing the results of the monitoring with the local investigators; (7) ensuring that all personnel are fulfilling their obligations; (8) maintaining morale and enthusiasm of the staff; (9) handling ad hoc problems and maintaining communication; (10) ensuring between site consistency; and (11) proposing improvements to the monitoring activities. **(FTE-20%, Requested \$ 7823)**

Shivaprasad Goudar, MD, Site-Co Principal Investigator will help Site Principal Investigator in monitoring responsibilities. He will be responsible for the day-to-day implementation of the study including establishing liaisons between the Hospital and Government establishments. He/she will also be responsible for coordination between the Indian and other research teams at all stages of the study with respect to study protocol. Along with the PI, he/she will be responsible for generating study progress. (FTE-5%, Requested \$2726)

Meenakshi, Site Principal Investigator -Nagpur, will help Site Principal Investigator in monitoring responsibilities. She will be responsible for the day-to-day implementation of the study including establishing liaisons between the Hospital and Government establishments. He/she will also be responsible for coordination between the Indian and other research teams at all stages of the study with respect to study protocol. Along with the PI, he/she will be responsible for generating study progress. Will be responsible to coordinate the Hospital in Nagpur.(FTE-10%, Requested \$ 1800)

Sunil Vernakar, Project Coordinator, will systematically plan, implement and evaluate progressive and effective programs that train, educate, and develop the study staff and birth attendants to meet current protocol needs. He will direct the development, implementation and execution of programs to maintain protocol requirements. Will be responsible to coordinate the Hospital in Belgaum and Hubballi. (FTE-20%, Requested \$ 5883)

- Maintaining and monitoring project implementation plan
- project schedules & work hour
- budgets and expenditures
- Organizing, attending and participating in stakeholder meetings

Yogesh Kumar, Project Coordinator, will systematically plan, implement and evaluate progressive and effective programs that train, educate, and develop the study staff and birth attendants to meet current protocol needs. He will direct the development, implementation and execution of programs to maintain protocol requirements. Will be responsible to coordinate the Hospital in Nagpur. (FTE-20%, Requested \$ 5883)

- Maintaining and monitoring project implementation plan
- project schedules & work hour
- budgets and expenditures
- Organizing, attending and participating in stakeholder meetings

Will be the overall responsibilities of both the Study/projects Coordinators.

Site Co-Investigator – Pediatrician, will help Site Principal Investigator in monitoring responsibilities. He will be responsible for the day-to-day implementation of the study including establishing liaisons between the Hospital and Government establishments. He/she will also be responsible for coordination between the Indian and other research teams at all stages of the study with respect to study protocol. Along with the PI, he/she will be responsible for generating study progress. (We have budgeted 6 Site Co-Investigator – Pediatrician, for Belgaum-KLESH, Nagpur-DAGA Hospital, Nagpur-GMC Hospital, Nagpur-IGG Medical College, MGIMS Wardha & KIMS Hubballi. – Budget Requested \$ 1410 for each Site Co-Investigator – Pediatrician)

Site Co-Invesigator – OBGYN, will help Site Principal Investigator in monitoring responsibilities for the individual Facility respectively. S/he will be responsible for the day-to-day implementation of the study including establishing liaisons between the Hospital. He/she will also be responsible for coordination between the Indian and other research teams at all stages of the study with respect to study protocol. Along with the PI, he/she will be responsible for generating study progress. (We have budgeted 6 Site Co-Investigator – OBGYN, for Belgaum-KLESH, Nagpur-DAGA Hospital, Nagpur-GMC Hospital, , Nagpur-IGG Medical College, MGIMS Wardha & KIMS Hubballi. -Budget Requested \$ 1410 for each Site Co-Investigator – OBGYN)

Administrative Coordinator – Pediatrician/OBGYN- Will coordinate all administrative activities related to project. will be key personnel to lesion all activities related to the protocol. (We have budgeted 8 Administrative Coordinators – Pediatrician & OBGYN for Nagpur-GMC Hospital(1 each), Nagpur-IGG Medical College(1 each), MGIMS Wardha(1 each) & KIMS Hubballi (1 each). - Requested \$ 564 each for Administrative Coordinator – Pediatrician & OBGYN) and one Administrative Coordinator for Nagpur – DAGA Hospital (Requested \$ 564)

Data Management/Logistics, will collect the forms from the field and key them in to the DMS, will initiate any correction in the forms in consultation with the Data Coordinator, and ensure secure storage of the forms. The will be responsible for synchronization of the tablets & also assist the Study staff in any technical support. (*We have budgeted 5 Data Management/Logistics for Nagpur-DAGA Hospital, Nagpur-GMC Hospital, Nagpur-IGG Medical College, MGIMS Wardha & KIMS Hubballi. - Requested \$ 2000/per year for each Data Management/Logistics)*

Research Officers(RO), will supervise all the sites and monitor the day to day activities of the staff. They will be responsible for completing follow-up visit for babies enrolled in the study.

They will be responsible for reviewing the forms that have been submitted before data entry and resolve any discrepancies. They will be in direct contact with community and will help the counselors in the community to establish confidence among the community workers and the health workers. 3 and 2 people at 40%. (We have budgeted 11 Research Officers @ Belagavi-KLESH(1), Nagpur-DAGA Hospital(2), Nagpur-GMC Hospital(2), Nagpur-IGG Medical College(2), MGIMS Wardha(2) & KIMS Hubballi(2). - Requested \$ 4500 for Belagavi-KLESH & \$ 4000 for each Research officer in other centers)

Research Nurses, the research Nurse will be to assist the Post Graduates and the hospital staff on the study in enrolment of Participants. S/he will be responsible for tracking the participant from hospital admission. They will be responsible for checking all the study documentation of the participant for correctness and completion. They will prepare the CRF for data entry. S/he will be responsible for reviewing the forms that have been submitted before data entry and resolve any discrepancies. (We have budgeted 30 Research Nurses for Belgaum-KLESH(5), Nagpur-DAGAHospital (5), Nagpur-GMCHospital (5), Nagpur-IGG Medical College (5), MGIMS Wardha(5) & KIMS Hubballi(5). - Budget Requested \$ 1800 for each Research Nurse)

Amit Revankar, Data Management and IT Support, is responsible for maintaining the research unit network, printers, computers, and installing the necessary software for research officers, designing reports for monitoring and follow-up, regular updates, designing new reports as per requirements, development of transmitting program with encryption for transmission and transmitting the data regularly to Data Coordinating Centre. Regular updates to system. He will also provide any technical support required by the research staff. This position is directly related to this project.. (FTE-5%, Requested \$ 1629)

Bhim rao, Logistics Admin. Will provide/facilitate the day-to-day activities of the research nurses and the FRO studies. He will be responsible for material requirements for all the 6 sites. (FTE-50%, Requested \$1757)

Shweta, Clerk. He will be responsible for material requirements for all the 6 sites.

Shivanad, Budget Administrator: He will be responsible to maintain the budget. He will prepare the detailed statement of day to day expense and monthly salaries statements. He will also be responsible for quarterly audits and prepare the final audit statements at end of every financial year. .(FTE-50%, Requested \$1757)

Travel for regulatory Approvals - Domestic Travel

Travel to Delhi and Bangalore: Site PI or Co-PI will travel to these cities to seek necessary permission for the study and presentations to the ICMR for approvals prior to study inception. 1 trips to Delhi & Bangalore for Regulatory Approvals including Accommodation, Per Diem, Local Transportation etc.,.(Requested \$ 500)

National Travel

Travel to Other Centers by Center team staff for Monitoring to 6 Hospital: Amountof Rs 56000/- is budgeted for 1 members to travel to Other Centres, which included airfare & Accommodation, Per Diem etc - Round trip @ 23000 per person + 16500 room rent per person for three days + Rs 7500 per day incidentals and 3000 tax per day for 3 days

Monitoring trips to the field Rs. 3900/- Per trip for 8 trips per week. (Requested \$2340)

Transport and Loss to wages for Mother to get Baby for evaluations Rs. 3900/- Per trip for 8 trips per week.

Services and Small Supplies.

Internet connections: At 6 Centers at Rs 2000 Per month (Requested \$2057.14)

Printing and stationery supplies: At 6 Centers at Rs 5000 Per month (Requested \$ 5143)

Accounting services:

Computer supplies: At 6 Centers at Rs 2000 Per month (Requested \$ 2057)

Communications expenses: Rs 2000 per month per center for 6 centers Approximately (Requested \$ 2057)

Scanners: 5 Scanner @ \$\$582.86 each - We will be used to Scan all the investigation and medical records of the Participants before they are transferred to medical record section (**Requested \$ 2914**)

Printers: 6 Printer @ \$388.57 each (Requested \$2331)

Computers Cost: 6 Computers @ \$940.7 each – Will be used for data processing and for data entry (Requested \$5644)

Operating System With MS office: 5 User licenses for the computer for data processing (Requested \$ 1615.29)

Utility expenses : At 6 Centers \$100 per month Expense are approximately billed to take care of Electrical expenses and other incidental expense at all the 6 centers office (**Requested \$6994**)

Participant Cost:

Initial Screening Cost – These cost are to cover the enrollment of the women in the study amount will be paid to the non study staff who will be working for the project. (Requested \$22321)

MRI Brain – These cost are budget to conduct a brain MRI on the Babies enrolled in the study. (Requested \$ 36720)

ABG - Cost of doing a ABG test. (Requested \$4097)

CBC - Cost of doing a CBC test. (Requested \$ 4097)

Bayley III Evaluation of Babies - these cost will be paid to the evaluator who will be doing the Bayley III test on the babies.

Capital Equipment ;

We have budgeted for 8 Bayley Kit@\$1360 Per kit

Study Insurance - We have Budgeted \$10000 per year Clinical Research insurance. (Requested \$10000)

Translation Cost – This will cover the cost of translation of the Study documents and CRF to local language for the understanding of the participant and certain study staff who do not understand English. (Requested \$214)

Training Study Protocol with Site staff: 20 members X 7,500 - 3 days: includes Travel, Accommodation, Food and Training Material cost. (Requested \$ 2142.86)

Training workshop: at each site for Study Procedure 1 day: 100 participants (Birth Attendants) x2 sites plus trainers for 1day includes Travel, Food & Refreshment and Training Material Cost @ Rs.1000 per person. (Requested \$ 1428.57)

Training sessions:

- Ethical conduct training & GCP: The entire research team and the field staff will be trained on ethical conduct of research. They also will be provide training on Good Clinical Practice in human research, concepts and standards used in the ethical conduct of clinical research,
- Training of the central team in in project rationale, Protocol, study procedures, data collection, adverse events reporting,
- Training of the central team in project rationale, Protocol, study procedures, data collection, adverse events reporting.
- Training of the Hospital birth attendants in project rationale, Protocol, study procedures, data collection, adverse events reporting & reporting procedures.

Training: Study Protocol with Site staff Nagpur at Belgaum, 10 member's X 15000 - 2 days: includes Travel, Accommodation, Food and Training Material cost Training: Study Protocol with Site staff Cuttack at Belgaum 10 member's X 50000 - 3 days: includes Travel, Accommodation, Food and Training Material cost

Training workshop: at each site for Study Procedure 1 day: 50 participants (Birth Attendants) x 7 sites plus trainers for 1 day includes Travel, Food & Refreshment and Training Material Cost @ Rs.2000 per person

DMS Development and Management & Support for 4 years (Requested \$25,714.29)

Dissemination activities at the end of 4th Year

Cost of Setting Up evaluation Center : 1 Cupboard +I Cabinets with drawers + 1 table + 4 Chairs + Steps + Matting for centers

Subaward Number:

RSUB1233529

	Attachme	ent 6	L
	Research Sul	baward	
	Invoice		
		have to a He	
BILL TO: PTE		Invoice #:	
Attention		Invoice Date:	
Address line 1		Contract/Award#:	
Address line		Federal ID #:	
email			
Subaward Agreem	ent number		
Contract Term:			-
Start Date:	End Date:		
Period Covered By This Invoice			
From:	To:		
EXPENDITURES	BUDGETED	CURRENT	CUMULATIVE
SALARIES AND WAGES	BUDGETED	CURRENI	CONUCATIVE
FRINGE BENEFITS			1
EQUIPMENT			
MATERIALS			
PUBLICATION COSTS			
OTHER (Specify)			
			1
TUITION			
F&A base %			
F&A base %			

CERTIFICATION:

By signing this report, I certify to the best of my knowledge and belief that the report is true, complete, and accurate, and the expenditures disbursements and cash receipts are for the purposes and objectives set forth in the terms and conditions of the Prime Award. I am aware that any false, fictitious, or fraudulent information, or the omission of any material fact, may subject me to criminal, civil or administrative penalties for fraud, false statements, false claims or otherwise.

Subrecipient Authorized Officer (Signature)

Title

Date

REMIT TO ADDRESS

PAYMENT AUTHORIZATION:

The subrecipient has demonstrated satisfactory project performance and progress, and the charges represented on this invoice appear to be appropriate with that progress. As Principal Investigator, I approve this payment.

Attachment 7

Notice of Award (NOA), DUA, and any additional documents

The following pages include the NOA and if applicable any additional documentation referenced throughout this Subaward.



۲

Not incorporating the NOA or any additional documentation to this Subaward.



Recipient Information	Federal Award Information
1. Recipient Name	
NEMOURS FOUNDATION, THE	11. Award Number
1600 ROCKLAND RD	1R01HD102967-01A1
WILMINGTON, DE 19803	40 Hatters Parland An and blachtfracture bland (PAIN)
	12. Unique Federal Award Identification Number (FAIN)
2. Congressional District of Recipient	R01HD102967
00	
	13. Statutory Authority
3. Payment System Identifier (ID)	42 USC 241 42 CFR 52
1590634433A2	
133003443382	14. Federal Award Project Title
4. Employee Identification Number (EIN)	A Cluster Randomized Clinical Trial of Umbilical Cord Milking to Improve Short and
4. Employer Identification Number (EIN)	Long-term Outcomes in Neonates Who are Non-Vigorous at Birth
590634433	
	15. Assistance Listing Number
5. Data Universal Numbering System (DUNS)	93.865
038004941	55.005
	16. Assistance Listing Program Title
6. Recipient's Unique Entity Identifier	Child Health and Human Development Extramural Research
ETGMYV7CKAJ7	
7. Project Director or Principal Investigator	17. Award Action Type
ZUBAIR H AGHAI, MD (Contact)	New Competing (REVISED)
zubair.aghai@nemours.org	18. Is the Award R&D?
215-955-6523	Yes
8. Authorized Official	Summary Federal Award Financial Information
Mrs. Jasmine Boyce	19. Budget Period Start Date 08/01/2021 - End Date 07/31/2022
	20. Total Amount of Federal Funds Obligated by this Action \$0
	20 a. Direct Cost Amount \$0
	20 b. Indirect Cost Amount \$0
	21. Authorized Carryover \$0
Federal Agency Information	22. Offset \$0
9. Awarding Agency Contact Information	23. Total Amount of Federal Funds Obligated this budget period \$587,446
Hong Cao	24. Total Approved Cost Sharing or Matching, where applicable \$0
Grants Management Specialist	25. Total Federal and Non-Federal Approved this Budget Period \$587,446
EUNICE KENNEDY SHRIVER NATIONAL	
	26. Project Period Start Date 08/01/2021 - End Date 07/31/2025
INSTITUTE OF CHILD HEALTH & HUMAN	
DEVELOPMENT	
hongca@mail.nih.gov	Sharing or Matching this Project Period
301-435-6999	
10. Program Official Contact Information	28. Authorized Treatment of Program Income
Maurice Davis	Additional Costs
EUNICE KENNEDY SHRIVER NATIONAL	29. Grants Management Officer - Signature
INSTITUTE OF CHILD HEALTH & HUMAN	Hong Cao
DEVELOPMENT	
Maurice.Davis@nih.gov	
(301) 435-6887	

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.



RESEARCH Department of Health and Human Services National Institutes of Health



EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT

SECTION I - AWARD DATA - 1R01HD102967-01A1 REVISED

Principal Investigator(s): ZUBAIR H AGHAI (contact), MD Sangappa Dhaded Anup C Katheria, MD

Award e-mailed to: resadm2@nemours.org

Dear Authorized Official:

The National Institutes of Health hereby revises this award (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to ALFRED I. DU PONT HOSP FOR CHILDREN in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health under Award Number R01HD102967. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website http://grants.nih.gov/grants/policy/coi/ for a link to the regulation and additional important information.

If you have any questions about this award, please direct questions to the Federal Agency contacts.

Sincerely yours,

Hong Cao Grants Management Officer EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT

Additional information follows

Cumulative Award Calculations for this Budget Period (U.S. Dollars)	
Salaries and Wages \$26	5,902
Fringe Benefits \$6	5,402
Personnel Costs (Subtotal) \$33	3,304
Travel \$26	5,363
Other \$5	5,454
Subawards/Consortium/Contractual Costs \$455	5,356
Federal Direct Costs \$520),477
Federal F&A Costs \$66	5,969
Approved Budget \$587	7,446
Total Amount of Federal Funds Authorized (Federal Share) \$587	7,446
TOTAL FEDERAL AWARD AMOUNT \$587	7,446

\$0

AMOUNT OF THIS ACTION (FEDERAL SHARE)

SUMMARY TOTALS FOR ALL YEARS (for this Document Number) THIS AWARD **CUMULATIVE TOTALS** YR \$587,446 1 \$587,446 2 \$556,130 \$556,130 3 \$557,364 \$557,364 \$557,568 4 \$557,568

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

Payment System Identifier:	1590634433A2
Document Number:	RHD102967A
PMS Account Type:	P (Subaccount)
Fiscal Year:	2021

IC	CAN	2021	2022	2023	2024
HD	8014702	\$557,446	\$526,130	\$527,364	\$527,568
TW	8476361	\$30,000	\$30,000	\$30,000	\$30,000

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:

PCC: PPB -MD / OC: 41021 / Released: Cao, Hong 10/14/2021 Award Processed: 10/15/2021 12:04:16 AM

SECTION II - PAYMENT/HOTLINE INFORMATION - 1R01HD102967-01A1 REVISED

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm

SECTION III - STANDARD TERMS AND CONDITIONS - 1R01HD102967-01A1 REVISED

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.
- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.

- c. 45 CFR Part 75.
- d. National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
- f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm for certain references cited above.)

Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See http://grants.nih.gov/grants/policy/awardconditions.htm for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) R01HD102967. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see http://grants.nih.gov/grants/policy/awardconditions.htm for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <u>http://publicaccess.nih.gov/.</u>

This award provides support for one or more clinical trials. By law (Title VIII, Section 801 of <u>Public Law</u> <u>110-85</u>), the "responsible party" must register "applicable clinical trials" on the <u>ClinicalTrials.gov Protocol</u> <u>Registration System Information Website</u>. NIH encourages registration of all trials whether required under the law or not. For more information, see <u>http://grants.nih.gov/ClinicalTrials_fdaaa/</u>

This award provides support for one or more NIH defined Phase III Clinical Trials. The NIH Policy for research supported as an NIH Phase III Clinical Trial has been amended in Section II.B. of the NIH Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research – Amended October 2001 (see http://grants.nih.gov/grants/funding/women_min/guidelines amended 10 2001.htm).

A description of plans to conduct analyses, as appropriate, by sex/gender and racial/ethnic groups must be included in clinical trial protocols. Cumulative subject accrual and progress in conducting subset analyses must be reported to NIH in the annual Progress Reports. Final analyses of sex/gender and racial/ethnic differences must be reported in the required Final Progress Report or Competitive Renewal Applications (or Contract Renewals/Extensions) as stated in Section II.B. of the Guidelines. This award is funded by the following list of institutes. Any papers published under the auspices of this award must cite the funding support of all institutes.

Eunice Kennedy Shriver National Institute Of Child Health & Human Development (NICHD) Fogarty International Center (FIC)

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

Treatment of Program Income:

Additional Costs

SECTION IV - HD SPECIFIC AWARD CONDITIONS - 1R01HD102967-01A1 REVISED

Clinical Trial Indicator: Yes

This award supports one or more NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

REVISION: This revised award removes the restriction on funding for and activities conducted at sites listed below in **India** indicated on the previous Notice of Award.

1. Jahwaharhlal Nehru Medical College (JNMC)/ KLE Academy of Higher Education and Research

- 2. Karnataka Institute of Medical Sciences
- 3. Srirama Chandra Bhanja (SCB) Medical College and Hospital
- 4. Government Medical College Nagpur
- 5. Daga Memorial Maternity and Children's Hospital
- 6. Mahatma Gandhi Institute of Medical Sciences/ Kasturba Hospital, Sewagram
- 7. Pravara Institute of Medical Sciences/The Rural Medical College and Hospital at Loni
- 8. Lata Mangeshkar Medical College Hospital/NKP Salve Institute of Medical Sciences

The previous terms and conditions of award remain in effect as stated below.

PREVIOUS TERMS AND CONDITIONS - 1st revision

REVISION: This revised award reflects NICHD acceptance of the certification of Institutional Review Board (IRB) approval and releases the restriction on the previous Notice of Award. Accordingly, the special terms and conditions prohibiting research involving human subjects are removed, effective as of the IRB approval date.

The previous terms and conditions of award remain in effect as stated below.

PREVIOUS TERMS AND CONDITIONS

NICHD reduction

In order to meet NICHD program objectives within FY2021 budget constraints, this grant is reduced 9.1 percent below the level recommended by the Integrated Review Group. Future year levels of support are determined by applying the same administrative reduction.

COVID-19

Due to the impact of the Coronavirus disease 2019 (COVID-19) outbreak, NICHD will consider providing greater flexibilities to recipients in meeting administrative, financial management and audit requirements. Please contact the Grants Management Specialist and Program Official indicated in Section IV of this Notice of Award for more information.

Escalation removed

In accordance with the NICHD FY2021 fiscal policy, escalation on recurring costs has been removed.

Dissemination Policy

The clinical trial(s) supported by this award are subject to the Dissemination Plan specified in the application dated 11/06/20 and the NIH policy on Dissemination of NIH-Funded Clinical Trial Information. The policy states that the clinical trial(s) funded by this award will be registered in ClinicalTrials.gov not later than 21 calendar days after enrollment of the first participant and that primary summary results will be reported in ClinicalTrials.gov not later than one year after the trial completion date. The reporting of summary results is required even if the primary trial completion date occurs after the period of performance.

This award is subject to additional certification requirements with submission of the Annual, Interim and Final Research Performance Progress Reports (RPPR). The recipient must agree to the following annual certification when submitting each RPPR. By submitting the RPPR, the Signing Official (SO) signifies compliance, as follows:

In submitting this RPPR, the SO (or PD/PI with delegated authority), certifies to the best of his/her knowledge that, for all clinical trials funded under this NIH award, the recipient and all investigators conducting NIH-funded clinical trials are in compliance with the recipient's plan addressing compliance with the NIH Policy on Dissemination of NIH-Funded Clinical Trial Information. Any clinical trial funded in whole or in part under this award has been registered in ClinicalTrials.gov or will be registered not later than 21 calendar days after enrollment of the first participant. Summary results have been submitted to ClinicalTrials.gov or will be submitted not later than one year after the trial completion date, even if the trial completion date occurs after the period of performance.

Medium Risk

Clinical Trial Study/Studies: 357284

The Clinical Trial Study or Studies listed above have been determined by NICHD to be considered MEDIUM risk requiring increased oversight by NICHD. An update on the status of the milestones included in Section 6 of the eRA Human Subjects System (HSS) and any additional agreed-upon milestones will be due once a year (generally halfway through the budget period) as well as being included in the annual RPPR. The update cycle due date is based on the budget period start date referenced in this Notice of Award. Information and procedures concerning these requirements are available at https://www.nichd.nih.gov/grants-contracts/process-strategies/policies/clinical-research. Updates must be provided through the eRA HSS accessible through the eRA Commons.

FOA

This award is subject to the requirements indicated in <u>PAR18-835</u>, which are hereby incorporated by reference. This Funding Opportunity Announcement is available at <u>http://grants.nih.gov/grants/guide/index.html</u>.

MULTI-PI

The recipient must follow the Multiple Principal Investigator Leadership Plan included in the application dated 11/06/20 and may not implement any changes in the plan without written NICHD prior approval.

Although the signatures of all PI/PD(s) are not required on prior approval requests, the recipient institution must secure and retain the signatures of all of PI/PD(s) within their own internal processes. See NIH Guide Notice NOT-OD-06-054 (<u>http://grants.nih.gov/grants/guide/notice-files/NOT-OD-06-054.html</u>).

Salary cap

No award funds shall be used to pay the salary of an individual at a rate in excess of the current salary cap. See NIH Guide Notice NOT-OD-21-057 (<u>https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-057.html</u>).

SPREADSHEET SUMMARY AWARD NUMBER: 1R01HD102967-01A1 REVISED

INSTITUTION: ALFRED I. DU PONT HOSP FOR CHILDREN

Budget	Year 1	Year 2	Year 3	Year 4
Salaries and Wages	\$26,902	\$26,901	\$26,956	\$26,897
Fringe Benefits	\$6,402	\$6,402	\$6,415	\$6,401
Personnel Costs (Subtotal)	\$33,304	\$33,303	\$33,371	\$33,298
Travel	\$26,363	\$26,362	\$26,416	\$26,358
Other	\$5,454	\$5,454	\$5,465	\$5,453
Subawards/Consortium/Co ntractual Costs	\$455,356	\$455,540	\$459,945	\$458,659
Publication Costs				\$4,545
TOTAL FEDERAL DC	\$520,477	\$520,659	\$525,197	\$528,313
TOTAL FEDERAL F&A	\$66,969	\$35,471	\$32,167	\$29,255
TOTAL COST	\$587,446	\$556,130	\$557,364	\$557,568

Facilities and Administrative Costs	Year 1	Year 2	Year 3	Year 4
F&A Cost Rate 1	42%	42%	42%	42%
F&A Cost Base 1	\$159,450	\$84,454	\$76,588	\$69,654
F&A Costs 1	\$66,969	\$35,471	\$32,167	\$29,255

Subaward Number:

Attachment 9

Research Subaward

Human Subjects Data

Include data exchange language here if Human Subjects Data is Applicable and you will not address Data in a separate DUA

Data Sharing Plan

As part of the close-out procedure, the Data Coordinating Center (DCoC) will: 1) perform a final data edit on the complete data set; 2) create a final data file; 3) send data to statistician for statistical analyses that support the study findings; 4) archive the final data set; 5) finalize the program and data management system documentation; 6) issue final reports to the committees; and 7) provide copies of the finalized datasets to NICHD and the investigative teams. The finalized dataset will be made public, as required, with the requisite documentation. The clinical trial investigators will be given the first and exclusive opportunity to analyze, present and publish data collected from their efforts. The study investigators will disseminate results and will write manuscripts including study design and primary results as well as other methodology and preplanned analyses of secondary outcomes supported actively by the DCoC. The data sharing plans also include sharing with the scientific community and ultimately the public. Upon request and prior to completion of the study, examples of data collection forms and instructions, the study protocol as well as other critical information (e.g., clear documentation of derived variables) will be made available to assist others in their developmental work of similar studies. This supports the overall concept of collaboration in the use of federal research dollars and may also provide the opportunity for investigators to be consultants or co-investigators. A data inventory will be kept so that others may use some information in planning their trials. We also recognize that Fogarty International Center and NICHD may have additional needs for access to the data and/or special reports that may benefit the overall work of the Institute.

The study investigators strongly believe the breadth of the data collected through this application and potential uses of the data extend substantially beyond the interest and resources of the investigators specific to this trial. It is projected that within two years of publication of the primary results paper, an archived dataset with documentation will be made available for additional uses by outside investigators, in collaboration with the study investigators. We will work with program staff at Fogarty International Center and NICHD in the development of a broad data sharing plan over time. Datasets will not contain personal identifying information on research participants. We will work with the Fogarty International Center and NICHD to have the materials made publicly available.

The Publications and Presentations (P&P) policies and procedures for this trial can be modeled after those that have been used successfully in other studies. These will be developed, implemented, and enforced by a P&P Committee, chaired by a to-be-named individual for the trial, with representation of study members from the trial. The P&P policies and procedures will be developed as part of the Manual of Operations and communicated to participating sites as part of the site initiation activities. It will also be available on the Trial website. All investigators will be encouraged to participate in opportunities for presentation and publications; resources within the DCoC will be available to facilitate this. These policies will provide for optimizing the use of the valuable data collected by the study and provide an additional non-financial incentive for participating investigators.



20, AVENUE APPIA - CH-1211 GENEVA 27 - SWITZERLAND - TEL CENTRAL +41 22 791 2111 - FAX CENTRAL +41 22 791 3111 - WWW.WHO.INT

Tel. direct:	+41 22 791 4226 +41 79 751 6265
Fax direct:	+41 22 791
E-mail:	oladapoo@who.int

In reply please refer to: oladapoo@who.int Dr Shivaprasad S Goudar MD, MHPE Professor of Physiology & Research Coordinator, Women's and Children's Health Research Unit, KLE Academy of Higher Education and Research Jawaharlal Nehru Medical College, Belgaum 590010 Karnataka India

23 May 2021

Dear Dr Goudar,

Simplified Treatment for Eclampsia Prevention using Magnesium sulfate: A phase III, randomized, open label, active controlled, multinational, multicenter, non-inferiority trial of simplified magnesium sulfate regimen for eclampsia prophylaxis (The STEP-Mag Trial [A66014])

This letter is to officially confirm that WHO is the sponsor of a randomized trial: "Simplified Treatment for Eclampsia Prevention using Magnesium sulfate: A phase III, randomized, open label, active controlled, multinational, multicenter, non-inferiority trial of simplified magnesium sulfate regimen for eclampsia prophylaxis (The STEP-Mag Trial)".

The UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP) at the WHO Department of Sexual and Reproductive Health and Research has been awarded a grant from MSD-for-Mothers to implement the internal pilot phase of this study. The trial will also be supported by HRP through its Trust Fund.

As agreed, your institution (KLE Academy of Higher Education and Research's J N Medical College) is the coordinating centre for the grant in India, which will be conducted in the following hospitals:

- 1. Chigateri General Hospital affiliated to JJM Medical College, Davanagere, Karnataka
- 2. Raichur Institute of Medical Sciences (RIMS) Hospital, Raichur, Karnataka
- 3. Mahila Chikitsalaya affiliated to Sawai Man Singh Medical College, Jaipur, Rajasthan
- 4. SCB Medical College and Hospital, Cuttack, Odisha

A total budget of USD 606,332 has been allocated towards the implementation of the trial in the above institutions. We look forward to a successful collaboration on this trial.

世界卫生组织 • منظمة الصحة العالمية

Organisation mondiale de la Santé • Всемирная организация здравоохранения • Organización Mundial de la Salud

Yours sincerely,

Dr Olufemi T. Oladapo Head, Maternal and Perinatal Health Unit (MPH) Department of Sexual and Reproductive Health and Research (SRH) (*includes UNDP-UNFPA-UNICEF-WHO-World Bank* Special Programme of Research, Development and Research Training in Human Reproduction HRP)



20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW. WHO.INT

20 December 2020

Professor Shivaprasad Goudar

KLE Academy of Higher Education and Research's J N Medical College Women's and Children's Health Research Unit Belagavi, Karnataka, India

Dear Professor Goudar,

RE: The WHO ACTION (<u>A</u>ntenatal <u>C</u>orticos<u>T</u>eroids for <u>I</u>mproving <u>O</u>utcomes in Preterm <u>N</u>ewborns) Trials: ACTION III trial

We confirm that WHO have been awarded a grant from the Bill & Melinda Gates Foundation for the ACTION III trial: A multi-country, multi-centre, three-arm, parallel group, double-blind, placebocontrolled, randomized trial of two doses of antenatal corticosteroids for women with a high probability of birth in the late preterm period in hospitals in low-resource countries to improve newborn outcomes

Your institution (KLE Academy of Higher Education and Research's J N Medical College) will lead the implementation of the trial in the following three hospitals:

KLE Hospital, Belagavi Karnataka Institute of Medical Sciences, Hubli SCB Hospital, Cuttack

A budget of USD 1 526 334 has been allocated towards the implementation of the trial in the above institutions. We look forward to a successful collaboration on this trial.

Kind regards,

Ayesha Mariette De Costa MD, Phd Scientist, Dept of Maternal, newborn, child and adolescent health, World Health Organization, Geneva deay@who.int Tel: +41 227-911-965

世界卫生组织 • منظمة الصحة العالمية

		FDP Re Amend				reement		
	Pass-Through Enti		nent (i	vumber) Subred	cipient	
_	s Jefferson University				lawabarla	Nehru Medical Colleg		
	the second s			L.	Tablices shows	an and all a constant of the second	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
	ith St, 2nd Floor Sheridan	, Philadelphia, PA 1		1	-	jnmc.edu, bkilledar@j	inmc.edu,	
Richard	Derman		Princip	oal Investiga	tor Shive	prasad Goudar	-	
Project 7	Title: TJU-JNMC Globa	I Network for Wom	en's & Chil	ldren's Heal	th Researc	h Unit		
PTE	E Federal Award No:			Federa	I Awarding	Agency:		
2U	G1HD076457-07			Nation	al Institute	s of Health (NIH)		
	ubaward Period of Pe		Amount F	Funded This	Action:	Subaward No:		
Start Da	ate: Jun 1, 2019 End D	Date: May 31, 2020	\$ 478,08	36.00		080-70000-S229	02	
Effectly	e Date of Amendment:	Total Amount of I		nds Obligate	d to Date:	Subject to FFATA:	Automatic	-
	Jun 1, 2019	\$ 478	8,086.00			Yes ()No	() Yes	No No
	This Amen			iginal Terms enced Resea		d <mark>itions</mark> ard Agreement as foll	ows:	
31, 20 If ther	thorize funding of \$ 020. e are funds remain itted, along with the	ning from the p	rior budg	jet period	, a requ	est for carryover	may be	
	Forclar	ity: all amounts stated	in this amer	ndment are in	United State	s Dollars.		
		- Contraction of the second se		100 C	and the second second	emain in full force	and effect.	
By an A	Authorized Official of PTE			By an	Authorized	Official of Subrecipier	nt:	
Am	andvollar	cy [10/16/10	1	KA.	5 .	Jul 1	6, 2019
Name:	Timothy Schailey	D	ate	Name:	Dr. (Hrs.) N	iranjana S. Mahanlashetti	Date	
Title	Director, Office of Resea	arch Administration		Title	Principal			

FDP Bilateral Mod Sept.2017

Attachment 1

RESEARCH & RELATED BUDGET - Budget Period 1

OMB Number: 4040-0001 Expiration Date: 10/31/2019

End Date: 05/31/2020

Start Date: 06/01/2019

Budget Period: 1

Enter name of Organization: RIE Society's Jawaharlal Nehru Medical College 6502512130000 **ORGANIZATIONAL DUNS:**

Budget Type: 🗌 Project 🛛 Subaward/Consortium

A. Senior/Key Person

Prefix	First	Middle	Last	Suffix	Months Base Salary (5) Cal. Acad. Sum.	Requested m. Salary (S)	Fringe Benefits (\$)	Funds Reguested (S)
Dr.	Shivaprasad S.	S.	Goudar		49,011.00 3.00	12,253.00	00.0	12,253.00
Project Role:	Sr. Foreign Investigator	ivestigatoi						
Dr.	Bhalachandra		Kodkany		66,470.00 0.40	2,216.00	00.0	00 310 0
Project Role:	Project Role: Senior Research Adviser	th Adviser						
Dr.	Niranjana		Mahantashett		36,886.00 0.50	1,536.00	0.00	1,536.00
Project Role:	Project Role: Sentor Research Adviser	h Adviser						
Dr.	Manjunath		Somannavar		23,460.00 4.20	8,211.00	100°C	8.211 00
Project Role:	Project Role: Research Coordinator	linztor						5
Dr.	Sangappa		Dhaded	-	36,163.00 2.20	6, 630.00	9.60	6, 630. 00
Project Role:	Pediatric Research Coordinator	arch Coord	linator					
Dr.	Mrutyunjaya		Bellad		36,886.00 1.30	3,994.00	0.00	3,994.00
Project Role:	Project Role: Obstetric Research Coordinator	arch Coord	inator				~	
4								
itional Senior	Additional Senior Key Persons:			Add Attachment	nt Delete Attachment View Attachment	Totz	Il Funds requested for all Senior Kev Persons in the attached file	
						" int	all nation the	

34,840.00

Total Senior/Key Person

.	L
Ĕ	ŀ
sol	L
9	
Г	l
he	þ
ō	
ю	Į.

Number of Personnel	of el	Project Role	Cal.	Months Acad.	Sum.	Requested Salary (\$)	Fringe Benefits (\$)	Funds Requested (\$)
		Post Doctoral Associates						
	1	Graduate Students						
		Undergraduate Students						
		Secretarial/Clerical						
	-	Data Mgr/IT Coord.	2.50			3,371.00	0.00	3,371.00
	П	Asst Res Coord/Data Entry Spec.	5.00			4,636.00	0.00	4,636.00
	-	Ex. Adm/Finance	5.50			6,506.00	0.00	6,506.00
	9	Field Research Officer	25.80			38,700.00	0.00	38,700.00
	8	Data Management/Log Support/County Coordination	15.10			14,397.00	0.00	14,397.00
	Н	Senior Field Research Officer/Data Coordinator	8.30			12,450.00	0.00	12,450.00

18 Total Number Other Personnel

 Total Other Personnel
 80,060.00

 Total Salary, Wages and Fringe Benefits (A+B)
 114,900.00

C. Equipment Description

List items and dollar amount for each item exceeding \$5,000

Equipment item		L	Funds Requested (\$)
Additional Equipment:	Add Attachment	Delete Attachment	View Attachment
Total funds requ	Total funds requested for all equipment listed in the attached file Total Equipment	the attached file Total Equipment	
D. Travel		Fun	Funds Requested (\$)
1. Domestic Travel Costs (Incl. Canada, Mexico and U.S. Possessions)	J.S. Possessions)		13,020.00
2. Foreign Travel Costs			16,156.00
	Total	Total Travel Cost	29,176.00

	Funds Requested (\$)
1. Materials and Supplies	8.483.00
2. Publication Costs	
3. Consultant Services	179.626.00
4. ADP/Computer Services	
5. Subawards/Consortium/Contractual Costs	
6. Equipment or Facility Rental/User Fees	00 201 0
7. Alterations and Renovations	20.000
8. Other	101.362.00
ö	
10.	
Total Other Direct Costs	sts 298,596.00
G. DIRECT COSTS	Funds Requested (\$)
Total Direct Costs (A thru F)	
n. Indirect costs	
Indirect Cost Type Indirect Cost Rate (%) Indirect Cost Base (\$)	5) Funds Requested (\$)
Foreign 8.00 442, 672.00	35,413.00
Total Indiract Costs	
Cognizant Federal Agency (Agency Name, POC Name, and POC Phone Number)	00.018/00 3
I. Total Direct and Indirect Costs	Funds Requested (5)
Total Direct and Indirect Institutional Costs (G + H)	
J. Fee	Funds Requested (S)
K. Total Costs and Fee	Funds Renuested (S)
Total Costs and Fee (I + J)	

Attachment 2

Notice of Award

Federal Award Date: 06/13/2019



R.

Cooperative Agreement Department of Health and Human Services National Institutes of Health

EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT

Grant Number: 5UG1HD076457-07 FAIN: UG1HD076457

Principal Investigator(s): RICHARD J DERMAN, MD

Project Title: TJU-JNMC Global Network for Women's & Children's Health Research Unit

Margaret Burwell Assistant to the Director 125 S. 9th Street Philadelphia, PA 191075125

Award e-mailed to: resadmin@jefferson.edu

Period Of Performance: Budget Period: 06/01/2019 - 05/31/2020 Project Period: 07/01/2013 - 05/31/2023

Dear Business Official:

The National Institutes of Health hereby awards a grant In the amount of \$607,360 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to THOMAS JEFFERSON UNIVERSITY in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 31 USC 6305 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health under Award Number UG1HD076457. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards, Consult the NIH website http://grants.nih.gov/grants/policy/coi/ for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

NIH NGA R [Version: 56 - 12/16/2018 2.22:00 PM] Generated on: 6/13/2019 12;12:13 AM

Kimberly Durkin Grants Management Officer EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT

Additional information follows

Page-2 NIH NGA R | Version 55 - 12/26/2016 2:22(00 PM) Generated eri: 6/10/2019 12:12:13 AM

Award Calculation (U.S. Dollars)	
Salaries and Wages	\$36,764
Fringe Benefits	\$8,750
Personnel Costs (Subtotal)	\$45,514
Consultant Services	\$27,524
Travel	\$9,830
Other	\$403,030
Subawards/Consortium/Contractual Costs	\$75,056
Federal Direct Costs	\$560,954
Federal F&A Costs	\$46,406
Approved Budget	\$607,360
Total Amount of Federal Funds Obligated (Federal Share)	\$607,360
TOTAL FEDERAL AWARD AMOUNT	\$607,360

AMOUNT OF THIS ACTION (FEDERAL SHARE)

SECTION I - AWARD DATA - 5UG1HD076457-07

\$607,360

SUMMARY TOTALS FOR ALL YEARS					
YR	THIS AWARD	CUMULATIVE TOTALS			
7	\$607,360	\$607,360			
8	\$607,360	\$607,360			
9	\$607,360	\$607,360			
10	\$607.360	\$607,360			

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

CFDA Name:	Child Health and Human Development Extramural Research
CFDA Number:	93.865
EIN:	1231352651A1
Document Number:	UHD076457C
PMS Account Type:	P (Subaccount)
Fiscal Year:	2019

IC	CAN	2019	2020	2021	2022
HD	8014707	\$607,360	\$607,360	\$607,360	\$607,360

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:

PCC: PPB -PS / OC: 414P / Released: SHAWK00 06/12/2019 Award Processed: 06/13/2019 12:12:13 AM

SECTION II - PAYMENT/HOTLINE INFORMATION - 5UG1HD076457-07

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm

SECTION III - TERMS AND CONDITIONS - 5UG1HD076457-07

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.
- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- c. 45 CFR Part 75.

Page-3

NPH NGA R | Version: 56 - 12/26/2015 2 22:00 FM| Generated on: 6/13/2019 12 12 13 AM

- d. National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
- f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm for certain references cited above.)

Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

Carry over of an unobligated balance into the next budget period requires Grants Management Officer prior approval.

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See

http://grants.nih.gov/grants/policy/awardconditions.htm for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) UG1HD076457. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see http://grants.nih.gov/grants/policy/awardconditions.htm for additional award applicability information,

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: http://publicaccess.nih.gov/.

This award provides support for one or more clinical trials. By law (Title VIII, Section 801 of <u>Public Law 110-85</u>), the "responsible party" must register "applicable clinical trials" on the <u>ClinicalTrials.gov Protocol Registration System Information Website</u>. NIH encourages registration of all trials whether required under the law or not. For more information, see <u>http://grants.nih.gov/ClinicalTrials_fdaaa/</u>

This award provides support for one or more NIH defined Phase III Clinical Trials. The NIH Policy for research supported as an NIH Phase III Clinical Trial has been amended in Section II.B. of the NIH Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research – Amended October 2001 (see

http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm).

A description of plans to conduct analyses, as appropriate, by sex/gender and racial/ethnic groups must be included in clinical trial protocols. Cumulative subject accrual and progress in conducting subset analyses must be reported to NIH in the annual Progress Reports. Final analyses of sex/gender and racial/ethnic differences must be reported in the required Final

Page-4 NIH NGA R | Version: 56 - 12/20/2018 2:22/00 PMJ Generated on: 6/13/2018 12:12:13 AM Progress Report or Competitive Renewal Applications (or Contract Renewals/Extensions) as stated in Section II.B. of the Guidelines.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

Treatment of Program Income: Additional Costs

SECTION IV - HD Special Terms and Conditions - 5UG1HD076457-07

Clinical Trial Indicator: Yes

This award supports one or more NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

NIH staff has determined that the submitted Continuation Progress Report is within the approved scope of work.

TOTAL COSTS

This award is funded at a total cost ceiling of \$607,360. Funds may be rebudgeted as necessary between direct and facilities and administrative costs consistent with policy and institutional requirements for prior approval; however, no additional funds will be provided.

CLINICAL TRIALS

The clinical trial(s) supported by this award are subject to the plan dated 11/24/2017 submitted to NICHD and the NIH policy on Dissemination of NIH-Funded Clinical Trial Information. The policy states that the clinical trial(s) funded by this award will be registered in ClinicalTrials.gov not later than 21 calendar days after enrollment of the first participant and that primary summary results will be reported in ClinicalTrials.gov not later than one year after the completion date. The reporting of summary results is required even if the primary completion date occurs after the period of performance.

This award is subject to additional certification requirements with submission of the Annual, Interim and Final Research Performance Progress Reports (RPPR). The recipient must agree to the following annual certification when submitting each RPPR. By submitting the RPPR, the AOR signifies compliance, as follows:

In submitting this RPPR, the SO (or PD/PI with delegated authority), certifies to the best of his/her knowledge that, for all clinical trials funded under this NIH award, the recipient and all investigators conducting NIH-funded clinical trials are in compliance with the recipient's plan addressing compliance with the NIH Policy on Dissemination of NIH-Funded Clinical Trial Information. Any clinical trial funded in whole or in part under this award has been registered in ClinicalTrials.gov or will be registered not later than 21 calendar days after enrollment of the first participant. Summary results have been submitted to ClinicalTrials.gov or will be submitted not later than one year after the completion date, even if the completion date occurs after the period of performance.

Page-5

MIH NGA R | Vertion: 56 - 12/26/2015 2 22:00 PM Generated en: 6/13/2019 12:12:13 AM

CONSORTIA

This award includes funds awarded for consortium activity with KLE Society's Jawaharlal Nehru Medical College in Karnataka, India .

Consortia are to be established and administered as described in the NIH Grants Policy Statement (rev. 10/17) (<u>http://grants.nih.gov/grants/policy/nihgps/nihgps.pdf</u>).

FOREIGN COMPONENT

This award includes funding for the following sites: KLE Society's Jawaharlal Nehru Medical College in Karnataka, India .

COOPERATIVE AGREEMENTS

This award is issued as a cooperative agreement, a financial assistance mechanism in which substantial NIH scientific and/or programmatic involvement is anticipated in the performance of the activity. This award is subject to the terms and conditions of award as set forth in the SPECIAL REQUIREMENTS section of RFA-HD-HD18-009, "Re-Competition of Global Network for Women's and Children's Health Research (UG1)," posted date July 18, 2017, which are hereby incorporated by reference as special terms and conditions of award.

Copies of this RFA are available at http://www.nih.gov/grants/guide/index.html

These special terms and conditions of award are in addition to, and not in lieu of, otherwise applicable OMB administrative guidelines; Federal Regulations, including HHS Grant Administration Regulations at 45 CFR Part 75; other HHS regulations; and the NIH Grants Policy Statement (rev. 10/17).

Project Scientist Contact Information:

Project Scientist: Marion Koso-Thomas, MD Email: <u>kosomari@mail.nih.gov</u> Phone: 301.435.6873

FUNDING OPPORTUNITY

This award is subject to the requirements Indicated in RFA-HD18-009, which are hereby incorporated by reference. Copies of this Funding Opportunity Announcement are available at http://grants.nih.gov/grants/guide/index.html.

STAFF CONTACTS

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

Grants Management Specialist: Kimberly Durkin Email: kimberly.durkin@nih.gov Phone: 301-451-0820

Program Official: Caroline Signore Email: signorec@mail.nlh.gov Phone: (301) 496-5577 Fax: (301) 496-3790

Page-6

NiH NGA R | Version, 56 - 12/26/2018 2 22.00 PMJ Generated on: 6/10/2019 12/12 13 AM

SPREADSHEET SUMMARY GRANT NUMBER: 5UG1HD076457-07

INSTITUTION: THOMAS JEFFERSON UNIVERSITY

Budget	Year 7	Year 8	Year 9	Year 10
Salaries and Wages	\$36,764	\$36,764	\$36,764	\$36,764
Fringe Benefits	\$8,750	\$8,750	\$8,750	\$8,750
Personnel Costs (Subtotal)	\$45,514	\$45,514	\$45,514	\$45,514
Consultant Services	\$27,524	\$27,524	\$27,524	\$27,524
Travel	\$9,830	\$9,830	\$9,830	\$9,830
Other	\$403,030	\$403,030	\$403,030	\$403,030
Subawards/Consortium/Contractual Costs	\$75,056	\$75,056	\$75,056	\$75,056
TOTAL FEDERAL DC	\$560,954	\$560,954	\$560,954	\$560,954
TOTAL FEDERAL F&A	\$46,406	\$46,406	\$46,406	\$46,406
TOTAL COST	\$607,360	\$607,360	\$607,360	\$607,360

Facilities and Administrative Costs	Year 7	Year 8	Year 9	Year 10
F&A Cost Rate 1	56%	56%	56%	56%
F&A Cost Base 1	\$82,868	\$82,868	\$82,868	\$82,868
F&A Costs 1	\$46,406	\$46,406	\$46,406	\$46,406

Page-7 NIH NGA R | Version: 56 - 12/26/2018 2:22 00 PM| Generaled on: 6/13/2019 12:12.03 AM Notice of Award

Federal Award Date: 08/01/2018



B HUMM SLAVICES . IS

Cooperative Agreement Department of Health and Human Services National Institutes of Health

EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT

 Grant Number:
 2UG1HD076457-06

 FAIN:
 UG1HD076457

Principal Investigator(s): RICHARD J DERMAN, MD

Project Title: TJU-JNMC Global Network for Women's & Children's Health Research Unit

Margaret Burwell Assistant to the Director 125 S. 9th Street Philadelphia, PA 191075125

Award e-mailed to: resadmin@jefferson.edu

Period Of Performance: Budget Period: 08/01/2018 – 05/31/2019 Project Period: 07/01/2013 – 05/31/2023

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$621,360 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to THOMAS JEFFERSON UNIVERSITY in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 31 USC 6305 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health under Award Number UG1HD076457. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website http://grants.nih.gov/grants/policy/coi/ for a link to the regulation and additional important

<u>http://grants.nih.gov/grants/policy/coi/</u> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Kimberly Durkin Grants Management Officer EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT

Additional information follows

SECTION 1 - AWARD DATA - 200 1100/045/-00	
Award Calculation (U.S. Dollars)	
Salaries and Wages	\$36,764
Fringe Benefits	\$8,750
Personnel Costs (Subtotal)	\$45,514
Consultant Services	\$27,524
Travel	\$9,830
Other	\$403,030
Subawards/Consortium/Contractual Costs	\$75,056
Federal Direct Costs	\$560,954
Federal F&A Costs	\$60,406
Approved Budget	\$621,360
Total Amount of Federal Funds Obligated (Federal Share)	\$621,360
TOTAL FEDERAL AWARD AMOUNT	\$621,360
AMOUNT OF THIS ACTION (FEDERAL SHARE)	\$621,360
Amount of this Action (LEELAE CHARE)	ψ021,000

SECTION I - AWARD DATA - 2UG1HD076457-06

SUMMARY TOTALS FOR ALL YEARS					
YR	THIS AWARD	CUMULATIVE TOTALS			
6	\$621,360	\$621,360			
7	\$607,360	\$607,360			
8	\$607,360	\$607,360			
9	\$607,360	\$607,360			
10	\$607,360	\$607,360			

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

CFDA Name:	Child Health and Human Development Extramural Research
CFDA Number:	93.865
EIN:	1231352651A1
Document Number:	UHD076457C
PMS Account Type:	P (Subaccount)
Fiscal Year:	2018

IC	CAN	2018	2019	2020	2021	2022
HD	8014707	\$621,360	\$607,360	\$607,360	\$607,360	\$607,360

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:

PCC: PPB -TR / OC: 414M / Released: SHAWK00 07/30/2018 Award Processed: 08/01/2018 12:17:21 AM

SECTION II - PAYMENT/HOTLINE INFORMATION - 2UG1HD076457-06

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm

SECTION III – TERMS AND CONDITIONS – 2UG1HD076457-06

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.
- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.

- c. 45 CFR Part 75.
- d. National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
- f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm for certain references cited above.)

Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

Carry over of an unobligated balance into the next budget period requires Grants Management Officer prior approval.

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See

http://grants.nih.gov/grants/policy/awardconditions.htm for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) UG1HD076457. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see http://grants.nih.gov/grants/policy/awardconditions.htm for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <u>http://publicaccess.nih.gov/</u>.

This award provides support for one or more clinical trials. By law (Title VIII, Section 801 of <u>Public</u> <u>Law 110-85</u>), the "responsible party" must register "applicable clinical trials" on the <u>ClinicalTrials.gov Protocol Registration System Information Website</u>. NIH encourages registration of all trials whether required under the law or not. For more information, see <u>http://grants.nih.gov/ClinicalTrials_fdaaa/</u>

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements

SECTION IV – HD Special Terms and Conditions – 2UG1HD076457-06

Clinical Trial Indicator: Yes This award supports one or more NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

TOTAL COSTS

This award is funded at a total cost ceiling of \$621,360. Funds may be rebudgeted as necessary between direct and facilities and administrative costs consistent with policy and institutional requirements for prior approval; however, no additional funds will be provided.

FUNDING PLAN

This award includes funds for twelve months of support. The competing budget period is awarded for less than 12 months. Continuation awards will cycle on June 1. [NICHD is taking this action to redistribute start dates more evenly throughout the year.] Allowable preaward costs may be charged to this award, in accordance with institutional requirements for prior approval and the conditions outlined in the NIH Grants Policy Statement (rev. 10/17) (http://grants.nih.gov/grants/policy/nihgps/nihgps.pdf).

RESTRICTED PROTOCOL FUNDS

This award includes restricted protocol funds [in the amount of \$403,030], as described in the RFA HD18-009. The restricted protocol funding is included as *Other Expenses*. RUs will be required to complete protocol budgets for those protocols underway in the Network. The annual negotiated protocol budgets will consist of specific protocol-related allowances (protocol costs), which may include funds for study start up (e.g., training expenses to implement the study, and funds for the conduct of the study (which requires IRB approval). Based on participation, compliance, and performance in protocol activities by the network sites, the protocol funds may be reduced and/or redistributed depending on the needs of the Global Network as a whole.

CLINICAL TRIALS

The clinical trial(s) supported by this award are subject to the plan dated 11/24/2017 submitted to NICHD and the NIH policy on Dissemination of NIH-Funded Clinical Trial Information. The policy states that the clinical trial(s) funded by this award will be registered in ClinicalTrials.gov not later than 21 calendar days after enrollment of the first participant and that primary summary results will be reported in ClinicalTrials.gov not later than one year after the completion date. The reporting of summary results is required even if the primary completion date occurs after the period of performance.

This award is subject to additional certification requirements with submission of the Annual, Interim and Final Research Performance Progress Reports (RPPR). The recipient must agree to the following annual certification when submitting each RPPR. By submitting the RPPR, the AOR signifies compliance, as follows:

In submitting this RPPR, the SO (or PD/PI with delegated authority), certifies to the best of his/her knowledge that, for all clinical trials funded under this NIH award, the recipient and all investigators conducting NIH-funded clinical trials are in compliance with the recipient's plan

Page-5

addressing compliance with the NIH Policy on Dissemination of NIH-Funded Clinical Trial Information. Any clinical trial funded in whole or in part under this award has been registered in ClinicalTrials.gov or will be registered not later than 21 calendar days after enrollment of the first participant. Summary results have been submitted to ClinicalTrials.gov or will be submitted not later than one year after the completion date, even if the completion date occurs after the period of performance.

CONSORTIA

This award includes funds awarded for consortium activity with KLE Society's Jawaharlal Nehru Medical College in Karnataka, India .

Consortia are to be established and administered as described in the NIH Grants Policy Statement (rev. 10/17) (<u>http://grants.nih.gov/grants/policy/nihgps/nihgps.pdf</u>).

FOREIGN COMPONENT

This award includes funding [**in the amount of \$** 75,056 **total costs**] for the following sites: KLE Society's Jawaharlal Nehru Medical College in Karnataka, India .

COOPERATIVE AGREEMENTS

This award is issued as a cooperative agreement, a financial assistance mechanism in which substantial NIH scientific and/or programmatic involvement is anticipated in the performance of the activity. This award is subject to the terms and conditions of award as set forth in the SPECIAL REQUIREMENTS section of RFA-HD-HD18-009, "Re-Competition of Global Network for Women's and Children's Health Research (UG1)," posted date July 18, 2017, which are hereby incorporated by reference as special terms and conditions of award.

Copies of this RFA are available at http://www.nih.gov/grants/guide/index.html

These special terms and conditions of award are in addition to, and not in lieu of, otherwise applicable OMB administrative guidelines; Federal Regulations, including HHS Grant Administration Regulations at 45 CFR Part 75; other HHS regulations; and the NIH Grants Policy Statement (rev. 10/17).

Project Scientist Contact Information:

Project Scientist: Marion Koso-Thomas, MD Email: <u>kosomari@mail.nih.gov</u> Phone: 301.435.6873 And Project Scientist: Menachem Miodovnik, MD Email: menachem.miodovnik@nih.gov Phone: 301.451.5031

COMPETING AWARDS

In accordance with the NICHD FY2018 fiscal policy, escalation on recurring costs has been removed.

FUNDING OPPORTUNITY

This award is subject to the requirements indicated in RFA-HD18-009, which are hereby incorporated by reference. Copies of this Funding Opportunity Announcement are available at http://grants.nih.gov/grants/guide/index.html.

Page-6

STAFF CONTACTS

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

Grants Management Specialist: Kimberly Durkin Email: kimberly.durkin@nih.gov Phone: 301-451-0820

Program Official: Tonse N. Raju Email: rajut@mail.nih.gov Phone: (301) 402-1872 Fax: (301) 496-3790

SPREADSHEET SUMMARY GRANT NUMBER: 2UG1HD076457-06

INSTITUTION: THOMAS JEFFERSON UNIVERSITY

Budget	Year 6	Year 7	Year 8	Year 9	Year 10
Salaries and Wages	\$36,764	\$36,764	\$36,764	\$36,764	\$36,764
Fringe Benefits	\$8,750	\$8,750	\$8,750	\$8,750	\$8,750
Personnel Costs (Subtotal)	\$45,514	\$45,514	\$45,514	\$45,514	\$45,514
Consultant Services	\$27,524	\$27,524	\$27,524	\$27,524	\$27,524
Travel	\$9,830	\$9,830	\$9,830	\$9,830	\$9,830
Other	\$403,030	\$403,030	\$403,030	\$403,030	\$403,030
Subawards/Consortium/Contractual	\$75,056	\$75,056	\$75,056	\$75,056	\$75,056
Costs					
TOTAL FEDERAL DC	\$560,954	\$560,954	\$560,954	\$560,954	\$560,954
TOTAL FEDERAL F&A	\$60,406	\$46,406	\$46,406	\$46,406	\$46,406
TOTAL COST	\$621,360	\$607,360	\$607,360	\$607,360	\$607,360

Facilities and Administrative Costs	Year 6	Year 7	Year 8	Year 9	Year 10
F&A Cost Rate 1	56%	56%	56%	56%	56%
F&A Cost Base 1	\$107,868	\$82,868	\$82,868	\$82,868	\$82,868
F&A Costs 1	\$60,406	\$46,406	\$46,406	\$46,406	\$46,406

Notice of Award

Federal Award Date: 08/01/2018



B HUMM SLAVICES . IS

Cooperative Agreement Department of Health and Human Services National Institutes of Health

EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT

 Grant Number:
 2UG1HD076457-06

 FAIN:
 UG1HD076457

Principal Investigator(s): RICHARD J DERMAN, MD

Project Title: TJU-JNMC Global Network for Women's & Children's Health Research Unit

Margaret Burwell Assistant to the Director 125 S. 9th Street Philadelphia, PA 191075125

Award e-mailed to: resadmin@jefferson.edu

Period Of Performance: Budget Period: 08/01/2018 – 05/31/2019 Project Period: 07/01/2013 – 05/31/2023

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$621,360 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to THOMAS JEFFERSON UNIVERSITY in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 31 USC 6305 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health under Award Number UG1HD076457. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website http://grants.nih.gov/grants/policy/coi/ for a link to the regulation and additional important

<u>http://grants.nih.gov/grants/policy/coi/</u> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Kimberly Durkin Grants Management Officer EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT

Additional information follows

SECTION 1 - AWARD DATA - 200 1100/045/-00	
Award Calculation (U.S. Dollars)	
Salaries and Wages	\$36,764
Fringe Benefits	\$8,750
Personnel Costs (Subtotal)	\$45,514
Consultant Services	\$27,524
Travel	\$9,830
Other	\$403,030
Subawards/Consortium/Contractual Costs	\$75,056
Federal Direct Costs	\$560,954
Federal F&A Costs	\$60,406
Approved Budget	\$621,360
Total Amount of Federal Funds Obligated (Federal Share)	\$621,360
TOTAL FEDERAL AWARD AMOUNT	\$621,360
AMOUNT OF THIS ACTION (FEDERAL SHARE)	\$621,360
Amount of this Action (LEELAE CHARE)	ψ021,000

SECTION I - AWARD DATA - 2UG1HD076457-06

SUMMARY TOTALS FOR ALL YEARS			
YR THIS AWARD CUMULATIVE TOTALS			
6	\$621,360	\$621,360	
7	\$607,360	\$607,360	
8	\$607,360	\$607,360	
9	\$607,360	\$607,360	
10	\$607,360	\$607,360	

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

CFDA Name:	Child Health and Human Development Extramural Research
CFDA Number:	93.865
EIN:	1231352651A1
Document Number:	UHD076457C
PMS Account Type:	P (Subaccount)
Fiscal Year:	2018

IC	CAN	2018	2019	2020	2021	2022
HD	8014707	\$621,360	\$607,360	\$607,360	\$607,360	\$607,360

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:

PCC: PPB -TR / OC: 414M / Released: SHAWK00 07/30/2018 Award Processed: 08/01/2018 12:17:21 AM

SECTION II - PAYMENT/HOTLINE INFORMATION - 2UG1HD076457-06

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm

SECTION III – TERMS AND CONDITIONS – 2UG1HD076457-06

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.
- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.

- c. 45 CFR Part 75.
- d. National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
- f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm for certain references cited above.)

Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

Carry over of an unobligated balance into the next budget period requires Grants Management Officer prior approval.

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See

http://grants.nih.gov/grants/policy/awardconditions.htm for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) UG1HD076457. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see http://grants.nih.gov/grants/policy/awardconditions.htm for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <u>http://publicaccess.nih.gov/</u>.

This award provides support for one or more clinical trials. By law (Title VIII, Section 801 of <u>Public</u> <u>Law 110-85</u>), the "responsible party" must register "applicable clinical trials" on the <u>ClinicalTrials.gov Protocol Registration System Information Website</u>. NIH encourages registration of all trials whether required under the law or not. For more information, see <u>http://grants.nih.gov/ClinicalTrials_fdaaa/</u>

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements

SECTION IV – HD Special Terms and Conditions – 2UG1HD076457-06

Clinical Trial Indicator: Yes This award supports one or more NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

TOTAL COSTS

This award is funded at a total cost ceiling of \$621,360. Funds may be rebudgeted as necessary between direct and facilities and administrative costs consistent with policy and institutional requirements for prior approval; however, no additional funds will be provided.

FUNDING PLAN

This award includes funds for twelve months of support. The competing budget period is awarded for less than 12 months. Continuation awards will cycle on June 1. [NICHD is taking this action to redistribute start dates more evenly throughout the year.] Allowable preaward costs may be charged to this award, in accordance with institutional requirements for prior approval and the conditions outlined in the NIH Grants Policy Statement (rev. 10/17) (http://grants.nih.gov/grants/policy/nihgps/nihgps.pdf).

RESTRICTED PROTOCOL FUNDS

This award includes restricted protocol funds [in the amount of \$403,030], as described in the RFA HD18-009. The restricted protocol funding is included as *Other Expenses*. RUs will be required to complete protocol budgets for those protocols underway in the Network. The annual negotiated protocol budgets will consist of specific protocol-related allowances (protocol costs), which may include funds for study start up (e.g., training expenses to implement the study, and funds for the conduct of the study (which requires IRB approval). Based on participation, compliance, and performance in protocol activities by the network sites, the protocol funds may be reduced and/or redistributed depending on the needs of the Global Network as a whole.

CLINICAL TRIALS

The clinical trial(s) supported by this award are subject to the plan dated 11/24/2017 submitted to NICHD and the NIH policy on Dissemination of NIH-Funded Clinical Trial Information. The policy states that the clinical trial(s) funded by this award will be registered in ClinicalTrials.gov not later than 21 calendar days after enrollment of the first participant and that primary summary results will be reported in ClinicalTrials.gov not later than one year after the completion date. The reporting of summary results is required even if the primary completion date occurs after the period of performance.

This award is subject to additional certification requirements with submission of the Annual, Interim and Final Research Performance Progress Reports (RPPR). The recipient must agree to the following annual certification when submitting each RPPR. By submitting the RPPR, the AOR signifies compliance, as follows:

In submitting this RPPR, the SO (or PD/PI with delegated authority), certifies to the best of his/her knowledge that, for all clinical trials funded under this NIH award, the recipient and all investigators conducting NIH-funded clinical trials are in compliance with the recipient's plan

Page-5

addressing compliance with the NIH Policy on Dissemination of NIH-Funded Clinical Trial Information. Any clinical trial funded in whole or in part under this award has been registered in ClinicalTrials.gov or will be registered not later than 21 calendar days after enrollment of the first participant. Summary results have been submitted to ClinicalTrials.gov or will be submitted not later than one year after the completion date, even if the completion date occurs after the period of performance.

CONSORTIA

This award includes funds awarded for consortium activity with KLE Society's Jawaharlal Nehru Medical College in Karnataka, India .

Consortia are to be established and administered as described in the NIH Grants Policy Statement (rev. 10/17) (<u>http://grants.nih.gov/grants/policy/nihgps/nihgps.pdf</u>).

FOREIGN COMPONENT

This award includes funding [**in the amount of \$** 75,056 **total costs**] for the following sites: KLE Society's Jawaharlal Nehru Medical College in Karnataka, India .

COOPERATIVE AGREEMENTS

This award is issued as a cooperative agreement, a financial assistance mechanism in which substantial NIH scientific and/or programmatic involvement is anticipated in the performance of the activity. This award is subject to the terms and conditions of award as set forth in the SPECIAL REQUIREMENTS section of RFA-HD-HD18-009, "Re-Competition of Global Network for Women's and Children's Health Research (UG1)," posted date July 18, 2017, which are hereby incorporated by reference as special terms and conditions of award.

Copies of this RFA are available at http://www.nih.gov/grants/guide/index.html

These special terms and conditions of award are in addition to, and not in lieu of, otherwise applicable OMB administrative guidelines; Federal Regulations, including HHS Grant Administration Regulations at 45 CFR Part 75; other HHS regulations; and the NIH Grants Policy Statement (rev. 10/17).

Project Scientist Contact Information:

Project Scientist: Marion Koso-Thomas, MD Email: <u>kosomari@mail.nih.gov</u> Phone: 301.435.6873 And Project Scientist: Menachem Miodovnik, MD Email: menachem.miodovnik@nih.gov Phone: 301.451.5031

COMPETING AWARDS

In accordance with the NICHD FY2018 fiscal policy, escalation on recurring costs has been removed.

FUNDING OPPORTUNITY

This award is subject to the requirements indicated in RFA-HD18-009, which are hereby incorporated by reference. Copies of this Funding Opportunity Announcement are available at http://grants.nih.gov/grants/guide/index.html.

Page-6

STAFF CONTACTS

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

Grants Management Specialist: Kimberly Durkin Email: kimberly.durkin@nih.gov Phone: 301-451-0820

Program Official: Tonse N. Raju Email: rajut@mail.nih.gov Phone: (301) 402-1872 Fax: (301) 496-3790

SPREADSHEET SUMMARY GRANT NUMBER: 2UG1HD076457-06

INSTITUTION: THOMAS JEFFERSON UNIVERSITY

Budget	Year 6	Year 7	Year 8	Year 9	Year 10
Salaries and Wages	\$36,764	\$36,764	\$36,764	\$36,764	\$36,764
Fringe Benefits	\$8,750	\$8,750	\$8,750	\$8,750	\$8,750
Personnel Costs (Subtotal)	\$45,514	\$45,514	\$45,514	\$45,514	\$45,514
Consultant Services	\$27,524	\$27,524	\$27,524	\$27,524	\$27,524
Travel	\$9,830	\$9,830	\$9,830	\$9,830	\$9,830
Other	\$403,030	\$403,030	\$403,030	\$403,030	\$403,030
Subawards/Consortium/Contractual	\$75,056	\$75,056	\$75,056	\$75,056	\$75,056
Costs					
TOTAL FEDERAL DC	\$560,954	\$560,954	\$560,954	\$560,954	\$560,954
TOTAL FEDERAL F&A	\$60,406	\$46,406	\$46,406	\$46,406	\$46,406
TOTAL COST	\$621,360	\$607,360	\$607,360	\$607,360	\$607,360

Facilities and Administrative Costs	Year 6	Year 7	Year 8	Year 9	Year 10
F&A Cost Rate 1	56%	56%	56%	56%	56%
F&A Cost Base 1	\$107,868	\$82,868	\$82,868	\$82,868	\$82,868
F&A Costs 1	\$60,406	\$46,406	\$46,406	\$46,406	\$46,406

File No. M.12021/04/2021-Hep(NPSVH) Ministry of Health and Family Welfare Directorate General of Health Services National Centre for Disease Control National Program for Surveillance of Viral Hepatitis

Dated: 14.09.2021

To Dr. M.B. Nafounde The Nodal Officers Department of Microbiology JNIMC. Belgaum.

* Sub: Orientation Workshop on National Program for Surveillance of Viral Hepatitis

Dear Ma'am/Sir

National Program on Surveillance of Viral Hepatitis, a central sector program under the aegis of National Centre for Disease Control is carrying out Surveillance of viral hepatitis in the country. Currently, laboratories of Department of Microbiology from fifteen medical colleges/institutions from across the country are already a part of the surveillance network. The program is now in the phase of expansion and it is planned to include fifteen more laboratories in the existing network for carrying out the activities planned under the program.

An orientation workshop on National Program on Surveillance of Viral Hepatitis is being convened from 2:30-5:00PM on 16th September 2021 through a virtual platform to sensitise the concerned laboratories on the program and the activities being carried out under the program and the areas of strengthening of the concerned laboratories along with pattern of

It is requested to kindly to make it convenient to attend the meeting.

812hu 1418/21

Dr. Sandhya Kabra Deputy Commissioner NVHCP & Additional Director & Head Surveillance of Viral Hepatitis

Copy to:

- 1. Principal/Dean of concerned Medical College

distriction

2. Head of Department of Microbiology of concerned medical College

3. PS to Director, NCDC, 22-Shamnath Marg, Civil Lines, Delhi-54

LEGE LAWAHARLAL NEHRU MEDU RELAGAVI-590010

Funded project- Karnataka State AIDS Prevention Society

(STUNMERT)
and the second sec
Department of Health & Family Welfare
KARNATAKA STATE AIDS PREVENTION SOCIETY
2 nd Floor, Sir. C. V. Raman Hospital, 80 feet Road, Indiranagar, Bengaluru -560 038.
No. : KSAPS/Lab service/Viral Load/02/2017-18 Date: 27.04.2017
То
The Director/Principal/District Surgeon,
Medical Institute/Medical College/District Hospital,
Karnataka.
Dear Sir/Madam,
Sub: Scaling up Viral Load testing in the National HIV Programme at
Karnataka State for the FY: 2017-18

With reference to the above subject, I am please to inform you that NACO has
planned to procure Viral Load Machine and all other necessary equipment related to
the viral load testing and also providing Rs.10, 00,000/- for renovation work. Hence
requested to prepare budget in the prescribed attachment and make sure that your
institute to be ready before setting up the laboratory.
Thanking you,
Yours faithfully,
Project Director,
Or KSAPS, Bengaluru.
Copy to:
1, Additional Project Director, KSAPS, Bengaluru.
2. Joint Director (CST), KSAPS, Bengaluru.
3. Director, NIMHANS, Bengaluru.
4. Director, JSS MC, Mysuru.
5. Director, VIIMS, Bellari.
6. Director, BMCRI, Bengaluru.
7. Principal, BLDEMC, Vijayapura. 8. Director, KIMS, Huballi.
9. Director, JNMC, Belgavi. 10. District Surgeon, District Hospital, Kalburgi.
11. District Surgeon, District Hospital, Shivmogga.
12. NRL/SRL, In -Charge's (NIMHANS, JSS, JNMC, KIMS, BLDEMC, VIMS, BMCR)
13. Regional Coordinator, KSAPS, Bengaluru.
14. Quality Manager (Lab Services) KSAPS, Bengaluru.
15. Office Copy

S-12015/01/2008-NACO (LS) Government of India Ministry of Health & Family Welfare National AIDS Control Organisation

> 9th Floor, Chandralok Building 36 Janpath, New Delhi-110001 5th April, 2017

The Head Department of Microbiology JN Medical College, Belagavi, Karnataka

Subject: Nomination of SRL status to laboratory for External Quality Assurance Scheme of NACO.

Reference: Letter No. T-11013/08/2006- NACO (R&D) dated 2nd July, 2007.

Sir/Madam,

То

It is informed that "Department of Microbiology, JN Medical College, Belagavi, Karnataka" has been nominated as State Reference Laboratory for External Quality Assurance Scheme of NACO vide letter No. T-11013/08/2006-NACO dated 2nd July, 2007.

For this State Reference Laboratory, the referral laboratory is "National Institute of Mental Health and Neuro Sciences" (National Reference Laboratory).

Yours faithfully,

ters of m (Dr. Naresh Goel) DDG (Lab Services)

Copy to

The Project Director, Karnataka State AIDS Preventive Society, Karnataka.
 The Dean/Principal, JN Medical College, Belagavi, Karnataka.

the.

3. Dr. V. Ravi, Department of Neurovirology, NIMHANS, Bangalore.

S-12015/01/2008-NACO (LS) Government of India Ministry of Health & Family Welfare National AIDS Control Organisation

> 9th Floor, Chandralok Building 36 Janpath, New Delhi-110001 5th April, 2017

The Head Department of Microbiology JN Medical College, Belagavi, Karnataka

Subject: Nomination of SRL status to laboratory for External Quality Assurance Scheme of NACO.

Reference: Letter No. T-11013/08/2006- NACO (R&D) dated 2nd July, 2007.

Sir/Madam,

То

It is informed that "Department of Microbiology, JN Medical College, Belagavi, Karnataka" has been nominated as State Reference Laboratory for External Quality Assurance Scheme of NACO vide letter No. T-11013/08/2006-NACO dated 2nd July, 2007.

For this State Reference Laboratory, the referral laboratory is "National Institute of Mental Health and Neuro Sciences" (National Reference Laboratory).

Yours faithfully,

ters of m (Dr. Naresh Goel) DDG (Lab Services)

Copy to

The Project Director, Karnataka State AIDS Preventive Society, Karnataka.
 The Dean/Principal, JN Medical College, Belagavi, Karnataka.

the.

3. Dr. V. Ravi, Department of Neurovirology, NIMHANS, Bangalore.

Science and Engineering Research Board

(Statutory Body Established Through an Act of Parliament : SERB Act 2008) Department of Science and Technology, Government of India

SCIENCE & ENGINEERING RESEARCH BOARD (SERB)

(Statutory Body Established Through an Act of Parliament : SERB Act 2008)

Science and Engineering Research Board 3rd & 4th Floor, Block II Technology Bhavan, New Mehrauli Road New Delhi - 110016

Approval Letter

File Number: CRG/2022/003365

Dated: 25-Oct-2022

Subject: Project titled "Development of multi-markers-based electronic kit for the rapid and accurate detection of prostate cancer through urine samples".

Dear Dr. Ruma Ghosh,

The project cited above has been recommended by the related **Core Research Grant** to the Science and Engineering Research Board (SERB) for funding. The following are the items recommended for a period of 3 years. The final budget to be sanctioned would be based on quotations received, existing norms, funds availability etc.

The committee recommended the following budget

Manpower:

-> Research Associate-I - 1 Equipment Details : Rs. 750000 -> Low temperature Centrifuge - 1 -> Data Acquisition unit - 1 -> Regulated Power Supply - 1 Consumables : Rs. 2400000 Travel Cost : As per norms Contingencies : As per norms Overhead : As per norms

You need to accept the above budgetary allocation before proceeding further. To accept the budgetary recommendations, you may follow the following steps :

1. Go to www.serbonline.in through your credentials

- 2. Go to Menu --> Proposal submission --> View submitted proposals
- 3. Click on the link under Status column "Proposal Approved, Acknowledgment pending from PI"

You are requested to upload the following documents of the approved budget strictly within one week from the date of this letter.

- 1. Upload the lowest quotation for equipment/s (including freight, insurance, customs charges etc., if any).
- 2. Salary structure for the project staff (including HRA, Medical Benefits, if applicable etc.).
- 3. A certificate stating that any visit abroad for a period more than eight weeks would be undertaken after due permission from SERB, may also be submitted.
- 4. RTGS details of the implementing institute to facilitate transfer of the fund as per the template.

AM

5. Any other documents (as detailed bellow specific the programme concerned).

ERB has adopted the Scientific Social Responsibility (SSR) Policy which mandates SERB Grantees to Indertake some SSR activities during their project period. You are requested to read the SSR guidelines available under SSR menu and choose the activities according to your preference. Depending on the activity chosen, additional budget would be provided under separate head to carry out the chosen activities. Please note that choosing the SSR activities is mandatory for issue of financial sanction subject to submission and acceptance of other necessary documents

Kindly upload the documents related viz., animal ethical clearance certificate, institutional bio safety clearance certificate, etc., matching with exact approved title of project submitted to SERB.

If the project does not require (viz., animal ethical clearance certificate, institutional bio safety clearance certificate, etc.,) please confirm with a self-certification saying that it does not involve any animal/human studies or genetic modification in any organisms or bio safety issues.

(Kindly note that during the issue of sanction order or during the implementation of this project, if SERB come across/found that the project work involves/requires animal/human studies or genetic modification in any organisms or bio safety issues, RCGM approval/ approval from Biodiversity Management Committee Environmental clearance, the project may be terminated without any notice.)

Please note that release of grant is subject to availability of funds under the scheme. Kindly quote the reference number in all future correspondence. The project's reference no. CRG/2022/003365 may also be mentioned in all research communications arising from the above project.

Yours sincerely,

(Dr. Anima Johari)

Scientist D

Email: anima.johari@serb.gov.in

Dr. Ruma Ghosh

Electrical Engineering

Indian Institute Of Technology, Dharwad, Walmi Campus, Belur Industrial Area, Near High Court, Pb Road, Dharwad, Karnataka-580011

Please do not reply to this mail !!

[SERB is now on Social-Media. Kindly follow us on Twitter: @serbonline https://www.twitter.com/serbonline]

This is a system generated information and does not require any signature. This E-Mail may contain Confidential and/or legally privileged Information and is meant for the intendedrecipient(s) only. If you have received this e-mail in error and are not the intended recipient/s, kindly notify us at info@serbonline.in and then delete this e-mail immediately from your system. Any unauthorized review, use, disclosure, dissemination, forwarding, printing or copying of this email or any action taken in reliance on this e-mail is strictly prohibited and may be unlawful. Internet communications cannot be guaranteed to be timely, secure, error or virus-free. The sender does not accept any liability for any errors, omissions, viruses or computer problems experienced by any recipient as a result of this e-mail.

'SAVE PAPER - THINK BEFORE YOU PRINT!'

* Donï¿1/2t want to receive such notification anymore?Click here to send a mail to unsubscribe

https://mail.google.com/mail/u/0/#inbox/EMfcgzGrbRXpmgitpHfrPbPgsRRRzROf





भारतीय आयुर्विज्ञान अनुसंधान परिषद स्वास्थ्य अनुसंधान विभाग, स्वास्थ्य एवं परिवार कल्याण मंत्रालय, भारत खरकार

Indian Council of Medical Research

Department of Health Research, Ministry of Health and Family Welfare, Government of India

Dated:- 08.02.2023

No. NER/62/(6)/2018 -ECD-I

Principal

To.

Jawaharlal Nehru Medical College, K.L.E. University, Belgaum – 590 010 Karnataka

Multicentric Project entitled, "Human pulmonary paragonimiasis in crab eating communities and smear negative suspected TB cases from some states of India".

Sir,

Sub:

This has reference to the above mentioned project which was sanctioned by ICMR for duration of 3 years and further extended for one year w.e.f. 16.10.2018 to 15.10.2022, in which your Institute is one of the participating study site.

In this regard, it is to kindly inform you that the Competent Authority of ICMR has accorded his approval to grant further extension of 11 months (5th year) w.e.f. 16.10.2022 to 15.09.2023 with budget allocation of Rs. 12,00,000/- (Rupees twelve lakh only) to your study site. This budget will be released by ICMR from the total unspent balance left in the project i.e., Rs. 16,02,592/- which has been recently received by ICMR. After completion of the extended period of 11 months (on 15/09/2023) it is requested to kindly submit the Final Report & final UC & SoE to ICMR, immediately.

The detailed break-up of budget for your Institute/Centre for the extended period is enclosed herewith.

The Poincip.D. minc fro 10

Thanking you.

Yours faithfully.

(Harjeet Kaur Bajaj) Administrative Officer

Accounts Section, ICMR

Levor to pu

- Copy to: Dr. Mahantesh B. Nagamoti, Professor, Dept. of Microbiology, Jawaharlal Nehru Medical College,
- K.L.E. University, Belgaum 590 010, Karnataka.
- 2. Mrs. Vandana, TO, ECD, ICMR Hqrs., New Delhi.

वी, संमलियस्वामी भवन, पोस्ट बीवरा में 491) अंसरी नगर, नई दिल्ली - 110,029, भारत V Ramaingaswami Bhayan, PO, Box No, 491), Ansar Nasag, Nov Dein - 110,029, India 1e); +9)+11-265888995 / 26589890 / 26589/94 +91-11-26589336 / 26588707 Fax +91-11-26588662 | icminic.in

BUDGET BREAK-UP

Period 16.10.2022 to 15.09.2023 (11 months)

The budget of the project entitled, "Human pulmonary paragonimiasis in crab eating communities and smear negative suspected TB cases from some states of India" under Dr. Mahantesh B. Nagamoti, Professor, Dept. of Microbiology, Jawaharlal Nehru Medical College, K.L.E. University, Belgaum, Karnataka, has been prepared as under:-

Sh 100 Budget Head Grant Total (I A Staff (Salary) 5th Year (11 Mont i: Project Technical Officer-1 @ 32,000/- PM 3,52,00 ii. Field investigator:1 @ 31,000/- PM 3,41,00 iii. Project Technician-III-1 @ 18,000/- PM 1,98,00 III. Project Technician-III-1 @ 18,000/- PM 1,98,00 B Travel 2,00,00	Proposed Budget for Karnataka (JNMC Belagavi)		
A Staff (Salary) 5th Year (11 Mont I. Project Technical Officer-1 @ 32,000/- PM 3,52,00 ii. Field investigator-1 @ 31,000/- PM 3,41,00 iii. Project Technician-III-1 @ 18,000/- PM 1,98,00 III. Project Technician-III-1 @ 18,000/- PM 1,98,00 B Travel 8,91,00 C Contingency Consumable Min. Min. P 2,00,00	Sl. No	Budget Head	Grant Total (Re)
ii. Field investigator: 1 @ 31,000/- PM 3,52,00 iii. Project Technician-III-1 @ 18,000/- PM 3,41,00 iii. Project Technician-III-1 @ 18,000/- PM 1,98,00 B Travel 8,91,00 C Contingency Consumable Min. N 2,00,00		Staff (Salary)	
iii. Project Technician-III-1 @ 18,000/- PM 3,41,00 B Travel 8,91,00 C Contingency Consumable Minute 2,00,00		Project Technical Officer-1 @ 32,000/- PM	3,52,000/-
Total 8,91,00 B Travel. C Contingency Consumable Minute	a 📖 🖉 🛞 (a. 1/	Preid investigator 1 @ 31,000/- PM	3,41,000/-
B Travel 8,91,00 Contingency Consumable March 2,00,00		Project Technician-III-1 @ 18,000/- PM	1,98,000/-
Contingency Consumable Mi II 2,00,00	D	The second	8,91,000/-
	A		2,00,000/-
D Uver Head (3%)	D	Over Head (3%)	1,00,000/-
Total $(A+B+C+D)$ 9,00			9,000/- 12,00,000/-

Rs. 12,00,000/- (Rupees twelve lakh only)

ECD/NER/4/2018-19, date; 13/08/2018

T

Received Content

(Harjeet Kaur Bajaj) Administrative Officer

mcipal Jawahara Nehru Medical College BELAGAVI



Dr. V.A.Kothiwale Registrar

(Deemed-to-be-University u/s 3 of the UGC Act, 1956) Belagavi,590,010 Karnetek



भारतीय आयुर्विज्ञान अनुराधान परिषद रवास्थ्य अनुसंधान विभाग रवास्थ्य एवं परिवार कत्साण मंत्रालय, भारत सरकार

Indian Council of Medical Research Department of Health Research, Ministry of Health and Family Welfare, Government of India

Dated : 08.02.2023

File no. NER/62/(6)/2018 -ECD-1

Subject: - Payment of 1st & final installment of 5th year project entitled "Human pulmonary paragonimiasis in crab eating communities and smear negative suspected TB cases from some states of India" under Dr. Mahantesh B. Nagamoti, Professor, Dept. of Microbiology, Jawaharlal Nehru Medical College, K.L.E. University, Belgaum, Karnataka.

MEMORANDUM

Reference this office letter No. NER/62/(6)/2018 -ECD-1

Dated ----

The Director-General, ICMR sanctions the payment Rs. 12,00,000/- (Rupees twelve lakh only) as the 1st & final installment of 5th year of the grant for incurring expenditure in connection with the above mentioned research scheme. The amount of Rs. 12,00,000/- may be debited in the provision of Rs. 12,00,000/-made for the above mentioned research scheme for the current financial year.

A formal bill for Rs. 12,00,000/- is sent herewith for payment by cheque/ demand draft to the Principal, Jawaharlal Nehru Medical College, Belgaum, Karnataka.

(Harjeet Kaur Bajaj) Administrative Officer

Accounts Section, ICMR

¥ 333

2 2 2

- 1. Principal, Jawaharlal Nehru Medical College, K.L.E. University, Belgaum 590 010, Copy to: -Karnataka.
- Dr. Harpreet Kaur, Scientist-F, Indian Council of Medical Research, Ansari Nagar, New Delhi.
- Dr. Mahantesh B. Nagamoti, Professor, Dept. of Microbiology, Jawaharlal Nchru Medical 2.
- 3. College, K.L.E. University, Belgaum - 590 010, Karnataka.
- Technical Officer, (ECD), ICMR. 4.

for Director General

वी, रामलिंगरवामी भवन, गोस्ट बीवस स. 491, अलारी जनुर, मई दिल्ली -110 029, भारत V Ratialing-swam Bhawan, P.O. Box No. 4911, Antari Negar, New Dahi - 110 029. India

Tel: +91-11-26568895 / 26588980 / 26589794 + 31-11-26589336 / 26588707 Fax: +91-11-26588562 | icmrnicIn



Pushkar Pathak Systems Analyst RP Division Incharge Tel #011-26716690 E-mail: rpdivision@icssr.org Indian Council of Social Science Research (Ministry of Education) JNU Institutional Area, Aruna Asaf Ali Marg New Delhi – 110067 Website: <u>www.icssr.org</u>

SANCTION ORDER

F.No.02/91/2022-23/ICSSR/RP/MN/SC

Dated: 05-05-2023

The Registrar KLE Academy of Higher Education and Research JNMC Campus, Nehru Nagar, Belgaum -590010 Karnataka

Subject: Sanction of Minor Research Project entitled "Adequacy of treatment and food practices in Diabetes and Hypertension: A Cross-sectional study" to Dr. Jang Bahadur Prasad, Associate Professor, Department of Epidemiology & Biostatistics, KLE Academy of Higher Education and Research, JNMC Campus, Nehru Nagar, Belgaum -590010, Karnataka.

Dear Sir/Madam,

- The Indian Council of Social Science Research (ICSSR) approved the award of "Adequacy of treatment and food practices in Diabetes and Hypertension: A Cross-sectional study" the above Minor Research Project submitted by Dr.Jang Bahadur Prasad along with Dr. Rajeshwari Biradar as Co-Project Director of your Institution.
- 2. The study, as proposed by the researcher, is to be located at and financially administered by your institution as per the guidelines of this award.
- The ICSSR has sanctioned a grant-in-aid of Rs.494000 /- (Rupees Four Lakh Ninty Four Thousand Only) for the above Research Project and the grant will be released as follows:

First instalment (40 % of Instalment)	:Rs. 197600 /-
Second instalment (40 % of Instalment)	:Rs. 197600 /-
Final instalment (15 % of Instalment)	:Rs. 74100/-
Publication Cost (5% of Instalment)	:Rs. 24700/-
Total	:Rs. 494000/-
Overhead charges over and above 5% or maximum Rs.100000	:Rs. 24700/-**

* This is to be retained by the ICSSR. ICSSR would publish it subject to recommendation by the expert and relevant Committees for the purpose, from the overall budget, so to be retained by the ICSSR .

** This amount will be released on successful completion of project after evaluation. (The break-up budget approved by the ICSSR of **Rs.494000 /-** is enclosed.)

4. The **First** installment of the approved grant-in-aid will be released after receiving the grant-in-aid bill duly filled in, stamped and signed by the Project Director as well as the affiliating organization.

Cathat

- 5. In case, the study involves survey research, the finalized schedules/questionnaires (2 copies) designed to elicit information should be sent to the ICSSR as per the following schedule:
 - a) If the schedule /questionnaire for eliciting information is as per standard questionnaire, these will have to be sent to ICSSR immediately,
 - b) If the schedule /questionnaire for eliciting information are to be designed afresh keeping in view the requirements of the project, these will have to be sent to the ICSSR within a period of six months in any case.
- The Second instalment will be released after receiving a satisfactory Six Months progress report along with a Budget statement of account of the account for the first instalment (Depending upon the duration of the Project).
- 7. The Third/Final instalment will be released on the receipt of:
 - (a) Satisfactory book length of the Final Report (Two Hard Copies plus one Soft Copy in CD or Pen-Drive) in the publishable form after incorporating all corrections, suggestions of the expert.
 - (b) Statement of accounts with Utilization Certificate in GFR of 12A form for the entire project amount duly signed by the Finance Officer/Registrar/Principal/Director of the affiliating institution.
 - (c) A certificate of statement of assets and books purchased out of the project fund issued by the affiliating institution
- 8. The scholar shall acknowledge support of ICSSR in all publications resulting from the project output (Research Paper, Books, Articles, Reports, etc.) and should submit a copy of the same to the ICSSR during its course and after completion. Non –Compliance to the condition may lead to action against the Project Director by ICSSR.
- 9. The University/Institution of affiliation will provide to the scholar office accommodation including furniture, library and research facilities and messengerial services. For this, the ICSSR shall pay to the University/Institution of affiliation **Overhead Charges @ 5%** of the total expenditure incurred on the project only after successful completion of the project.
- 10. The Contingency Grant may be utilized for research and office assistance, books, stationary, computer cost, research assistance and the field work expenses of Project Director, Co-Project Directors and research personnel connected with the research work.
- 11. The overhead charges to the affiliating institution over and above @ 5% or maximum Rs.1,00,000 will be released only after successful completion of the project after evaluation. The accounts and the Utilization Certificate will be signed by the Finance Officer/Registrar/Principal/Director in the case of accounts of the institution are audited by CAG/AG. Otherwise, they need to be signed by the Finance Officer and the Chartered Account.
- The Director of the research project will be Dr.Jang Bahadur Prasad, who will be responsible for its completion within 12 Months from the date of commencement of the project, which is 28 March 2023 as intimated by the Project Director.
- 13. In case, the Project Director does not submit the periodic / final project report as per schedule with adequate justification, the researcher may be debarred from availing all future financial assistance and ICSSR may take any necessary action against the Project Director/Affiliating/ Institute as it is deem fit.

14. All grants from ICSSR are subject to the general provision of GFR 2017.

- 15. The Project Director will ensure that the expenditure incurred by him/her conforms to the approved budget heads. The grant-in-aid is subject to all the conditions laid down in the Indian Council of Social Science Research (ICSSR) Research Projects available in the ICSSR website www.icssr.org and other relevant Orders / Guidelines passed by ICSSR time to time.
- 16. The expenditure on this account is debatable to the **Budget Head-ICSSR (Scheme Code 0877); OH** 31.09 Research Projects.
- 17. All project instalments will be transferred through Public Finance Management System (PFMS) and ICSSR shall implement the EAT module for ensuring transparency of expenditure at all levels and to ensure that there is no parking of funds.
- 18. As per MOE instruction, the amount of grant sanctioned herein is to be utilized by **the end of the project duration**. Any amount of the grant remaining unspent shall be refunded to the ICSSR immediately after the expiry of the duration of the project. If the grantee fails to utilize the grant for the purpose for which the same has been sanctioned/or fails to submit the audited statement of expenditure within the stipulated period, the grantee will be required to refund the amount of the grant with interest thereon @ 10% per annum.

Yours faithfully,

(Pushkar Pathak) for MEMBER-SECRETARY

Encl: as above

Copy to:

- 1. Dr.Jang Bahadur Prasad Associate Professor Department of Epidemiology & Biostatistics KLE Academy of Higher Education & Research Belgaum -590010, JNMC Campus, Karnataka
- 2. Dr. Rajeshwari Biradar Assistant Professor Dept. of Epidemiology and Biostatistics KLE Academy of Higher Education and Research, Belgaum – 590010, Karnataka
- 3. Dr. Sudhir H Patil Director Population welfare and Research Foundation, Belgaum– 590010, Karnataka
- 4. Mr. Sanjay Kumar Yadav Senior Tutor Department of Anatomy JN Medical College, Belgaum– 590010, Karnataka
- 5. Finance Branch, ICSSR, New Delhi
- 6. Record file

(Pushkar Pathak) for MEMBER-SECRETARY

PROJECT BUDGET

Adequacy of treatment and food practices in Diabetes and Hypertension: A Cross-sectional study Title:

Dr.Jang Bahadur Prasad By:

S.No	Heads of Expenditure	Value (Rs.)
1	Project Director/Co-PD	
2	Research Staff: Full time/part time/Hired services	Not exceeding 45% of the total budget
3	Field work	Not exceeding 35%
4	Equipment and study material	Not exceeding 10%
5	Contingency	Not exceeding 5%
6	Publication of report	5%*
- <u> </u>	Grand Total	100%
	Institutional Overheads (over and above the total cost of the project)	Affiliating Institutional overheads @ 5% of the approved budget, subject to a maximum upper limit of Rs.1,00,000/-

* The five percent (5%) publication amount will be spent by the ICSSR Publication Division if the Final report is found publishable by an Expert Committee constituted by the ICSSR.

Remuneration and Emoluments of Project Staff

- (a) Project staff could be engaged by the Project Director on a full/ part-time basis during the research work and the duration/consolidated monthly emoluments of their employment may be decided by the project director within the limits of the sanctioned financial allocation and as per the ICSSR rules.
- (b) Research Associate @Rs.20,000/- p.m. (Qualification Post graduate in any social science discipline with minimum 55% marks and NET/SLET/M.Phil/Ph.D).
- (c) Research Assistant @Rs.16,000/- p.m.(Qualification-Ph.D./M.Phil./ Post graduate in social science discipline with minimum 55% marks.
- (d) Field Investigator @ Rs.15,000/- p.m. (not exceeding 6 months) (Qualification- Post graduate in any social science discipline with minimum 55% marks)
- (e) Retrospective payment for work already done is not permissible.

> Re-appropriation: The Project Investigator may with the permission of the Institution, re-appropriate expenditure from one sub-head to another, subject to a maximum of 10% of the particular budget heads. If the study necessitates re-appropriation beyond 10%, it may be done only after the approval of the ICSSR.

> Selection of Research Staff should be done through an advertisement and a selection committee consisting of (1) Project Director; (2) One outside Expert (other than the institute where the project is located); (3) a nominee of the Vice Chancellor/Head of the Institution and (4) Head of the Department)/Dean of relevant faculty duly approved by the competent authority.

> For all field work related expenses of Project Director, Co-Director and project personnel, rules pertaining to affiliating institutes shall be followed.

> All equipment and books purchased out of the project fund shall be the property of the affiliating institutions. On completion of the study, the Project Director shall submit an undertaking in this regard. The ICSSR, however, reserves the right to take charge of equipment and books, if it thinks it fit in a case.

> Purchase of equipment/ assets for the research Project is permissible only if it is originally proposed and approved by the ICSSR and does not exceed the permissible amount.

> The scholar should acknowledge the support of ICSSR in all publications resulting from the research project output (Research Paper, Books, Articles, Reports, etc.) and should submit a copy of the same to the ICSSR during its course and even after completion.

Hathat



HRD/Head/STS-2023/01 Date: 14.08.2023

SHORT-TERM STUDENTSHIP (STS-2023)

Proposal Result

- The final list of students selected for STS-2023 program is displayed below in order of their STS-2023 Reference ID.
 <u>Please note:</u> Always quote your STS Reference ID for any future correspondence emails to ICMR.
- 2. The 'Selected' students as listed in table below for STS-2023 may carry out the proposed research work and prepare the report in any two months *w.e.f.* 17th August, 2023 to 29th December, 2023
- 3. Research should be done after appropriate Institutional Ethics Committee (IEC) approval has been obtained. The ethical clearance letter has to be submitted along with report (IEC approvals should be taken latest by 30th November, 2023. Any IEC letter/approvals taken after 30th November, 2023 will not be considered as the student will not get two months of time for carrying out the work by the deadline given above).
- 4. The online report submission dates will be declared by the ICMR in due course of time.
- 5. The proposal result declared below by the ICMR is final. No further correspondence in the matter will be entertained.

Kindly read the detailed report preparation guidelines and instructions given on the ICMR website

GENERAL ENQUIRIES to be sent through email to <u>stshrd2017@gmail.com</u> or call on extn.no. 306, 369

Final result list of STS-2023 approved proposals in order of reference ID.

S. No.	STS Reference ID
1.	2023-00004
2.	2023-00008
3.	2023-00017
4.	2023-00035
5.	2023-00037
6.	2023-00051

7.	2022 00055
8.	2023-00055
	2023-00057
9.	2023-00071
10.	2023-00077
11.	2023-00082
12.	2023-00090
13.	2023-00106
14.	2023-00125
15.	2023-00131
16.	2023-00134
17.	2023-00146
18.	2023-00149
19.	2023-00155
20.	2023-00156
21.	2023-00173
22.	2023-00175
23.	2023-00192
24.	2023-00199
25.	2023-00204
26.	2023-00209
27.	2023-00213
28.	2023-00220
29.	2023-00221
30.	2023-00225
31.	2023-00230
32.	2023-00231
33.	2023-00236
34.	2023-00239
35.	2023-00240
36.	2023-00243
37.	2023-00246
38.	2023-00257
39.	2023-00280
40.	2023-00284
41.	2023-00289
42.	2023-00330
43.	2023-00331
44.	2023-00341
45.	2023-00342
46.	2023-00342
47.	2023-00365
48.	2023-00367
49.	2023-00406
50.	2023-00406
50.	2023-00411 2023-00421
51.	
52.	2023-00425

53.	2022 00426
54.	2023-00436
55.	2023-00442 2023-00446
56.	2023-00440
57.	2023-00453
58.	
59.	2023-00463
60.	2023-00494
61.	2023-00496
62.	2023-00498
63.	2023-00506
64.	2023-00509
65.	2023-00514
	2023-00523
66.	2023-00524
67.	2023-00527
68.	2023-00530
69.	2023-00538
70.	2023-00542
71.	2023-00546
72.	2023-00553
73.	2023-00564
74.	2023-00584
75.	2023-00585
76.	2023-00603
77.	2023-00608
78.	2023-00625
79.	2023-00643
80.	2023-00649
81.	2023-00665
82.	2023-00667
83.	2023-00679
84.	2023-00696
85.	2023-00700
86.	2023-00706
87.	2023-00714
88.	2023-00730
89.	2023-00735
90.	2023-00736
91.	2023-00742
92.	2023-00712
93.	2023-00752
94.	2023-00752
95.	2023-00768
96.	2023-00708
97.	2023-00800
98.	2023-00807

99.	
	2023-00839
100.	2023-00843
	2023-00866
102.	2023-00874
103.	2023-00890
104.	2023-00904
105.	2023-00917
106.	2023-00919
107.	2023-00940
108.	2023-00958
109.	2023-00967
110.	2023-00969
111.	2023-00970
112.	2023-00990
113.	2023-01001
114.	2023-01024
115.	2023-01034
116.	2023-01035
117.	2023-01040
118.	2023-01053
119.	2023-01055
120.	2023-01059
121.	2023-01070
122.	2023-01085
123.	2023-01131
124.	2023-01145
125.	2023-01148
126.	2023-01149
127.	2023-01159
128.	2023-01167
129.	2023-01172
130.	2023-01180
131.	2023-01188
132.	2023-01196
133.	2023-01208
134.	2023-01217
135.	2023-01228
136.	2023-01252
137.	2023-01273
138.	2023-01274
139.	2023-01277
140.	2023-01288
141.	2023-01291
142.	2023-01302
143.	2023-01314
144.	2023-01321
L I	

145.	2023-01325
146.	2023-01338
147.	2023-01353
148.	2023-01360
149.	2023-01361
150.	2023-01363
151.	2023-01369
152.	2023-01374
153.	2023-01385
154.	2023-01391
155.	2023-01416
156.	2023-01425
157.	2023-01432
158.	2023-01460
159.	2023-01461
160.	2023-01465
161.	2023-01468
162.	2023-01473
163.	2023-01474
164.	2023-01474
165.	2023-01495
166.	2023-01509
167.	2023-01502
168.	2023-01512
169.	2023-01514
170.	2023-01530
171.	2023-01541
172.	2023-01542
173.	2023-01558
174.	2023-01572
175.	2023-01583
176.	2023-01585
177.	2023-01588
178.	2023-01588
179.	2023-01608
180.	2023-01616
181.	2023-01020
182.	2023-01632
183.	2023-01633
184.	2023-01634
185.	2023-01646
185.	
180.	2023-01674
187.	2023-01679
188.	2023-01698
189.	2023-01703
170.	2023-01722

191.	2023-01726
192.	2023-01737
193.	2023-01740
194.	2023-01743
195.	2023-01754
196.	2023-01757
197.	2023-01760
198.	2023-01770
199.	2023-01776
200.	2023-01785
201.	2023-01794
202.	2023-01804
203.	2023-01805
204.	2023-01828
205.	2023-01840
206.	2023-01847
207.	2023-01871
208.	2023-01881
209.	2023-01892
210.	2023-01936
211.	2023-01944
212.	2023-01951
213.	2023-01963
214.	2023-01973
215.	2023-01980
216.	2023-01982
217.	2023-01991
218.	2023-01992
219.	2023-01999
220.	2023-02011
221.	2023-02015
222.	2023-02041
223.	2023-02056
224.	2023-02060
225.	2023-02083
226.	2023-02096
227.	2023-02099
228.	2023-02119
229.	2023-02122
230.	2023-02130
231.	2023-02145
232.	2023-02143
233.	2023-02178
234.	2023-02179
235.	2023-02192
236.	2023-02192
- **	2025-02170

237.	2023-02215
238.	2023-02242
239.	2023-02262
240.	2023-02271
241.	2023-02278
242.	2023-02281
243.	2023-02282
244.	2023-02333
245.	2023-02344
246.	2023-02357
247.	2023-02374
248.	2023-02383
249.	2023-02385
250.	2023-02414
251.	2023-02426
252.	2023-02442
253.	2023-02449
254.	2023-02466
255.	2023-02479
256.	2023-02490
257.	2023-02495
258.	2023-02498
259.	2023-02501
260.	2023-02506
261.	2023-02515
262.	2023-02521
263.	2023-02536
264.	2023-02566
265.	2023-02593
266.	2023-02594
267.	2023-02600
268.	2023-02602
269.	2023-02621
270.	2023-02629
271.	2023-02631
272.	2023-02653
273.	2023-02684
274.	2023-02686
275.	2023-02702
276.	2023-02704
277.	2023-02705
278.	2023-02710
279.	2023-02718
280.	2023-02731
281.	2023-02738
282.	2023-02757
L L	

283.	2023-02767
284.	2023-02768
285.	2023-02783
286.	2023-02791
287.	2023-02802
288.	2023-02808
289.	2023-02817
290.	2023-02833
291.	2023-02835
292.	2023-02837
293.	2023-02838
294.	2023-02867
295.	2023-02879
296.	2023-02880
297.	2023-02881
298.	2023-02882
299.	2023-02888
300.	2023-02911
301.	2023-02923
302.	2023-02928
303.	2023-02929
304.	2023-02931
305.	2023-02934
306.	2023-02950
307.	2023-02977
308.	2023-02992
309.	2023-02999
310.	2023-03012
311.	2023-03013
312.	2023-03059
313.	2023-03081
314.	2023-03082
315.	2023-03088
316.	2023-03107
317.	2023-03110
318.	2023-03125
319.	2023-03142
320.	2023-03146
321.	2023-03153
322.	2023-03154
323.	2023-03157
324.	2023-03161
325.	2023-03185
326.	2023-03198
327.	2023-03204
328.	2023-03218
	2020 00210

329.	2022 02225
330.	2023-03225
331.	2023-03231
332.	2023-03233
	2023-03236
333.	2023-03241
334.	2023-03250
335.	2023-03267
336.	2023-03275
337.	2023-03284
338.	2023-03286
339.	2023-03287
340.	2023-03288
341.	2023-03308
342.	2023-03311
343.	2023-03314
344.	2023-03339
345.	2023-03356
346.	2023-03359
347.	2023-03365
348.	2023-03411
349.	2023-03439
350.	2023-03442
351.	2023-03445
352.	2023-03455
353.	2023-03471
354.	2023-03483
355.	2023-03485
356.	2023-03490
357.	2023-03495
358.	2023-03509
359.	2023-03518
360.	2023-03564
361.	2023-03573
362.	2023-03576
363.	2023-03597
364.	2023-03601
365.	2023-03602
366.	2023-03626
367.	2023-03650
368.	2023-03664
369.	2023-03674
370.	2023-03684
371.	2023-03691
372.	2023-03694
373.	2023-03708
374.	2023-03741
	2023 03171

375.	2023-03745
376.	2023-03749
377.	2023-03759
378.	2023-03779
379.	2023-03787
380.	2023-03807
381.	2023-03825
382.	2023-03851
383.	2023-03854
384.	2023-03864
385.	2023-03873
386.	2023-03906
387.	2023-03916
388.	2023-03920
389.	2023-03941
390.	2023-03957
391.	2023-03959
392.	2023-03964
393.	2023-03974
394.	2023-03979
395.	2023-03981
396.	2023-04006
397.	2023-04007
398.	2023-04009
399.	2023-04010
400.	2023-04015
401.	2023-04021
402.	2023-04027
403.	2023-04031
404.	2023-04034
405.	2023-04037
406.	2023-04053
407.	2023-04057
408.	2023-04062
409.	2023-04066
410.	2023-04068
411.	2023-04078
412.	2023-04086
413.	2023-04089
414.	2023-04094
415.	2023-04100
416.	2023-04112
417.	2023-04117
418.	2023-04127
419.	2023-04129
420.	2023-04141

421.	
	2023-04144
422.	2023-04148
423.	2023-04160
424.	2023-04184
425.	2023-04187
426.	2023-04193
427.	2023-04199
428.	2023-04211
429.	2023-04215
430.	2023-04216
431.	2023-04233
432.	2023-04237
433.	2023-04256
434.	2023-04258
435.	2023-04262
436.	2023-04270
437.	2023-04278
438.	2023-04292
439.	2023-04310
440.	2023-04311
441.	2023-04313
442.	2023-04321
443.	2023-04329
444.	2023-04332
445.	2023-04342
446.	2023-04352
447.	2023-04356
448.	2023-04362
449.	2023-04365
450.	2023-04368
451.	2023-04380
452.	2023-04391
453.	2023-04397
454.	2023-04400
455.	2023-04409
456.	2023-04434
457.	2023-04449
458.	2023-04455
459.	2023-04456
460.	2023-04459
461.	2023-04471
462.	2023-04481
463.	2023-04494
464.	2023-04497
465.	2023-04502
466.	2023-04502
	2023 07301

167	
467.	2023-04514
468.	2023-04516
469.	2023-04517
470.	2023-04526
471.	2023-04530
472.	2023-04531
473.	2023-04538
474.	2023-04539
475.	2023-04542
476.	2023-04549
477.	2023-04555
478.	2023-04566
479.	2023-04574
480.	2023-04581
481.	2023-04585
482.	2023-04589
483.	2023-04595
484.	2023-04600
485.	2023-04601
486.	2023-04605
487.	2023-04610
488.	2023-04635
489.	2023-04639
490.	2023-04666
491.	2023-04692
492.	2023-04706
493.	2023-04709
494.	2023-04722
495.	2023-04724
496.	2023-04734
497.	2023-04740
498.	2023-04750
499.	2023-04765
500.	2023-04774
501.	2023-04779
502.	2023-04809
503.	2023-04811
504.	2023-04814
505.	2023-04816
506.	2023-04841
507.	2023-04848
508.	2023-04852
509.	2023-04890
510.	2023-04902
511.	2023-04902
512.	2023-04910
	2023-04722

513.	2023-04955
514.	2023-04985
515.	2023-05002
516.	2023-05009
517.	2023-05019
518.	2023-05027
519.	2023-05033
520.	2023-05035
521.	2023-05047
522.	2023-05061
523.	2023-05068
524.	2023-05076
525.	2023-05078
526.	2023-05087
527.	2023-05100
528.	2023-05128
529.	2023-05132
530.	2023-05148
531.	2023-05169
532.	2023-05200
533.	2023-05228
534.	2023-05250
535.	2023-05276
536.	2023-05283
537.	2023-05289
538.	2023-05309
539.	2023-05321
540.	2023-05327
541.	2023-05328
542.	2023-05348
543.	2023-05395
544.	2023-05404
545.	2023-05435
546.	2023-05456
547.	2023-05469
548.	2023-05484
549.	2023-05487
550.	2023-05525
551.	2023-05547
552.	2023-05561
553.	2023-05603
554.	2023-05617
555.	2023-05622
556.	2023-05628
557.	2023-05642
558.	2023-05649
L I	

559.	2023-05661
560.	2023-05683
561.	2023-05694
562.	2023-05700
563.	2023-05701
564.	2023-05740
565.	2023-05741
566.	2023-05759
567.	2023-05789
568.	2023-05790
569.	2023-05794
570.	2023-05802
571.	2023-05804
572.	2023-05810
573.	2023-05833
574.	2023-05875
575.	2023-05884
576.	2023-05898
577.	2023-05901
578.	2023-05905
579.	2023-05944
580.	2023-05950
581.	2023-05957
582.	2023-05958
583.	2023-05978
584.	2023-05995
585.	2023-05997
586.	2023-06011
587.	2023-06023
588.	2023-06042
589.	2023-06074
590.	2023-06078
591.	2023-06091
592.	2023-06098
593.	2023-06102
594.	2023-06117
595.	2023-06123
596.	2023-06128
597.	2023-06142
598.	2023-06169
599.	2023-06173
600.	2023-06184
601.	2023-06195
602.	2023-06199
603.	2023-06212
604.	2023-06220
L	

CO5	
605.	2023-06235
606.	2023-06249
607.	2023-06257
608.	2023-06262
609.	2023-06277
610.	2023-06281
611.	2023-06290
612.	2023-06323
613.	2023-06336
614.	2023-06356
615.	2023-06392
616.	2023-06406
617.	2023-06414
618.	2023-06419
619.	2023-06443
620.	2023-06447
621.	2023-06469
622.	2023-06488
623.	2023-06492
624.	2023-06494
625.	2023-06537
626.	2023-06538
627.	2023-06577
628.	2023-06578
629.	2023-06587
630.	2023-06594
631.	2023-06596
632.	2023-06606
633.	2023-06608
634.	2023-06609
635.	2023-06610
636.	2023-06618
637.	2023-06623
638.	2023-06625
639.	2023-06626
640.	2023-06633
641.	2023-06634
642.	2023-06034
643.	2023-06648
644.	2023-06655
645.	
646.	2023-06663
647.	2023-06674
648.	2023-06679
649.	2023-06681
650.	2023-06684
0.50.	2023-06686

651.	2023-06688
652.	2023-06710
653.	2023-06721
654.	2023-06727
655.	2023-06734
656.	2023-06736
657.	2023-06746
658.	2023-06772
659.	2023-06791
660.	2023-06801
661.	2023-06807
662.	2023-06824
663.	2023-06825
664.	2023-06866
665.	2023-06873
666.	2023-06875
667.	2023-06879
668.	2023-06887
669.	2023-06901
670.	2023-06922
671.	2023-06928
672.	2023-06944
673.	2023-06945
674.	2023-06958
675.	2023-06966
676.	2023-06986
677.	2023-06990
678.	2023-07008
679.	2023-07010
680.	2023-07035
681.	2023-07040
682.	2023-07068
683.	2023-07080
684.	2023-07104
685.	2023-07134
686.	2023-07140
687.	2023-07141
688.	2023-07152
689.	2023-07158
690.	2023-07160
691.	2023-07185
692.	2023-07186
693.	2023-07187
694.	2023-07190
695.	2023-07197
696.	2023-07202
<u> </u>	

697.	2023-07215
698.	2023-07255
699.	2023-07258
700.	2023-07265
701.	2023-07284
702.	2023-07289
703.	2023-07294
704.	2023-07295
705.	2023-07319
706.	2023-07332
707.	2023-07339
708.	2023-07345
709.	2023-07346
710.	2023-07353
711.	2023-07356
712.	2023-07360
713.	2023-07361
714.	2023-07369
715.	2023-07370
716.	2023-07378
717.	2023-07396
718.	2023-07406
719.	2023-07423
720.	2023-07427
721.	2023-07430
722.	2023-07446
723.	2023-07450
724.	2023-07460
725.	2023-07461
726.	2023-07480
727.	2023-07482
728.	2023-07496
729.	2023-07498
730.	2023-07499
731.	2023-07501
732.	2023-07503
733.	2023-07513
734.	2023-07516
735.	2023-07519
736.	2023-07523
737.	2023-07534
738.	2023-07535
739.	2023-07539
740.	2023-07543
741.	2023-07545
742.	2023-07547

742	
743.	2023-07565
744.	2023-07580
745.	2023-07583
746.	2023-07594
747.	2023-07595
748.	2023-07607
749.	2023-07621
750.	2023-07634
751.	2023-07637
752.	2023-07644
753.	2023-07652
754.	2023-07653
755.	2023-07684
756.	2023-07689
757.	2023-07691
758.	2023-07694
759.	2023-07696
760.	2023-07707
761.	2023-07708
762.	2023-07720
763.	2023-07722
764.	2023-07726
765.	2023-07744
766.	2023-07764
767.	2023-07773
768.	2023-07780
769.	2023-07785
770.	2023-07787
771.	2023-07796
772.	2023-07798
773.	2023-07803
774.	2023-07804
775.	2023-07805
776.	2023-07806
777.	2023-07813
778.	2023-07817
779.	2023-07824
780.	2023-07828
781.	2023-07830
782.	2023-07833
783.	2023-07839
784.	2023-07840
785.	2023-07842
786.	2023-07845
787.	2023-07849
788.	2023-07852
L I	

789.	2023-07858
790.	2023-07865
791.	2023-07874
792.	2023-07876
793.	2023-07898
794.	2023-07907
795.	2023-07908
796.	2023-07921
797.	2023-07925
798.	2023-07926
799.	2023-07934
800.	2023-07935
801.	2023-07973
802.	2023-07986
803.	2023-07989
804.	2023-07990
805.	2023-07996
806.	2023-07998
807.	2023-08000
808.	2023-08008
809.	2023-08016
810.	2023-08035
811.	2023-08052
812.	2023-08053
813.	2023-08069
814.	2023-08072
815.	2023-08083
816.	2023-08086
817.	2023-08087
818.	2023-08094
819.	2023-08096
820.	2023-08098
821.	2023-08099
822.	2023-08104
823.	2023-08107
824.	2023-08110
825.	2023-08127
826.	2023-08128
827.	2023-08132
828.	2023-08140
829.	2023-08143
830.	2023-08144
831.	2023-08149
832.	2023-08162
833.	2023-08163
834.	2023-08175

835.	2023-08179
836.	2023-08189
837.	2023-08205
838.	2023-08207
839.	2023-08220
840.	2023-08244
841.	2023-08247
842.	2023-08252
843.	2023-08259
844.	2023-08265
845.	2023-08279
846.	2023-08299
847.	2023-08300
848.	2023-08307
849.	2023-08330
850.	2023-08331
851.	2023-08334
852.	2023-08344
853.	2023-08345
854.	2023-08348
855.	2023-08351
856.	2023-08354
857.	2023-08356
858.	2023-08365
859.	2023-08369
860.	2023-08378
861.	2023-08382
862.	2023-08390
863.	2023-08393
864.	2023-08395
865.	2023-08416
866.	2023-08425
867.	2023-08428
868.	2023-08430
869.	2023-08431
870.	2023-08435
871.	2023-08436
872.	2023-08454
873.	2023-08457
874.	2023-08461
875.	2023-08462
876.	2023-08463
877.	2023-08466
878.	
879.	
880.	
875. 876. 877. 878. 879.	2023-08462 2023-08463

881.	2023-08487
882.	2023-08497
883.	2023-08504
884.	2023-08526
885.	2023-08529
886.	2023-08550
887.	2023-08552
888.	2023-08567
889.	2023-08588
890.	2023-08593
891.	2023-08619
892.	2023-08644
893.	2023-08647
894.	2023-08672
895.	2023-08687
896.	2023-08695
897.	2023-08708
898.	2023-08723
899.	2023-08728
900.	2023-08736
901.	2023-08746
902.	2023-08747
903.	2023-08761
904.	2023-08764
905.	2023-08774
906.	2023-08781
907.	2023-08788
908.	2023-08790
909.	2023-08801
910.	2023-08802
911.	2023-08809
912.	2023-08814
913.	2023-08816
914.	2023-08832
915.	2023-08841
916.	2023-08872
917.	2023-08873
918.	2023-08874
919.	2023-08881
920.	2023-08882
921.	2023-08886
922.	2023-08891
923.	2023-08892
924.	2023-08902
925.	2023-08903
926.	2023-08911

927.	2023-08912
928.	2023-08915
929.	2023-08916
930.	2023-08928
931.	2023-08938
932.	2023-08963
933.	2023-08966
934.	2023-09023
935.	2023-09026
936.	2023-09033
937.	2023-09039
938.	2023-09047
939.	2023-09048
940.	2023-09050
941.	2023-09054
942.	2023-09064
943.	2023-09068
944.	2023-09081
945.	2023-09082
946.	2023-09084
947.	2023-09088
948.	2023-09089
949.	2023-09092
950.	2023-09097
951.	2023-09098
952.	2023-09111
953.	2023-09112
954.	2023-09135
955.	2023-09136
956.	2023-09139
957.	2023-09152
958.	2023-09165
959.	2023-09172
960.	2023-09191
961.	2023-09192
962.	2023-09197
963.	2023-09218
964.	2023-09222
965.	2023-09225
966.	2023-09239
967.	2023-09240
968.	2023-09247
969.	2023-09248
970.	2023-09258
971.	2023-09275
972.	2023-09289

973. 974. 975.	<u>2023-09294</u> 2023-09301
975.	2023-09301
076	2023-09305
976.	2023-09309
977.	2023-09317
978.	2023-09318
979.	2023-09335
980.	2023-09344
981.	2023-09345
982.	2023-09359
983.	2023-09376
984.	2023-09383
985.	2023-09396
986.	2023-09412
987.	2023-09430
988.	2023-09453
989.	2023-09454
990.	2023-09455
991.	2023-09460
992.	2023-09478
993.	2023-09482
994.	2023-09486
995.	2023-09487
996.	2023-09491
997.	2023-09509
998.	2023-09515
999.	2023-09528
1000.	2023-09540
1001.	2023-09558
1002.	2023-09559
1003.	2023-09568
1004.	2023-09569
1005.	2023-09577
1006.	2023-09579
1007.	2023-09583
1008.	2023-09588
1009.	2023-09589
1010.	2023-09598
1011.	2023-09607
1012.	2023-09615
1013.	2023-09634
1014.	2023-09638
1015.	2023-09653
1016.	2023-09657
1017.	2023-09678
1018.	2023-09682

1019.	
	2023-09697
1020.	2023-09705
1021.	2023-09707
1022.	2023-09715
1023.	2023-09724
1024.	2023-09746
1025.	2023-09750
1026.	2023-09757
1027.	2023-09767
1028.	2023-09768
1029.	2023-09780
1030.	2023-09781
1031.	2023-09782
1032.	2023-09790
1033.	2023-09795
1034.	2023-09799
1035.	2023-09800
1036.	2023-09803
1037.	2023-09804
1038.	2023-09809
1039.	2023-09811
1040.	2023-09814
1041.	2023-09815
1042.	2023-09838
1043.	2023-09842
1044.	2023-09846
1045.	2023-09851
1046.	2023-09863
1047.	2023-09870
1048.	2023-09871
1049.	2023-09874
1050.	2023-09876
1051.	2023-09878
1052.	2023-09880
1053.	2023-09891
1054.	2023-09893
1055.	2023-09904
1056.	2023-09906
1057.	2023-09910
1058.	2023-09937
1059.	2023-09939
1060.	2023-09941
1061.	2023-09949
1062.	2023-09959
1063.	2023-09963
1064.	2023-09968
	2023 07700

1065.	2023-09972
1066.	2023-09985
1067.	2023-09986
1068.	2023-09996
1069.	2023-09999
1070.	2023-10007
1071.	2023-10027
1072.	2023-10029
1073.	2023-10030
1074.	2023-10031
1075.	2023-10035
1076.	2023-10038
1077.	2023-10050
1078.	2023-10058
1079.	2023-10065
1080.	2023-10073
1081.	2023-10075
1082.	2023-10095
1083.	2023-10097
1084.	2023-10099
1085.	2023-10101
1086.	2023-10102
1087.	2023-10106
1088.	2023-10110
1089.	2023-10112
1090.	2023-10118
1091.	2023-10128
1092.	2023-10130
1093.	2023-10138
1094.	2023-10141
1095.	2023-10143
1096.	2023-10144
1097.	2023-10159
1098.	2023-10160
1099.	2023-10179
1100.	2023-10184
1101.	2023-10185
1102.	2023-10193
1103.	2023-10205
1104.	2023-10223
1105.	2023-10227
1106.	2023-10227
1107.	2023-10247
1108.	2023-10266
1109.	2023-10286
1110.	2023-10295
II	

1111.	2023-10297
1112.	2023-10308
1113.	2023-10312
1114.	2023-10318
1115.	2023-10322
1116.	2023-10391
1117.	2023-10398
1118.	2023-10402
1119.	2023-10403
1120.	2023-10410
1121.	2023-10428
1122.	2023-10475
1123.	2023-10496
1124.	2023-10512
1125.	2023-10540
1126.	2023-10551
1127.	2023-10563
1128.	2023-10573
1129.	2023-10576
1130.	2023-10586
1131.	2023-10600
1132.	2023-10604
1133.	2023-10605
1134.	2023-10608
1135.	2023-10614
1136.	2023-10632
1137.	2023-10636
1138.	2023-10663
1139.	2023-10668
1140.	2023-10675
1141.	2023-10701
1142.	2023-10704
1143.	2023-10712
1144.	2023-10724
1145.	2023-10730
1146.	2023-10737
1147.	2023-10752
1148.	2023-10763
1149.	2023-10766
1150.	2023-10769
1151.	2023-10773
1152.	2023-10774
1153.	2023-10780
1154.	2023-10795
1155.	2023-10838
1156.	2023-10841
L I	

1157.	2023-10849
1158.	2023-10855
1159.	2023-10856
1160.	2023-10866
1161.	2023-10874
1162.	2023-10876
1163.	2023-10886
1164.	2023-10900
1165.	2023-10912
1166.	2023-10916
1167.	2023-10939
1168.	2023-10941
1169.	2023-10944
1170.	2023-10975
1171.	2023-10977
1172.	2023-10982
1173.	2023-10991
1174.	2023-10996
1175.	2023-11000
1176.	2023-11015
1177.	2023-11021
1178.	2023-11032
1179.	2023-11035
1180.	2023-11041
1181.	2023-11042
1182.	2023-11071
1183.	2023-11076
1184.	2023-11083
1185.	2023-11086
1186.	2023-11094
1187.	2023-11099
1188.	2023-11106
1189.	2023-11108
1190.	2023-11112
1191.	2023-11117
1192.	2023-11119
1193.	2023-11155
1194.	2023-11156
1195.	2023-11157
1196.	2023-11169
1197.	2023-11172
1198.	2023-11176
1199.	2023-11177
1200.	2023-11178
1201.	2023-11200
1202.	2023-11206

1202	
1203.	2023-11214
1204.	2023-11221
1205.	2023-11223
1206.	2023-11226
1207.	2023-11246
1208.	2023-11249
1209.	2023-11250
1210.	2023-11278
1211.	2023-11281
1212.	2023-11287
1213.	2023-11290
1214.	2023-11312
1215.	2023-11314
1216.	2023-11319
1217.	2023-11328
1218.	2023-11329
1219.	2023-11356
1220.	2023-11372
1221.	2023-11386
1222.	2023-11390
1223.	2023-11396
1224.	2023-11405
1225.	2023-11429
1226.	2023-11433
1227.	2023-11434
1228.	2023-11438
1229.	2023-11446
1230.	2023-11447
1231.	2023-11456
1232.	2023-11459
1233.	2023-11473
1234.	2023-11490
1235.	2023-11508
1236.	2023-11513
1237.	2023-11513
1238.	2023-11524
1239.	2023-11578
1240.	2023-11579
1241.	2023-11579
1242.	2023-11580
1243.	2023-11594
1244.	2023-11601
1245.	2023-11601
1245.	
1240.	<u>2023-11652</u> 2023-11658
1247.	2023-11658 2023-11666
12 10.	2023-11000

1240	
1249.	2023-11670
1250.	2023-11680
1251.	2023-11682
1252.	2023-11688
1253.	2023-11693
1254.	2023-11715
1255.	2023-11731
1256.	2023-11769
1257.	2023-11775
1258.	2023-11784
1259.	2023-11785
1260.	2023-11788
1261.	2023-11794
1262.	2023-11797
1263.	2023-11800
1264.	2023-11807
1265.	2023-11820
1266.	2023-11838
1267.	2023-11844
1268.	2023-11849
1269.	2023-11858
1270.	2023-11866
1271.	2023-11867
1272.	2023-11868
1273.	2023-11874
1274.	2023-11887
1275.	2023-11890
1276.	2023-11894
1277.	2023-11916
1278.	2023-11938
1279.	2023-11988
1280.	2023-12001
1281.	2023-12001
1282.	2023-12003
1283.	2023-12024
1284.	2023-12010
1285.	2023-12031
1286.	2023-12083
1287.	2023-121087
1288.	2023-12103
1289.	2023-12110
1290.	2023-12148
1290.	2023-12151 2023-12162
1291.	
1292.	2023-12180
1293.	2023-12181
1277.	2023-12188

1295.	2023-12189
1296.	2023-12190
1297.	2023-12191
1298.	2023-12193
1299.	2023-12201
1300.	2023-12204
1301.	2023-12210
1302.	2023-12211
1303.	2023-12235
1304.	2023-12243
1305.	2023-12261
1306.	2023-12275
1307.	2023-12305
1308.	2023-12321
1309.	2023-12322
1310.	2023-12327
1311.	2023-12334
1312.	2023-12338
1313.	2023-12365
1314.	2023-12368
1315.	2023-12399
1316.	2023-12400
1317.	2023-12401
1318.	2023-12415
1319.	2023-12419
1320.	2023-12464
1321.	2023-12469
1322.	2023-12470
1323.	2023-12471
1324.	2023-12478
1325.	2023-12485
1326.	2023-12495
1327.	2023-12502
1328.	2023-12505
1329.	2023-12515
1330.	2023-12517
1331.	2023-12528
1332.	2023-12533
1333.	2023-12536
1334.	2023-12540
1335.	2023-12563
1336.	2023-12568
1337.	2023-12588
1338.	2023-12594
1339.	2023-12594
1340.	2023-12575
_ • •	<i>2</i> 0 <i>2J</i> ⁻ 1 <i>2</i> 000

1341.	
	2023-12603
1342.	2023-12610
1343.	2023-12613
1344.	2023-12630
1345.	2023-12631
1346.	2023-12652
1347.	2023-12659
1348.	2023-12668
1349.	2023-12671
1350.	2023-12677
1351.	2023-12703
1352.	2023-12720
1353.	2023-12722
1354.	2023-12737
1355.	2023-12749
1356.	2023-12767
1357.	2023-12796
1358.	2023-12812
1359.	2023-12819
1360.	2023-12827
1361.	2023-12828
1362.	2023-12832
1363.	2023-12836
1364.	2023-12840
1365.	2023-12879
1366.	2023-12883
1367.	2023-12898
1368.	2023-12899
1369.	2023-12906
1370.	2023-12907
1371.	2023-12931
1372.	2023-12937
1373.	2023-12946
1374.	2023-12951
1375.	2023-12969
1376.	2023-12975
1377.	2023-12982
1378.	2023-12991
1379.	2023-12001
1380.	2023-13009
1381.	2023-13019
1382.	2023-13040
1383.	2023-13040
1384.	2023-13063
1385.	2023-13008
1386.	2023-13077
	2025-13000

1387. $2023-13161$ $1388.$ $2023-13180$ $1389.$ $2023-13201$ $1390.$ $2023-13201$ $1391.$ $2023-13209$ $1392.$ $2023-13238$ $1393.$ $2023-13238$ $1393.$ $2023-13239$ $1394.$ $2023-13242$ $1395.$ $2023-13243$ $1396.$ $2023-13245$ $1398.$ $2023-13245$ $1399.$ $2023-13252$ $1399.$ $2023-13256$ $1400.$ $2023-13265$ $1401.$ $2023-13265$ $1402.$ $2023-13270$ $1403.$ $2023-13270$ $1404.$ $2023-13304$ $1405.$ $2023-13327$ $1406.$ $2023-13327$ $1406.$ $2023-13329$ $1407.$ $2023-13330$ $1408.$ $2023-13329$ $1410.$ $2023-13329$ $1411.$ $2023-13332$ $1409.$ $2023-13332$ $1414.$ $2023-13339$ $1414.$ $2023-13343$ $1414.$ $2023-13352$ $1414.$ $2023-13352$ $1414.$ $2023-13353$ $1414.$ $2023-13353$ $1414.$ $2023-13353$ $1414.$ $2023-13353$ $1414.$ $2023-13353$ $1414.$ $2023-13354$ $1414.$ $2023-13352$ $1414.$ $2023-13354$ $1414.$ $2023-13354$ $1414.$ $2023-13354$ $1414.$ $2023-13354$ $1414.$ $2023-13354$ $1414.$ $2023-13457$ 1414	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	
1414. 2023-13352 1415. 2023-13358 1416. 2023-13367 1417. 2023-13379 1418. 2023-13390 1419. 2023-13435 1420. 2023-13435 1421. 2023-13438 1422. 2023-13439 1423. 2023-13441 1424. 2023-13457	
1415. 2023-13358 1416. 2023-13367 1417. 2023-13379 1418. 2023-13390 1419. 2023-13435 1420. 2023-13438 1421. 2023-13439 1422. 2023-13443 1423. 2023-13443 1424. 2023-13457	
1416. 2023-13367 1417. 2023-13379 1418. 2023-13390 1419. 2023-13435 1420. 2023-13438 1421. 2023-13439 1422. 2023-13441 1423. 2023-13443 1424. 2023-13457	
1417. 2023-13307 1418. 2023-13390 1419. 2023-13435 1420. 2023-13438 1421. 2023-13439 1422. 2023-13441 1423. 2023-13443 1424. 2023-13457	
1417. 2023-13379 1418. 2023-13390 1419. 2023-13435 1420. 2023-13438 1421. 2023-13439 1422. 2023-13441 1423. 2023-13443 1424. 2023-13457	
1419. 2023-13350 1420. 2023-13435 1421. 2023-13439 1422. 2023-13441 1423. 2023-13443 1424. 2023-13457	
1420. 2023-13438 1421. 2023-13439 1422. 2023-13441 1423. 2023-13443 1424. 2023-13457	
1421. 2023-13439 1422. 2023-13441 1423. 2023-13443 1424. 2023-13457	
1422. 2023-13431 1423. 2023-13443 1424. 2023-13457	
1423. 2023-13443 1424. 2023-13457	
1424. 2023-13457	
2023 13437	
1425	
1425. 2023-13464	
1426. 2023-13476	
1427. 2023-13482	
1428. 2023-13493	
1429. 2023-13497	
1430. 2023-13517	
1431. 2023-13547	
1432. 2023-13555	

1433.	2023-13557
1434.	2023-13577
1435.	2023-13582
1436.	2023-13592
1437.	2023-13610
1438.	2023-13628
1439.	2023-13634
1440.	2023-13651
1441.	2023-13662
1442.	2023-13668
1443.	2023-13670
1444.	2023-13680
1445.	2023-13683
1446.	2023-13697
1447.	2023-13700
1448.	2023-13701
1449.	2023-13703
1450.	2023-13723
1451.	2023-13754
1452.	2023-13763
1453.	2023-13772
1454.	2023-13784
1455.	2023-13809
1456.	2023-13815
1457.	2023-13818
1458.	2023-13823
1459.	2023-13832
1460.	2023-13838
1461.	2023-13846
1462.	2023-13867
1463.	2023-13880
1464.	2023-13883
1465.	2023-13890
1466.	2023-13917
1467.	2023-13935
1468.	2023-13989
1469.	2023-13993
1470.	2023-14009
1471.	2023-14038
1472.	2023-14050
1473.	2023-14109
1474.	2023-14115
1475.	2023-14121
1476.	2023-14132
1477.	2023-14132
1478.	2023-14179
<u> </u>	

1479.	2022 4 44 02
1479.	2023-14183
	2023-14189
1481. 1482.	2023-14196
	2023-14197
1483.	2023-14208
1484.	2023-14214
1485.	2023-14218
1486.	2023-14239
1487.	2023-14240
1488.	2023-14250
1489.	2023-14262
1490.	2023-14264
1491.	2023-14288
1492.	2023-14292
1493.	2023-14300
1494.	2023-14305
1495.	2023-14312
1496.	2023-14327
1497.	2023-14328
1498.	2023-14334
1499.	2023-14339
1500.	2023-14341
1501.	2023-14367
1502.	2023-14385
1503.	2023-14387
1504.	2023-14389
1505.	2023-14394
1506.	2023-14396
1507.	2023-14399
1508.	2023-14425
1509.	2023-14426
1510.	2023-14428
1511.	2023-14431
1512.	2023-14435
1513.	2023-14442
1514.	2023-14471
1515.	2023-14477
1516.	2023-14483
1517.	2023-14494
1518.	2023-14499
1519.	2023-14505
1520.	2023-14532
1521.	2023-14535
1522.	2023-14536
1523.	2023-14562
1524.	2023-14571
L	

1525.	2023-14603
1526.	2023-14627
1527.	2023-14635
1528.	2023-14643
1529.	2023-14645
1530.	2023-14649
1531.	2023-14651
1532.	2023-14657
1533.	2023-14674
1534.	2023-14696
1535.	2023-14708
1536.	2023-14733
1537.	2023-14741
1538.	2023-14746
1539.	2023-14755
1540.	2023-14765
1541.	2023-14768
1542.	2023-14771
1543.	2023-14774
1544.	2023-14789
1545.	2023-14795
1546.	2023-14801
1547.	2023-14802
1548.	2023-14805
1549.	2023-14810
1550.	2023-14811
1551.	2023-14830
1552.	2023-14839
1553.	2023-14875
1554.	2023-14877
1555.	2023-14883
1556.	2023-14904
1557.	2023-14920
1558.	2023-14926
1559.	2023-14931
1560.	2023-14934
1561.	2023-14942
1562.	2023-14955
1563.	2023-14970
1564.	2023-14987
1565.	2023-14996
1566.	2023-15005
1567.	2023-15005
1568.	2023-15009
1569.	2023-15009
1570.	2023-15013
	2025 ⁻ 1302 1

1571.	2023-15051
1572.	2023-15053
1573.	2023-15091
1574.	2023-15152
1575.	2023-15170
1576.	2023-15193
1577.	2023-15194
1578.	2023-15243
1579.	2023-15279
1580.	2023-15313
1581.	2023-15330
1582.	2023-15350
1583.	2023-15364
1584.	2023-15378
1585.	2023-15380
1586.	2023-15398



Dr. KONGA GOPIKRISHNA Scientist – 'F' SEED Division E- Mail: k.gopikrishna@nic.in Phone: 011-26590298

भारत सरकार

विज्ञान और प्रौद्योगिकी मंत्रालय विज्ञान और प्रौद्योगिकी विभाग टेक्नोलॉजी भवन, नया मेहरौली मार्ग नयी दिल्ली-११० ०१६

GOVERNMENT OF INDIA

MINISTRY OF SCIENCE AND TECHNOLOGY DEPARTMENT OF SCIENCE AND TECHNOLOGY TECHNOLOGY BHAVAN, NEW MEHRAULI ROAD NEW DELHI – 110 016

DST/SEED/TSP/STI/2020/286

19.09.2023

Sub: Financial Assistance for the project titled "Feasibility and Impact of a Tribal Interactive Health, Behavioural and Demography Surveillance System in Belagavi, Karnataka.".

Dear Sir

This is to inform that the above mentioned project proposal has been approved at a total cost of Rs.1,36,29,174/- (Rs.1,09,05,174/- under General Component and Rs.27,24,000/- towards Capital Assets) (detailed break-up enclosed at Annexure I) for duration of 36 months with an initial release of Rs.65,07,058/- (Rs.37,83,058/- towards General Component and Rs.27,24,000/- towards Capital Assets) subject to the following conditions.

1. Submission of letter of consent to take up the project at the above cost.

2. The Organization/Institute/Principal Investigator that it has not obtained financial assistance from any other department of the Central/State Governments for this project or a similar project

3. Procurement of equipment as per General Financial Rules 2017.

4. Execution of construction work through Government Agency/PSU

5. The proposed equipment in the project are not available with the Host Institution and not procured under any project sanction by Central/State Government

6. The Goods (consumables and equipment) available in GeM portal are to be procured mandatorily online through GeM only

7. The Host Institution/PI will also follow DoE's guidelines for incurring expenditure under the different sub-heads

8. The Host Institution/PI should start using EAT module and next release will be made only after mapping and following EAT modules by the Grantee Institution

9. Selection of NGOs may be done with transparent manner for last mile delivery

10. The HI/PI may ensure involving the Industries for commercialization of technologies, if any, developed in the project

11. All interests and other earnings, against released Grant shall be remitted to Consolidated Fund of India (through Non-Tax Receipt Portal (NTRP), i.e., www.bharatkosh.gov.in), immediately after finalization of accounts, as it shall not be adjusted towards future release of grant.

13. The permanent assets/equipment procured if any, in the project should be used by the intended beneficiaries even after completion of project tenure. Retention of equipment if any for further research may be requested and such retention is subject to approval of competent authority.

2. As per the Ministry of Finance, Department of Expenditure OM No. 7 (1) E.Coord/2012 dated 14th November 2012, the release of the grant will be subject to declaration by the Organization/ Principal Investigator (s) that

(i) All Utilization Certificates due for rendition, for grant in aid released by the Central Government in respect of all the schemes/programmes/projects of a Ministry/Department of Government of India have been submitted for all the projects implemented (completed) by the Organization/ Principal Investigator (s) and Up to date Utilization Certificates have been submitted for grant in aid released by the Central Government in respect of all the schemes/programmes/projects of a Ministry/Department of India in case of ongoing projects

3. Further, in order to release the grant, you have to register your agency under "Public Financial Management System (PFMS)". If you have already registered your agency, please send us the unique code and details for both immediately. If not, please register your agency under PFMS or CPSMS. During the process of registration, the bank details should be added to the Scheme "INNOVATION, TECHNOLOGY DEVELOPMENT AND DEPLOYMENT (1819)" and it must be saving bank account in Union Bank of India (UBI).

4. A zero balance subsidiary account should be opened in Union Bank of India (UBI). For any help in opening of account, you may contact the Senior Manager of UBI, Sh. Dindayal Mishra (Mobile 7411403225). It will be linked to the Central Nodal Agency (CAN) account in PFMS. Here Science and Engineering Research Board (SERB) is CNA. Therefore, while adding this account in PFMS, you have to write Science and Engineering Research Board (SERB) as the agency from which you will be receiving the funds.

5. The release of the grant would be through electronic transfer of funds (RTGS). You are requested to provide the following details for facilitating e-payments.

- a. Account Holders /Organization name (or) designation
- b. Name of the bank
- c. Bank Account Number

d. IFSC Code e. MICR Code

It would be appreciated if you can send us a photocopy of a cancelled cheque, which has all the requisite details. The bank details in the photocopy of the cancelled cheque should match with the details given during CPSMS registration.

Enclosures: As above

Yours Sincerely,

Yours Sincerely,

1 Silve

(Gopikrishna Konga)

То

Dr. Mubashir KLE Academy of Higher Education and Research, JNMC Campus, Nehrnagar – 590010, Belgavi Karnataka

DECLARATION

It is certified that all Utilization Certificates due for rendition, for grant in aid released by the Central Government in respect of all the schemes/programmes/projects have been submitted for all the projects implemented (completed) by the Organization/ Principal Investigator (s) and Up to date Utilization Certificates have been submitted for grant in aid released by the Central Government in respect of all the schemes/programmes/projects in case of ongoing projects

Signature of the Head of the Institute/ Principal Investigator with seal/stamp

Place:

Date:

DECLARATION

It is certified/declared that

1. We agree to take up the project at the sanctioned cost and abide by all the conditions.

2. The Organization/Institute/Principal Investigator has not obtained financial assistance from any other department of the Central/State Governments for this project or a similar project

3. The Institute/Organisation is not blacklisted

4. Equipment is procured as per General Financial Rules 2017.

5. Construction work will be executed through Government Agency/PSU

6. The proposed equipment in the project are not available with the Host Institution and not procured under any project sanctioned by Central/State Government

7. The Goods (consumables and equipment) available in GeM portal will be procured online through GeM

8. The Host Institution/PI will follow DoE's guidelines for incurring expenditure under the different sub-heads

9. The Host Institution/PI will use EAT module in PFMS

10. Selection of NGOs will be done in transparent manner for last mile delivery

11. The HI/PI will involve Industries for commercialization of technologies, if any, developed in the project

12. The institute will maintain separate audited account for the project and the entire amount of grant will be kept in an interest-bearing bank government bank account.

14. All interests and other earnings, against released Grant shall be remitted to Consolidated Fund of India and will not be adjusted towards future release of grant.

15. The permanent assets/equipment procured if any, in the project will be handed over to beneficiaries' completion of project tenure.

16. Retention of equipment if any for further research will be only after taking prior approval of DST.

Signature of the Head of the Institute/ Principal Investigator with seal/stamp

Place:

Date:

Annexure I

APPROVED BUDGET

1					1
UDGET HEADS		1 st Year	2 nd Year	3 rd Year	Total
A. GENERAL COMPONENT		(in Rs.)	(in Rs.)	(in Rs.)	(in Rs.)
MA	NPOWER				
1.	Project Coordinator – I (01)	7,20,000	7,20,000	7,20,000	21,60,000
	@ Rs.60,000/- per month				
2.	Project Assistant (04) @	10,46,400	10,46,400	10,46,400	31,39,200
	Rs.20,000/- + 9% HRA per				
	month				
3.	Scientific Assistant/	9,41,760	9,41,760	9,41,760	28,25,280
	Field Worker (04) @				
	Rs.18,000/- + 9% HRA per				
	month				
	SUB TOTAL	27,08,160	27,08,160	27,08,160	81,24,480
CON	ISUMABLES				
1.	Tablet & Capsule, Ointment,	3,00,000	3,00,000	3,00,000	9,00,000
	Lotion, Syrup, Drops, Powders	, ,	, ,	, ,	, , ,
	and Miscellaneous Items				
TRA	VEL				
1.	Project logistics	2,00,000	2,00,000	200,000	6,00,000
2.	Field activities				
3.	DST review meetings				
TRA	ININGS				
1.	Training Programme	2,00,000			2,00,000
	SUB TOTAL (A)	34,08,160	32,08,160	32,08,160	98,24,480
INSTITUTIONAL OVERHEADS @ 8% of RE					
1.	Overheads	2,72,653	2,56,653	2,56,653	7,85,959
CONTINGENCY @ 3% of RE					
1.	Unforeseen Expenditure and	1,02,245	96,245	96,245	2,94,735
	Incidental costs				
	TOTAL (A)	37,83,058	35,61,058	35,61,058	1,09,05,174
B. CAPITAL COMPONENT (EQUIPMENT)					
1.	Computer (HP I-S5 All in One)	1,60,000			1,60,000
	•		-	-	-

	(04) @ Rs.40,000/-				
2.	Printer (HP laserjet PRO M126 NW) (02) @ Rs.20,000/-	40,000			40,000
3.	Fuji TSU S13001 Sheetfiel (01) @ Rs.20,000/-	20,000			20,000
4.	Networking Per node (08) @ Rs.10,000/-	80,000			80,000
5.	9U rack (01) @ Rs.24,000/-	24,000			24,000
6.	Panasonic Tab 8' HD (10) @ Rs.12,000/-	1,20,000			1,20,000
7.	50 MBPS ILL with Firewall (01) @ Rs.4,00,000/-	4,00,000			4,00,000
8.	Data Management software (01) @ Rs.6,22,000/-	6,22,000			6,22,000
9.	Hb-301 Analyze (02) @ Rs.24,000/-	48,000			48,000
10.	Hb-301 Cuvettes (02) @ Rs.5,000/-	10,000			10,000
FAB	RICATION				
1.	Fabrication	2,00,000			2,00,000
CON	CONSTRUCTION COSTS				
1.	Construction Cost	10,00,000			10,00,000
	TOTAL (B)	27,24,000			27,24,000
	GRAND TOTAL (A+B)	65,07,058	35,61,058	35,61,058	1,36,29,174

BUDGET BREAK UP

General Component	Rs.1,09,05,174/-
Capital Assets	Rs.27,24,000/-
TOTAL	Rs.1,36,29,174/-





Date: 23-05 -2022

Amount received from: Christian Medical College and Hospital, Ludhiana

Amount received by (Name of the Institute): Jawaharlal Nehru Medical College, KLE Academy of

Higher Education & Research, Belagavi, Karnataka

Name of the Principal Investigator: Dr. Saroja A.O

Payment received for (Name of the Trial): INSTRUCT PHASE II

Amount (in INR): 1, 00000.00

Mode of transfer (select One):

✓ RTGS Cheque	Cash	
---------------	------	--

UTR Number: IOBAN22299098857/ Cheque Number: N/A

Purpose of payment: Research

Date of receiving the payment: 17-05-2022

Acknowledged by: Dr. Saroja A.O

Signature: Sarph No

Stamp: Dr. Saroja A.O. M.D. (Med) U.M.(Neuro) KMC Reg.No.20496 Consultant Neurologist. KLES Dr. Prabhakar Kore Hospital & MRC, Belgaum Professor of Neurology Jawaharlal Nehru Medical College, Belgaum

Payment receipt form INSTRUCT Network





Date: 10/Oct/2022

Amount received from: Christian Medical College and Hospital, Ludhiana

Amount received by (Name of the Institute): Jawaharlal Nehru Medical College, KLE Academy of Higher Education & Research, Belagavi, Karnataka

Name of the Principal Investigator: Dr. Saroja A.O

Payment received for (Name of the Trial): "INTRINSIC"

Amount (in INR): 1, 85,400/-

Mode of transfer (select One):

✓ RTGS Cheque Cash

UTR Number: IOBAN22273045718 / Cheque Number: N/A

Purpose of payment: Research

Date of receiving the payment: 30/09/2022

Acknowledged by: Dr. Saroja A.O

Lasph Ab

Signature:

Dr. Saroja A.O. M.D. (Men) D.M. (Neuro) Stamp: <u>KMC Reg. No. 28410 Consul</u>tent Neurologist. KLES Dr. Protector Kare Hospital & MHC, Belgaum Professor of Hernology Jawahariai Nehru Medical Oslinge, Belgaum

Payment receipt form INSTRUCT Network





Date: 24-10 -2022

Amount received from: Christian Medical College and Hospital, Ludhiana

Amount received by (Name of the Institute): Jawaharlal Nehru Medical College, KLE Academy of

Higher Education & Research, Belagavi, Karnataka

Name of the Principal Investigator: Dr. Saroja A.O

Payment received for (Name of the Trial): STENOSIS

Amount (in INR): 1, 98,275.00

Mode of transfer (select One):	✓ RTGS	Cheque	Cash	

UTR Number: IOBAN22299098857/ Cheque Number: N/A

Purpose of payment: Research

Date of receiving the payment: 26-10-2022

Acknowledged by: Dr. Saroja A.O

Signature: Laon No

Stamp: Dr. Saroja A.O. M.D. (Med) D.M.(Neuro) KMC Reg.No.26436 Consultant Neurologist. KLES Dr. Probakar Kore Hospital & MRC, Belgaum Professor of Neurology Jawaharial Nehru Medical College, Belgaum

Payment receipt form INSTRUCT Network



HRD/Head/STS-2023/01 Date: 14.08.2023

SHORT-TERM STUDENTSHIP (STS-2023)

Proposal Result

- The final list of students selected for STS-2023 program is displayed below in order of their STS-2023 Reference ID.
 <u>Please note:</u> Always quote your STS Reference ID for any future correspondence emails to ICMR.
- 2. The 'Selected' students as listed in table below for STS-2023 may carry out the proposed research work and prepare the report in any two months *w.e.f.* 17th August, 2023 to 29th December, 2023
- 3. Research should be done after appropriate Institutional Ethics Committee (IEC) approval has been obtained. The ethical clearance letter has to be submitted along with report (IEC approvals should be taken latest by 30th November, 2023. Any IEC letter/approvals taken after 30th November, 2023 will not be considered as the student will not get two months of time for carrying out the work by the deadline given above).
- 4. The online report submission dates will be declared by the ICMR in due course of time.
- 5. The proposal result declared below by the ICMR is final. No further correspondence in the matter will be entertained.

Kindly read the detailed report preparation guidelines and instructions given on the ICMR website

GENERAL ENQUIRIES to be sent through email to <u>stshrd2017@gmail.com</u> or call on extn.no. 306, 369

Final result list of STS-2023 approved proposals in order of reference ID.

S. No.	STS Reference ID
1.	2023-00004
2.	2023-00008
3.	2023-00017
4.	2023-00035
5.	2023-00037
6.	2023-00051

7.	2022 00055
8.	2023-00055
	2023-00057
9.	2023-00071
10.	2023-00077
11.	2023-00082
12.	2023-00090
13.	2023-00106
14.	2023-00125
15.	2023-00131
16.	2023-00134
17.	2023-00146
18.	2023-00149
19.	2023-00155
20.	2023-00156
21.	2023-00173
22.	2023-00175
23.	2023-00192
24.	2023-00199
25.	2023-00204
26.	2023-00209
27.	2023-00213
28.	2023-00220
29.	2023-00221
30.	2023-00225
31.	2023-00230
32.	2023-00231
33.	2023-00236
34.	2023-00239
35.	2023-00240
36.	2023-00243
37.	2023-00246
38.	2023-00257
39.	2023-00280
40.	2023-00284
41.	2023-00289
42.	2023-00330
43.	2023-00331
44.	2023-00341
45.	2023-00342
46.	2023-00342
47.	2023-00365
48.	2023-00367
49.	2023-00406
50.	2023-00406
50.	2023-00411 2023-00421
51.	
52.	2023-00425

53.	2022 00426
54.	2023-00436
55.	2023-00442 2023-00446
56.	2023-00440
57.	2023-00453
58.	
59.	2023-00463
60.	2023-00494
61.	2023-00496
62.	2023-00498
63.	2023-00506
64.	2023-00509
65.	2023-00514
	2023-00523
66.	2023-00524
67.	2023-00527
68.	2023-00530
69.	2023-00538
70.	2023-00542
71.	2023-00546
72.	2023-00553
73.	2023-00564
74.	2023-00584
75.	2023-00585
76.	2023-00603
77.	2023-00608
78.	2023-00625
79.	2023-00643
80.	2023-00649
81.	2023-00665
82.	2023-00667
83.	2023-00679
84.	2023-00696
85.	2023-00700
86.	2023-00706
87.	2023-00714
88.	2023-00730
89.	2023-00735
90.	2023-00736
91.	2023-00742
92.	2023-00712
93.	2023-00752
94.	2023-00752
95.	2023-00768
96.	2023-00708
97.	2023-00800
98.	2023-00807

99.	
	2023-00839
100.	2023-00843
	2023-00866
102.	2023-00874
103.	2023-00890
104.	2023-00904
105.	2023-00917
106.	2023-00919
107.	2023-00940
108.	2023-00958
109.	2023-00967
110.	2023-00969
111.	2023-00970
112.	2023-00990
113.	2023-01001
114.	2023-01024
115.	2023-01034
116.	2023-01035
117.	2023-01040
118.	2023-01053
119.	2023-01055
120.	2023-01059
121.	2023-01070
122.	2023-01085
123.	2023-01131
124.	2023-01145
125.	2023-01148
126.	2023-01149
127.	2023-01159
128.	2023-01167
129.	2023-01172
130.	2023-01180
131.	2023-01188
132.	2023-01196
133.	2023-01208
134.	2023-01217
135.	2023-01228
136.	2023-01252
137.	2023-01273
138.	2023-01274
139.	2023-01277
140.	2023-01288
141.	2023-01291
142.	2023-01302
143.	2023-01314
144.	2023-01321
L I	

145.	2023-01325
146.	2023-01338
147.	2023-01353
148.	2023-01360
149.	2023-01361
150.	2023-01363
151.	2023-01369
152.	2023-01374
153.	2023-01385
154.	2023-01391
155.	2023-01416
156.	2023-01425
157.	2023-01432
158.	2023-01460
159.	2023-01461
160.	2023-01465
161.	2023-01468
162.	2023-01473
163.	2023-01474
164.	2023-01483
165.	2023-01495
166.	2023-01509
167.	2023-01502
168.	2023-01512
169.	2023-01514
170.	2023-01530
171.	2023-01542
172.	2023-01542
173.	2023-01558
174.	2023-01572
175.	2023-01583
176.	2023-01585
177.	2023-01588
178.	2023-01588
179.	2023-01608
180.	2023-01616
181.	2023-01020
182.	2023-01632
183.	2023-01633
184.	2023-01634
185.	2023-01646
185.	
180.	2023-01674
187.	2023-01679
188.	2023-01698
189.	2023-01703
170.	2023-01722

191.	2023-01726
192.	2023-01737
193.	2023-01740
194.	2023-01743
195.	2023-01754
196.	2023-01757
197.	2023-01760
198.	2023-01770
199.	2023-01776
200.	2023-01785
201.	2023-01794
202.	2023-01804
203.	2023-01805
204.	2023-01828
205.	2023-01840
206.	2023-01847
207.	2023-01871
208.	2023-01881
209.	2023-01892
210.	2023-01936
211.	2023-01944
212.	2023-01951
213.	2023-01963
214.	2023-01973
215.	2023-01980
216.	2023-01982
217.	2023-01991
218.	2023-01992
219.	2023-01999
220.	2023-02011
221.	2023-02015
222.	2023-02041
223.	2023-02056
224.	2023-02060
225.	2023-02083
226.	2023-02096
227.	2023-02099
228.	2023-02119
229.	2023-02122
230.	2023-02130
231.	2023-02145
232.	2023-02143
233.	2023-02178
234.	2023-02179
235.	2023-02192
236.	2023-02192
- **	2025-02170

237.	2023-02215
238.	2023-02242
239.	2023-02262
240.	2023-02271
241.	2023-02278
242.	2023-02281
243.	2023-02282
244.	2023-02333
245.	2023-02344
246.	2023-02357
247.	2023-02374
248.	2023-02383
249.	2023-02385
250.	2023-02414
251.	2023-02426
252.	2023-02442
253.	2023-02449
254.	2023-02466
255.	2023-02479
256.	2023-02490
257.	2023-02495
258.	2023-02498
259.	2023-02501
260.	2023-02506
261.	2023-02515
262.	2023-02521
263.	2023-02536
264.	2023-02566
265.	2023-02593
266.	2023-02594
267.	2023-02600
268.	2023-02602
269.	2023-02621
270.	2023-02629
271.	2023-02631
272.	2023-02653
273.	2023-02684
274.	2023-02686
275.	2023-02702
276.	2023-02704
277.	2023-02705
278.	2023-02710
279.	2023-02718
280.	2023-02731
281.	2023-02738
282.	2023-02757
L L	

283.	2023-02767
284.	2023-02768
285.	2023-02783
286.	2023-02791
287.	2023-02802
288.	2023-02808
289.	2023-02817
290.	2023-02833
291.	2023-02835
292.	2023-02837
293.	2023-02838
294.	2023-02867
295.	2023-02879
296.	2023-02880
297.	2023-02881
298.	2023-02882
299.	2023-02888
300.	2023-02911
301.	2023-02923
302.	2023-02928
303.	2023-02929
304.	2023-02931
305.	2023-02934
306.	2023-02950
307.	2023-02977
308.	2023-02992
309.	2023-02999
310.	2023-03012
311.	2023-03013
312.	2023-03059
313.	2023-03081
314.	2023-03082
315.	2023-03088
316.	2023-03107
317.	2023-03110
318.	2023-03125
319.	2023-03142
320.	2023-03146
321.	2023-03153
322.	2023-03154
323.	2023-03157
324.	2023-03161
325.	2023-03185
326.	2023-03198
327.	2023-03204
328.	2023-03218
	2020 00810

329.	2022 02225
330.	2023-03225
331.	2023-03231
332.	2023-03233
	2023-03236
333.	2023-03241
334.	2023-03250
335.	2023-03267
336.	2023-03275
337.	2023-03284
338.	2023-03286
339.	2023-03287
340.	2023-03288
341.	2023-03308
342.	2023-03311
343.	2023-03314
344.	2023-03339
345.	2023-03356
346.	2023-03359
347.	2023-03365
348.	2023-03411
349.	2023-03439
350.	2023-03442
351.	2023-03445
352.	2023-03455
353.	2023-03471
354.	2023-03483
355.	2023-03485
356.	2023-03490
357.	2023-03495
358.	2023-03509
359.	2023-03518
360.	2023-03564
361.	2023-03573
362.	2023-03576
363.	2023-03597
364.	2023-03601
365.	2023-03602
366.	2023-03626
367.	2023-03650
368.	2023-03664
369.	2023-03674
370.	2023-03684
371.	2023-03691
372.	2023-03694
373.	2023-03708
374.	2023-03741
	2023 03171

375.	2023-03745
376.	2023-03749
377.	2023-03759
378.	2023-03779
379.	2023-03787
380.	2023-03807
381.	2023-03825
382.	2023-03851
383.	2023-03854
384.	2023-03864
385.	2023-03873
386.	2023-03906
387.	2023-03916
388.	2023-03920
389.	2023-03941
390.	2023-03957
391.	2023-03959
392.	2023-03964
393.	2023-03974
394.	2023-03979
395.	2023-03981
396.	2023-04006
397.	2023-04007
398.	2023-04009
399.	2023-04010
400.	2023-04015
401.	2023-04021
402.	2023-04027
403.	2023-04031
404.	2023-04034
405.	2023-04037
406.	2023-04053
407.	2023-04057
408.	2023-04062
409.	2023-04066
410.	2023-04068
411.	2023-04078
412.	2023-04086
413.	2023-04089
414.	2023-04094
415.	2023-04100
416.	2023-04112
417.	2023-04117
418.	2023-04127
419.	2023-04129
420.	2023-04141
L I	

421.	
	2023-04144
422.	2023-04148
423.	2023-04160
424.	2023-04184
425.	2023-04187
426.	2023-04193
427.	2023-04199
428.	2023-04211
429.	2023-04215
430.	2023-04216
431.	2023-04233
432.	2023-04237
433.	2023-04256
434.	2023-04258
435.	2023-04262
436.	2023-04270
437.	2023-04278
438.	2023-04292
439.	2023-04310
440.	2023-04311
441.	2023-04313
442.	2023-04321
443.	2023-04329
444.	2023-04332
445.	2023-04342
446.	2023-04352
447.	2023-04356
448.	2023-04362
449.	2023-04365
450.	2023-04368
451.	2023-04380
452.	2023-04391
453.	2023-04397
454.	2023-04400
455.	2023-04409
456.	2023-04434
457.	2023-04449
458.	2023-04455
459.	2023-04456
460.	2023-04459
461.	2023-04471
462.	2023-04481
463.	2023-04494
464.	2023-04494
465.	2023-04497 2023-04502
466.	2023-04502
	2023-04307

167	
467.	2023-04514
468.	2023-04516
469.	2023-04517
470.	2023-04526
471.	2023-04530
472.	2023-04531
473.	2023-04538
474.	2023-04539
475.	2023-04542
476.	2023-04549
477.	2023-04555
478.	2023-04566
479.	2023-04574
480.	2023-04581
481.	2023-04585
482.	2023-04589
483.	2023-04595
484.	2023-04600
485.	2023-04601
486.	2023-04605
487.	2023-04610
488.	2023-04635
489.	2023-04639
490.	2023-04666
491.	2023-04692
492.	2023-04706
493.	2023-04709
494.	2023-04722
495.	2023-04724
496.	2023-04734
497.	2023-04740
498.	2023-04750
499.	2023-04765
500.	2023-04774
501.	2023-04779
502.	2023-04809
503.	2023-04811
504.	2023-04814
505.	2023-04816
506.	2023-04841
507.	2023-04848
508.	2023-04852
509.	2023-04890
510.	2023-04902
511.	2023-04916
512.	2023-04910

513.	2023-04955
514.	2023-04985
515.	2023-05002
516.	2023-05009
517.	2023-05019
518.	2023-05027
519.	2023-05033
520.	2023-05035
521.	2023-05047
522.	2023-05061
523.	2023-05068
524.	2023-05076
525.	2023-05078
526.	2023-05087
527.	2023-05100
528.	2023-05128
529.	2023-05132
530.	2023-05148
531.	2023-05169
532.	2023-05200
533.	2023-05228
534.	2023-05250
535.	2023-05276
536.	2023-05283
537.	2023-05289
538.	2023-05309
539.	2023-05321
540.	2023-05327
541.	2023-05328
542.	2023-05348
543.	2023-05395
544.	2023-05404
545.	2023-05435
546.	2023-05456
547.	2023-05469
548.	2023-05484
549.	2023-05487
550.	2023-05525
551.	2023-05547
552.	2023-05561
553.	2023-05603
554.	2023-05617
555.	2023-05622
556.	2023-05628
557.	2023-05642
558.	2023-05649
L I	

559.	2023-05661
560.	2023-05683
561.	2023-05694
562.	2023-05700
563.	2023-05701
564.	2023-05740
565.	2023-05741
566.	2023-05759
567.	2023-05789
568.	2023-05790
569.	2023-05794
570.	2023-05802
571.	2023-05804
572.	2023-05810
573.	2023-05833
574.	2023-05875
575.	2023-05884
576.	2023-05898
577.	2023-05901
578.	2023-05905
579.	2023-05944
580.	2023-05950
581.	2023-05957
582.	2023-05958
583.	2023-05978
584.	2023-05995
585.	2023-05997
586.	2023-06011
587.	2023-06023
588.	2023-06042
589.	2023-06074
590.	2023-06078
591.	2023-06091
592.	2023-06098
593.	2023-06102
594.	2023-06117
595.	2023-06123
596.	2023-06128
597.	2023-06142
598.	2023-06169
599.	2023-06173
600.	2023-06184
601.	2023-06195
602.	2023-06199
603.	2023-06212
604.	2023-06220

<u>(05</u>	
605.	2023-06235
606.	2023-06249
607.	2023-06257
608.	2023-06262
609.	2023-06277
610.	2023-06281
611.	2023-06290
612.	2023-06323
613.	2023-06336
614.	2023-06356
615.	2023-06392
616.	2023-06406
617.	2023-06414
618.	2023-06419
619.	2023-06443
620.	2023-06447
621.	2023-06469
622.	2023-06488
623.	2023-06492
624.	2023-06494
625.	2023-06537
626.	2023-06538
627.	2023-06577
628.	2023-06578
629.	2023-06587
630.	2023-06594
631.	2023-06596
632.	2023-06606
633.	2023-06608
634.	2023-06609
635.	2023-06610
636.	2023-06618
637.	2023-06623
638.	2023-06625
639.	2023-06626
640.	2023-06633
641.	2023-06634
642.	2023-06641
643.	2023-06648
644.	2023-06655
645.	2023-06663
646.	2023-06674
647.	2023-06679
648.	2023-06681
649.	2023-06684
650.	2023-06686
· · · · ·	

651.	2023-06688
652.	2023-06710
653.	2023-06721
654.	2023-06727
655.	2023-06734
656.	2023-06736
657.	2023-06746
658.	2023-06772
659.	2023-06791
660.	2023-06801
661.	2023-06807
662.	2023-06824
663.	2023-06825
664.	2023-06866
665.	2023-06873
666.	2023-06875
667.	2023-06879
668.	2023-06887
669.	2023-06901
670.	2023-06922
671.	2023-06928
672.	2023-06944
673.	2023-06945
674.	2023-06958
675.	2023-06966
676.	2023-06986
677.	2023-06990
678.	2023-07008
679.	2023-07010
680.	2023-07035
681.	2023-07040
682.	2023-07068
683.	2023-07080
684.	2023-07104
685.	2023-07134
686.	2023-07140
687.	2023-07141
688.	2023-07152
689.	2023-07158
690.	2023-07160
691.	2023-07185
692.	2023-07186
693.	2023-07187
694.	2023-07190
695.	2023-07197
696.	2023-07202
<u> </u>	

697.	2023-07215
698.	2023-07255
699.	2023-07258
700.	2023-07265
701.	2023-07284
702.	2023-07289
703.	2023-07294
704.	2023-07295
705.	2023-07319
706.	2023-07332
707.	2023-07339
708.	2023-07345
709.	2023-07346
710.	2023-07353
711.	2023-07356
712.	2023-07360
713.	2023-07361
714.	2023-07369
715.	2023-07370
716.	2023-07378
717.	2023-07396
718.	2023-07406
719.	2023-07423
720.	2023-07427
721.	2023-07430
722.	2023-07446
723.	2023-07450
724.	2023-07460
725.	2023-07461
726.	2023-07480
727.	2023-07482
728.	2023-07496
729.	2023-07498
730.	2023-07499
731.	2023-07501
732.	2023-07503
733.	2023-07513
734.	2023-07516
735.	2023-07519
736.	2023-07523
737.	2023-07534
738.	2023-07535
739.	2023-07539
740.	2023-07543
741.	2023-07545
742.	2023-07547

742	
743.	2023-07565
744.	2023-07580
745.	2023-07583
746.	2023-07594
747.	2023-07595
748.	2023-07607
749.	2023-07621
750.	2023-07634
751.	2023-07637
752.	2023-07644
753.	2023-07652
754.	2023-07653
755.	2023-07684
756.	2023-07689
757.	2023-07691
758.	2023-07694
759.	2023-07696
760.	2023-07707
761.	2023-07708
762.	2023-07720
763.	2023-07722
764.	2023-07726
765.	2023-07744
766.	2023-07764
767.	2023-07773
768.	2023-07780
769.	2023-07785
770.	2023-07787
771.	2023-07796
772.	2023-07798
773.	2023-07803
774.	2023-07804
775.	2023-07805
776.	2023-07806
777.	2023-07813
778.	2023-07817
779.	2023-07824
780.	2023-07828
781.	2023-07830
782.	2023-07833
783.	2023-07839
784.	2023-07840
785.	2023-07842
786.	2023-07845
787.	2023-07849
788.	2023-07852
L I	

789.	2023-07858
790.	2023-07865
791.	2023-07874
792.	2023-07876
793.	2023-07898
794.	2023-07907
795.	2023-07908
796.	2023-07921
797.	2023-07925
798.	2023-07926
799.	2023-07934
800.	2023-07935
801.	2023-07973
802.	2023-07986
803.	2023-07989
804.	2023-07990
805.	2023-07996
806.	2023-07998
807.	2023-08000
808.	2023-08008
809.	2023-08016
810.	2023-08035
811.	2023-08052
812.	2023-08053
813.	2023-08069
814.	2023-08072
815.	2023-08083
816.	2023-08086
817.	2023-08087
818.	2023-08094
819.	2023-08096
820.	2023-08098
821.	2023-08099
822.	2023-08104
823.	2023-08107
824.	2023-08110
825.	2023-08127
826.	2023-08128
827.	2023-08132
828.	2023-08140
829.	2023-08143
830.	2023-08144
831.	2023-08149
832.	2023-08162
833.	2023-08163
834.	2023-08175

835.	2023-08179
836.	2023-08189
837.	2023-08205
838.	2023-08207
839.	2023-08220
840.	2023-08244
841.	2023-08247
842.	2023-08252
843.	2023-08259
844.	2023-08265
845.	2023-08279
846.	2023-08299
847.	2023-08300
848.	2023-08307
849.	2023-08330
850.	2023-08331
851.	2023-08334
852.	2023-08344
853.	2023-08345
854.	2023-08348
855.	2023-08351
856.	2023-08354
857.	2023-08356
858.	2023-08365
859.	2023-08369
860.	2023-08378
861.	2023-08382
862.	2023-08390
863.	2023-08393
864.	2023-08395
865.	2023-08416
866.	2023-08425
867.	2023-08428
868.	2023-08430
869.	2023-08431
870.	2023-08435
871.	2023-08436
872.	2023-08454
873.	2023-08457
874.	2023-08461
875.	2023-08462
876.	2023-08463
877.	2023-08466
878.	
879.	
880.	
875. 876. 877. 878. 879.	2023-08462 2023-08463

881.	2023-08487
882.	2023-08497
883.	2023-08504
884.	2023-08526
885.	2023-08529
886.	2023-08550
887.	2023-08552
888.	2023-08567
889.	2023-08588
890.	2023-08593
891.	2023-08619
892.	2023-08644
893.	2023-08647
894.	2023-08672
895.	2023-08687
896.	2023-08695
897.	2023-08708
898.	2023-08723
899.	2023-08728
900.	2023-08736
901.	2023-08746
902.	2023-08747
903.	2023-08761
904.	2023-08764
905.	2023-08774
906.	2023-08781
907.	2023-08788
908.	2023-08790
909.	2023-08801
910.	2023-08802
911.	2023-08809
912.	2023-08814
913.	2023-08816
914.	2023-08832
915.	2023-08841
916.	2023-08872
917.	2023-08873
918.	2023-08874
919.	2023-08881
920.	2023-08882
921.	2023-08886
922.	2023-08891
923.	2023-08892
924.	2023-08902
925.	2023-08903
926.	2023-08911

927. 2023-08912 928. 2003-08915 929. 2023-08916 930. 2023-08928 931. 2023-08938 932. 2023-08963 933. 2023-08966 934. 2023-09023 935. 2023-09026 936. 2023-09033 937. 2023-09039 938. 2023-09047 939. 2023-09048 940. 2023-09050 941. 2023-09054 942. 2023-09068 944. 2023-09081 945. 2023-09081 945. 2023-09081 946. 2023-09088 947. 2023-09089 948. 2023-09089 947. 2023-09081 948. 2023-09092 950. 2023-09092 951. 2023-09092 952. 2023-09172 954. 2023-09135 955. 2023-09136 956.	
929. 2023-08916 930. 2023-08928 931. 2023-08938 932. 2023-08966 933. 2023-09023 935. 2023-09023 936. 2023-09033 937. 2023-09039 938. 2023-09047 939. 2023-09047 939. 2023-09050 941. 2023-09054 942. 2023-09064 943. 2023-09088 944. 2023-09084 945. 2023-09082 946. 2023-09084 947. 2023-09082 948. 2023-09082 944. 2023-09082 945. 2023-09084 947. 2023-09082 948. 2023-09089 949. 2023-09082 945. 2023-09092 950. 2023-09092 951. 2023-09093 952. 2023-09112 953. 2023-09135 955.	
930. 2023-08928 931. 2023-08928 932. 2023-08963 933. 2023-08966 934. 2023-09023 935. 2023-09026 936. 2023-09033 937. 2023-09039 938. 2023-09047 939. 2023-09047 939. 2023-09050 941. 2023-09054 942. 2023-09064 943. 2023-09088 944. 2023-09088 945. 2023-09084 946. 2023-09084 947. 2023-09084 948. 2023-09082 946. 2023-09089 948. 2023-09092 950. 2023-09092 951. 2023-09098 945. 2023-09097 951. 2023-09098 952. 2023-09112 953. 2023-09135 955. 2023-09135 955. 2023-09135 955.	
931. 2023-08938 932. 2023-08963 933. 2023-08966 934. 2023-09023 935. 2023-09026 936. 2023-09033 937. 2023-09047 939. 2023-09047 939. 2023-09050 941. 2023-09050 942. 2023-09054 942. 2023-09064 943. 2023-09068 944. 2023-09088 944. 2023-09081 945. 2023-09082 946. 2023-09084 947. 2023-09082 948. 2023-09089 949. 2023-09089 949. 2023-09092 950. 2023-09092 951. 2023-09093 952. 2023-0911 953. 2023-0912 954. 2023-09135 955. 2023-09135 955. 2023-09136 955. 2023-09152 958. 20	
932. 2023-08963 933. 2023-08966 934. 2023-09023 935. 2023-09026 936. 2023-09033 937. 2023-09039 938. 2023-09047 939. 2023-09050 941. 2023-09054 942. 2023-09064 943. 2023-09064 944. 2023-09081 945. 2023-09082 946. 2023-09084 947. 2023-09082 948. 2023-09084 947. 2023-09082 945. 2023-09084 947. 2023-09088 948. 2023-09089 949. 2023-09097 951. 2023-09097 955. 2023-09111 953. 2023-09135 955. 2023-09135 955. 2023-09136 955. 2023-09136 956. 2023-09152 957. 2023-09152 958.	
933. 2023-08966 934. 2023-09023 935. 2023-09026 936. 2023-09033 937. 2023-09039 938. 2023-09047 939. 2023-09047 939. 2023-09047 939. 2023-09047 939. 2023-09048 940. 2023-09050 941. 2023-09054 942. 2023-09064 943. 2023-09068 944. 2023-09081 945. 2023-09082 946. 2023-09082 946. 2023-09084 947. 2023-09088 948. 2023-09089 949. 2023-09097 951. 2023-09097 952. 2023-09097 953. 2023-09112 954. 2023-09135 955. 2023-09136 956. 2023-09136 957. 2023-09152 958. 2023-09152 958.	
934. 2023-0003 935. 2023-09026 936. 2023-09033 937. 2023-09039 938. 2023-09047 939. 2023-09047 939. 2023-09048 940. 2023-09048 941. 2023-09050 941. 2023-09064 942. 2023-09068 944. 2023-09081 945. 2023-09082 946. 2023-09082 946. 2023-09084 947. 2023-09084 947. 2023-09082 946. 2023-09084 947. 2023-09088 948. 2023-09089 949. 2023-09089 951. 2023-09092 955. 2023-09111 953. 2023-09112 954. 2023-09135 955. 2023-09136 955. 2023-09136 956. 2023-09136 957. 2023-09152 958. 2	
935. 2023-09026 936. 2023-09033 937. 2023-09039 938. 2023-09047 939. 2023-09047 939. 2023-09048 940. 2023-09050 941. 2023-09054 942. 2023-09064 943. 2023-09068 944. 2023-09081 945. 2023-09082 946. 2023-09084 947. 2023-09084 947. 2023-09088 948. 2023-09089 949. 2023-09089 949. 2023-09092 950. 2023-09097 951. 2023-09098 945. 2023-09097 951. 2023-09111 953. 2023-09135 955. 2023-09112 954. 2023-09135 955. 2023-09136 955. 2023-09136 955. 2023-09136 955. 2023-09152 958.	
936. 2023-09033 937. 2023-09039 938. 2023-09047 939. 2023-09048 940. 2023-09050 941. 2023-09054 942. 2023-09064 943. 2023-09068 944. 2023-09081 945. 2023-09082 946. 2023-09082 946. 2023-09084 947. 2023-09084 947. 2023-09084 948. 2023-09089 949. 2023-09089 949. 2023-09092 950. 2023-09092 951. 2023-09098 952. 2023-09097 951. 2023-09098 952. 2023-09111 953. 2023-09135 955. 2023-09135 955. 2023-09136 955. 2023-09136 955. 2023-09136 955. 2023-09136 955. 2023-09152 958.	
937. 2023-09039 938. 2023-09047 939. 2023-09048 940. 2023-09050 941. 2023-09054 942. 2023-09064 943. 2023-09068 944. 2023-09081 945. 2023-09082 946. 2023-09084 947. 2023-09084 947. 2023-09084 944. 2023-09082 946. 2023-09084 947. 2023-09089 948. 2023-09089 949. 2023-09092 950. 2023-09092 951. 2023-09093 952. 2023-09094 953. 2023-09172 954. 2023-09135 955. 2023-09135 955. 2023-09136 956. 2023-09152 958. 2023-09152 958. 2023-09172 960. 2023-09172 960. 2023-09191 961.	
938. 2023-09047 939. 2023-09048 940. 2023-09050 941. 2023-09054 942. 2023-09064 943. 2023-09068 944. 2023-09081 945. 2023-09082 946. 2023-09084 947. 2023-09088 948. 2023-09089 949. 2023-09089 949. 2023-09092 950. 2023-09092 951. 2023-09093 952. 2023-09093 955. 2023-09111 953. 2023-09112 954. 2023-09135 955. 2023-09135 955. 2023-09135 955. 2023-09136 956. 2023-09152 958. 2023-09152 959. 2023-09172 960. 2023-09172 960. 2023-09191 961. 2023-09192	
939. 2023-09048 940. 2023-09050 941. 2023-09054 942. 2023-09064 943. 2023-09068 944. 2023-09081 945. 2023-09082 946. 2023-09084 947. 2023-09088 948. 2023-09089 949. 2023-09089 949. 2023-09092 950. 2023-09097 951. 2023-09098 952. 2023-09111 953. 2023-09112 954. 2023-09135 955. 2023-09135 955. 2023-09136 956. 2023-09136 957. 2023-09136 956. 2023-09136 957. 2023-09152 958. 2023-09152 959. 2023-09172 960. 2023-09191 961. 2023-09192	
940. 2023-09050 941. 2023-09054 942. 2023-09064 943. 2023-09068 944. 2023-09081 945. 2023-09082 946. 2023-09084 947. 2023-09088 948. 2023-09089 949. 2023-09092 950. 2023-09097 951. 2023-09098 952. 2023-09111 953. 2023-09112 954. 2023-09135 955. 2023-09136 956. 2023-09136 957. 2023-09136 956. 2023-09136 957. 2023-09136 956. 2023-09136 957. 2023-09152 958. 2023-09152 958. 2023-09172 960. 2023-09172 960. 2023-09191 961. 2023-09192	
941. 2023-09054 942. 2023-09064 943. 2023-09068 944. 2023-09081 945. 2023-09082 946. 2023-09084 947. 2023-09088 948. 2023-09089 949. 2023-09092 950. 2023-09097 951. 2023-09098 952. 2023-09098 955. 2023-09111 953. 2023-09135 955. 2023-09135 955. 2023-09136 955. 2023-09136 955. 2023-09136 955. 2023-09136 955. 2023-09136 956. 2023-09136 957. 2023-09152 958. 2023-09152 959. 2023-09172 960. 2023-09191 961. 2023-09192	
942. 2023-09064 943. 2023-09068 944. 2023-09081 945. 2023-09082 946. 2023-09084 947. 2023-09088 948. 2023-09089 949. 2023-09092 950. 2023-09092 951. 2023-09098 952. 2023-09111 953. 2023-09112 954. 2023-09135 955. 2023-09135 956. 2023-09136 957. 2023-09136 956. 2023-09136 957. 2023-09136 956. 2023-09136 957. 2023-09152 958. 2023-09152 959. 2023-09172 960. 2023-09172 960. 2023-09191 961. 2023-09192	
942. 2023-09064 943. 2023-09068 944. 2023-09081 945. 2023-09082 946. 2023-09084 947. 2023-09088 948. 2023-09089 949. 2023-09092 950. 2023-09097 951. 2023-09098 952. 2023-09111 953. 2023-09112 954. 2023-09135 955. 2023-09135 955. 2023-09136 956. 2023-09136 957. 2023-09136 956. 2023-09136 957. 2023-09152 958. 2023-09152 959. 2023-09172 960. 2023-09172 960. 2023-09191 961. 2023-09192	
944. 2023-09081 945. 2023-09082 946. 2023-09084 947. 2023-09088 948. 2023-09089 949. 2023-09092 950. 2023-09097 951. 2023-09098 952. 2023-09111 953. 2023-09112 954. 2023-09135 955. 2023-09135 955. 2023-09136 955. 2023-09135 955. 2023-09152 957. 2023-09152 958. 2023-09152 959. 2023-09172 960. 2023-09191 961. 2023-09192	
944. 2023-09081 945. 2023-09082 946. 2023-09084 947. 2023-09088 948. 2023-09089 949. 2023-09092 950. 2023-09097 951. 2023-09098 952. 2023-09098 953. 2023-09111 954. 2023-09135 955. 2023-09135 955. 2023-09136 955. 2023-09136 957. 2023-09152 958. 2023-09152 959. 2023-09172 960. 2023-09191 961. 2023-09192	
945. 2023-09082 946. 2023-09084 947. 2023-09088 948. 2023-09089 949. 2023-09092 950. 2023-09097 951. 2023-09098 952. 2023-09098 953. 2023-09111 953. 2023-09135 955. 2023-09135 955. 2023-09136 955. 2023-09136 955. 2023-09136 955. 2023-09152 957. 2023-09152 958. 2023-09152 959. 2023-09172 960. 2023-09191 961. 2023-09192	
946. 2023-09084 947. 2023-09088 948. 2023-09089 949. 2023-09092 950. 2023-09097 951. 2023-09098 952. 2023-09111 953. 2023-09112 954. 2023-09135 955. 2023-09136 956. 2023-09136 957. 2023-09152 958. 2023-09165 959. 2023-09172 960. 2023-09191 961. 2023-09192	
947. 2023-09088 948. 2023-09089 949. 2023-09092 950. 2023-09097 951. 2023-09098 952. 2023-09111 953. 2023-09112 954. 2023-09135 955. 2023-09136 956. 2023-09136 957. 2023-09152 958. 2023-09165 959. 2023-09172 960. 2023-09191 961. 2023-09192	
948. 2023-09089 949. 2023-09092 950. 2023-09097 951. 2023-09098 952. 2023-09111 953. 2023-09112 954. 2023-09135 955. 2023-09136 956. 2023-09136 957. 2023-09152 958. 2023-09152 959. 2023-09172 960. 2023-09191 961. 2023-09192	
949. 2023-09092 950. 2023-09097 951. 2023-09098 952. 2023-09111 953. 2023-09112 954. 2023-09135 955. 2023-09136 956. 2023-09152 957. 2023-09152 958. 2023-09165 959. 2023-09172 960. 2023-09191 961. 2023-09192	
950. 2023-09097 951. 2023-09098 952. 2023-09111 953. 2023-09112 954. 2023-09135 955. 2023-09136 956. 2023-09139 957. 2023-09152 958. 2023-09165 959. 2023-09172 960. 2023-09191 961. 2023-09192	
951. 2023-09098 952. 2023-09111 953. 2023-09112 954. 2023-09135 955. 2023-09136 956. 2023-09139 957. 2023-09152 958. 2023-09165 959. 2023-09172 960. 2023-09191 961. 2023-09192	
952. 2023-09111 953. 2023-09112 954. 2023-09135 955. 2023-09136 956. 2023-09139 957. 2023-09152 958. 2023-09165 959. 2023-09172 960. 2023-09191 961. 2023-09192	
953. 2023-09112 954. 2023-09135 955. 2023-09136 956. 2023-09139 957. 2023-09152 958. 2023-09165 959. 2023-09172 960. 2023-09191 961. 2023-09192	
954. 2023-09135 955. 2023-09136 956. 2023-09139 957. 2023-09152 958. 2023-09165 959. 2023-09172 960. 2023-09191 961. 2023-09192	
955. 2023-09136 956. 2023-09139 957. 2023-09152 958. 2023-09165 959. 2023-09172 960. 2023-09191 961. 2023-09192	
956. 2023-09139 957. 2023-09152 958. 2023-09165 959. 2023-09172 960. 2023-09191 961. 2023-09192	
957. 2023-09152 958. 2023-09165 959. 2023-09172 960. 2023-09191 961. 2023-09192	
958. 2023-09165 959. 2023-09172 960. 2023-09191 961. 2023-09192	
959. 2023-09172 960. 2023-09191 961. 2023-09192	
960. 2023-09191 961. 2023-09192	
962 2022 00107	
962. 2023-09197	
963. 2023-09218	
964. 2023-09222	
965. 2023-09225	
966. 2023-09239	
967. 2023-09240	
968. 2023-09247	
969. 2023-09248	
970. 2023-09258	
971. 2023-09275	
972. 2023-09289	

r	
973.	2023-09294
974.	2023-09301
975.	2023-09305
976.	2023-09309
977.	2023-09317
978.	2023-09318
979.	2023-09335
980.	2023-09344
981.	2023-09345
982.	2023-09359
983.	2023-09376
984.	2023-09383
985.	2023-09396
986.	2023-09412
987.	2023-09430
988.	2023-09453
989.	2023-09454
990.	2023-09455
991.	2023-09460
992.	2023-09478
993.	2023-09482
994.	2023-09486
995.	2023-09487
996.	2023-09491
997.	2023-09509
998.	2023-09515
999.	2023-09528
1000.	2023-09540
1001.	2023-09558
1002.	2023-09559
1003.	2023-09568
1004.	2023-09569
1005.	2023-09577
1006.	2023-09579
1007.	2023-09583
1008.	2023-09588
1009.	2023-09589
1010.	2023-09598
1011.	2023-09607
1012.	2023-09615
1013.	2023-09634
1014.	2023-09638
1015.	2023-09653
1016.	2023-09657
1017.	2023-09678
1018.	2023-09682

1019.	
	2023-09697
1020.	2023-09705
1021.	2023-09707
1022.	2023-09715
1023.	2023-09724
1024.	2023-09746
1025.	2023-09750
1026.	2023-09757
1027.	2023-09767
1028.	2023-09768
1029.	2023-09780
1030.	2023-09781
1031.	2023-09782
1032.	2023-09790
1033.	2023-09795
1034.	2023-09799
1035.	2023-09800
1036.	2023-09803
1037.	2023-09804
1038.	2023-09809
1039.	2023-09811
1040.	2023-09814
1041.	2023-09815
1042.	2023-09838
1043.	2023-09842
1044.	2023-09846
1045.	2023-09851
1046.	2023-09863
1047.	2023-09870
1048.	2023-09871
1049.	2023-09874
1050.	2023-09876
1051.	2023-09878
1052.	2023-09880
1053.	2023-09891
1054.	2023-09893
1055.	2023-09904
1056.	2023-09906
1057.	2023-09910
1058.	2023-09937
1059.	2023-09939
1060.	2023-09941
1061.	2023-09949
1062.	2023-09959
1063.	2023-09959 2023-09963
1064.	2023-09968
	2023-07700

1065.	2023-09972
1066.	2023-09985
1067.	2023-09986
1068.	2023-09996
1069.	2023-09999
1070.	2023-10007
1071.	2023-10027
1072.	2023-10029
1073.	2023-10030
1074.	2023-10031
1075.	2023-10035
1076.	2023-10038
1077.	2023-10050
1078.	2023-10058
1079.	2023-10065
1080.	2023-10073
1081.	2023-10075
1082.	2023-10095
1083.	2023-10097
1084.	2023-10099
1085.	2023-10101
1086.	2023-10102
1087.	2023-10106
1088.	2023-10110
1089.	2023-10112
1090.	2023-10118
1091.	2023-10128
1092.	2023-10130
1093.	2023-10138
1094.	2023-10141
1095.	2023-10143
1096.	2023-10144
1097.	2023-10159
1098.	2023-10160
1099.	2023-10179
1100.	2023-10184
1101.	2023-10185
1102.	2023-10193
1103.	2023-10205
1104.	2023-10223
1105.	2023-10227
1106.	2023-10227
1107.	2023-10247
1108.	2023-10266
1109.	2023-10286
1110.	2023-10295
II	

1111.	2023-10297
1112.	2023-10308
1113.	2023-10312
1114.	2023-10318
1115.	2023-10322
1116.	2023-10391
1117.	2023-10398
1118.	2023-10402
1119.	2023-10403
1120.	2023-10410
1121.	2023-10428
1122.	2023-10475
1123.	2023-10496
1124.	2023-10512
1125.	2023-10540
1126.	2023-10551
1127.	2023-10563
1128.	2023-10573
1129.	2023-10576
1130.	2023-10586
1131.	2023-10600
1132.	2023-10604
1133.	2023-10605
1134.	2023-10608
1135.	2023-10614
1136.	2023-10632
1137.	2023-10636
1138.	2023-10663
1139.	2023-10668
1140.	2023-10675
1141.	2023-10701
1142.	2023-10704
1143.	2023-10712
1144.	2023-10724
1145.	2023-10730
1146.	2023-10737
1147.	2023-10752
1148.	2023-10763
1149.	2023-10766
1150.	2023-10769
1151.	2023-10773
1152.	2023-10774
1153.	2023-10780
1154.	2023-10795
1155.	2023-10838
1156.	2023-10841
L I	

1157.	2023-10849
1158.	2023-10855
1159.	2023-10856
1160.	2023-10866
1161.	2023-10874
1162.	2023-10876
1163.	2023-10886
1164.	2023-10900
1165.	2023-10912
1166.	2023-10916
1167.	2023-10939
1168.	2023-10941
1169.	2023-10944
1170.	2023-10975
1171.	2023-10977
1172.	2023-10982
1173.	2023-10991
1174.	2023-10996
1175.	2023-11000
1176.	2023-11015
1177.	2023-11021
1178.	2023-11032
1179.	2023-11035
1180.	2023-11041
1181.	2023-11042
1182.	2023-11071
1183.	2023-11076
1184.	2023-11083
1185.	2023-11086
1186.	2023-11094
1187.	2023-11099
1188.	2023-11106
1189.	2023-11108
1190.	2023-11112
1191.	2023-11117
1192.	2023-11119
1193.	2023-11155
1194.	2023-11156
1195.	2023-11157
1196.	2023-11169
1197.	2023-11172
1198.	2023-11176
1199.	2023-11177
1200.	2023-11178
1201.	2023-11200
1202.	2023-11200

1202	
1203.	2023-11214
1204.	2023-11221
1205.	2023-11223
1206.	2023-11226
1207.	2023-11246
1208.	2023-11249
1209.	2023-11250
1210.	2023-11278
1211.	2023-11281
1212.	2023-11287
1213.	2023-11290
1214.	2023-11312
1215.	2023-11314
1216.	2023-11319
1217.	2023-11328
1218.	2023-11329
1219.	2023-11356
1220.	2023-11372
1221.	2023-11386
1222.	2023-11390
1223.	2023-11396
1224.	2023-11405
1225.	2023-11429
1226.	2023-11433
1227.	2023-11434
1228.	2023-11438
1229.	2023-11446
1230.	2023-11447
1231.	2023-11456
1232.	2023-11459
1233.	2023-11473
1234.	2023-11490
1235.	2023-11508
1236.	2023-11513
1237.	2023-11513
1238.	2023-11524
1239.	2023-11578
1240.	2023-11579
1241.	2023-11579
1242.	2023-11580
1243.	2023-11594
1244.	2023-11601
1245.	2023-11601
1245.	
1240.	<u>2023-11652</u> 2023-11658
1247.	2023-11658 2023-11666
12 10.	2023-11000

1240	
1249.	2023-11670
1250.	2023-11680
1251.	2023-11682
1252.	2023-11688
1253.	2023-11693
1254.	2023-11715
1255.	2023-11731
1256.	2023-11769
1257.	2023-11775
1258.	2023-11784
1259.	2023-11785
1260.	2023-11788
1261.	2023-11794
1262.	2023-11797
1263.	2023-11800
1264.	2023-11807
1265.	2023-11820
1266.	2023-11838
1267.	2023-11844
1268.	2023-11849
1269.	2023-11858
1270.	2023-11866
1271.	2023-11867
1272.	2023-11868
1273.	2023-11874
1274.	2023-11887
1275.	2023-11890
1276.	2023-11894
1277.	2023-11916
1278.	2023-11938
1279.	2023-11988
1280.	2023-12001
1281.	2023-12001
1282.	2023-12003
1283.	2023-12024
1284.	2023-12010
1285.	2023-12031
1286.	2023-12083
1287.	2023-121087
1288.	2023-12103
1289.	2023-12110
1290.	2023-12148
1290.	2023-12151 2023-12162
1291.	
1292.	2023-12180
1293.	2023-12181
1277.	2023-12188

1295.	2023-12189
1296.	2023-12190
1297.	2023-12191
1298.	2023-12193
1299.	2023-12201
1300.	2023-12204
1301.	2023-12210
1302.	2023-12211
1303.	2023-12235
1304.	2023-12243
1305.	2023-12261
1306.	2023-12275
1307.	2023-12305
1308.	2023-12321
1309.	2023-12322
1310.	2023-12327
1311.	2023-12334
1312.	2023-12338
1313.	2023-12365
1314.	2023-12368
1315.	2023-12399
1316.	2023-12400
1317.	2023-12401
1318.	2023-12415
1319.	2023-12419
1320.	2023-12464
1321.	2023-12469
1322.	2023-12470
1323.	2023-12471
1324.	2023-12478
1325.	2023-12485
1326.	2023-12495
1327.	2023-12502
1328.	2023-12505
1329.	2023-12515
1330.	2023-12517
1331.	2023-12528
1332.	2023-12533
1333.	2023-12536
1334.	2023-12540
1335.	2023-12563
1336.	2023-12568
1337.	2023-12588
1338.	2023-12594
1339.	2023-12594
1340.	2023-12575
_ • •	<i>2</i> 0 <i>2J</i> ⁻ 1 <i>2</i> 000

1341.	
	2023-12603
1342.	2023-12610
1343.	2023-12613
1344.	2023-12630
1345.	2023-12631
1346.	2023-12652
1347.	2023-12659
1348.	2023-12668
1349.	2023-12671
1350.	2023-12677
1351.	2023-12703
1352.	2023-12720
1353.	2023-12722
1354.	2023-12737
1355.	2023-12749
1356.	2023-12767
1357.	2023-12796
1358.	2023-12812
1359.	2023-12819
1360.	2023-12827
1361.	2023-12828
1362.	2023-12832
1363.	2023-12836
1364.	2023-12840
1365.	2023-12879
1366.	2023-12883
1367.	2023-12898
1368.	2023-12899
1369.	2023-12906
1370.	2023-12907
1371.	2023-12931
1372.	2023-12937
1373.	2023-12946
1374.	2023-12951
1375.	2023-12969
1376.	2023-12975
1377.	2023-12982
1378.	2023-12991
1379.	2023-12001
1380.	2023-13009
1381.	2023-13019
1382.	2023-13040
1383.	2023-13040
1384.	2023-13063
1385.	2023-13008
1386.	2023-13077
	2025-13000

1387. $2023-13161$ $1388.$ $2023-13180$ $1389.$ $2023-13201$ $1390.$ $2023-13201$ $1391.$ $2023-13209$ $1392.$ $2023-13238$ $1393.$ $2023-13238$ $1393.$ $2023-13239$ $1394.$ $2023-13242$ $1395.$ $2023-13243$ $1396.$ $2023-13245$ $1398.$ $2023-13245$ $1399.$ $2023-13252$ $1399.$ $2023-13256$ $1400.$ $2023-13265$ $1401.$ $2023-13265$ $1402.$ $2023-13270$ $1403.$ $2023-13270$ $1404.$ $2023-13304$ $1405.$ $2023-13327$ $1406.$ $2023-13327$ $1406.$ $2023-13329$ $1407.$ $2023-13330$ $1408.$ $2023-13329$ $1410.$ $2023-13329$ $1411.$ $2023-13332$ $1414.$ $2023-13332$ $1414.$ $2023-13339$ $1414.$ $2023-13343$ $1414.$ $2023-13352$ $1414.$ $2023-13352$ $1414.$ $2023-13353$ $1414.$ $2023-13352$ $1414.$ $2023-13353$ $1415.$ $2023-13352$ $1416.$ $2023-13353$ $1417.$ $2023-13352$ $1414.$ $2023-13352$ $1414.$ $2023-13457$ $1425.$ $2023-13438$ $1421.$ $2023-13439$ $1422.$ $2023-13439$ $1424.$ $2023-13457$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	
1414. 2023-13352 1415. 2023-13358 1416. 2023-13367 1417. 2023-13379 1418. 2023-13390 1419. 2023-13435 1420. 2023-13435 1421. 2023-13438 1422. 2023-13439 1423. 2023-13441 1424. 2023-13457	
1415. 2023-13358 1416. 2023-13367 1417. 2023-13379 1418. 2023-13390 1419. 2023-13435 1420. 2023-13438 1421. 2023-13439 1422. 2023-13443 1423. 2023-13443 1424. 2023-13457	
1416. 2023-13367 1417. 2023-13379 1418. 2023-13390 1419. 2023-13435 1420. 2023-13438 1421. 2023-13439 1422. 2023-13441 1423. 2023-13443 1424. 2023-13457	
1417. 2023-13307 1418. 2023-13390 1419. 2023-13435 1420. 2023-13438 1421. 2023-13439 1422. 2023-13441 1423. 2023-13443 1424. 2023-13457	
1417. 2023-13379 1418. 2023-13390 1419. 2023-13435 1420. 2023-13438 1421. 2023-13439 1422. 2023-13441 1423. 2023-13443 1424. 2023-13457	
1419. 2023-13350 1420. 2023-13435 1421. 2023-13439 1422. 2023-13441 1423. 2023-13443 1424. 2023-13457	
1420. 2023-13438 1421. 2023-13439 1422. 2023-13441 1423. 2023-13443 1424. 2023-13457	
1421. 2023-13439 1422. 2023-13441 1423. 2023-13443 1424. 2023-13457	
1422. 2023-13431 1423. 2023-13443 1424. 2023-13457	
1423. 2023-13443 1424. 2023-13457	
1424. 2023-13457	
2023 13437	
1425	
1425. 2023-13464	
1426. 2023-13476	
1427. 2023-13482	
1428. 2023-13493	
1429. 2023-13497	
1430. 2023-13517	
1431. 2023-13547	
1432. 2023-13555	

1433.	2023-13557
1434.	2023-13577
1435.	2023-13582
1436.	2023-13592
1437.	2023-13610
1438.	2023-13628
1439.	2023-13634
1440.	2023-13651
1441.	2023-13662
1442.	2023-13668
1443.	2023-13670
1444.	2023-13680
1445.	2023-13683
1446.	2023-13697
1447.	2023-13700
1448.	2023-13701
1449.	2023-13703
1450.	2023-13723
1451.	2023-13754
1452.	2023-13763
1453.	2023-13772
1454.	2023-13784
1455.	2023-13809
1456.	2023-13815
1457.	2023-13818
1458.	2023-13823
1459.	2023-13832
1460.	2023-13838
1461.	2023-13846
1462.	2023-13867
1463.	2023-13880
1464.	2023-13883
1465.	2023-13890
1466.	2023-13917
1467.	2023-13935
1468.	2023-13989
1469.	2023-13993
1470.	2023-14009
1471.	2023-14038
1472.	2023-14050
1473.	2023-14109
1474.	2023-14115
1475.	2023-14121
1476.	2023-14132
1477.	2023-14132
1478.	2023-14179
<u> </u>	

1479.	2022 4 44 02
1479.	2023-14183
	2023-14189
1481. 1482.	2023-14196
	2023-14197
1483.	2023-14208
1484.	2023-14214
1485.	2023-14218
1486.	2023-14239
1487.	2023-14240
1488.	2023-14250
1489.	2023-14262
1490.	2023-14264
1491.	2023-14288
1492.	2023-14292
1493.	2023-14300
1494.	2023-14305
1495.	2023-14312
1496.	2023-14327
1497.	2023-14328
1498.	2023-14334
1499.	2023-14339
1500.	2023-14341
1501.	2023-14367
1502.	2023-14385
1503.	2023-14387
1504.	2023-14389
1505.	2023-14394
1506.	2023-14396
1507.	2023-14399
1508.	2023-14425
1509.	2023-14426
1510.	2023-14428
1511.	2023-14431
1512.	2023-14435
1513.	2023-14442
1514.	2023-14471
1515.	2023-14477
1516.	2023-14483
1517.	2023-14494
1518.	2023-14499
1519.	2023-14505
1520.	2023-14532
1521.	2023-14535
1522.	2023-14536
1523.	2023-14562
1524.	2023-14571
L	

1525.	2023-14603
1526.	2023-14627
1527.	2023-14635
1528.	2023-14643
1529.	2023-14645
1530.	2023-14649
1531.	2023-14651
1532.	2023-14657
1533.	2023-14674
1534.	2023-14696
1535.	2023-14708
1536.	2023-14733
1537.	2023-14741
1538.	2023-14746
1539.	2023-14755
1540.	2023-14765
1541.	2023-14768
1542.	2023-14771
1543.	2023-14774
1544.	2023-14789
1545.	2023-14795
1546.	2023-14801
1547.	2023-14802
1548.	2023-14805
1549.	2023-14810
1550.	2023-14811
1551.	2023-14830
1552.	2023-14839
1553.	2023-14875
1554.	2023-14877
1555.	2023-14883
1556.	2023-14904
1557.	2023-14920
1558.	2023-14926
1559.	2023-14931
1560.	2023-14934
1561.	2023-14942
1562.	2023-14955
1563.	2023-14970
1564.	2023-14987
1565.	2023-14996
1566.	2023-15005
1567.	2023-15005
1568.	2023-15009
1569.	2023-15009
1570.	2023-15013
	2025 ⁻ 1502 1

1571.	2023-15051
1572.	2023-15053
1573.	2023-15091
1574.	2023-15152
1575.	2023-15170
1576.	2023-15193
1577.	2023-15194
1578.	2023-15243
1579.	2023-15279
1580.	2023-15313
1581.	2023-15330
1582.	2023-15350
1583.	2023-15364
1584.	2023-15378
1585.	2023-15380
1586.	2023-15398

ವಿಜ್ಞಾನ ಮತ್ತು ತಂತ್ರಜ್ಞಾನ ದಾರ್ಶನಿಕ ಸಮೂಹ

ವಿದ್ಯುನ್ಮಾನ, ಮಾಹಿತಿ ತಂತ್ರಜ್ಞಾನ, ಜೈವಿಕ ತಂತ್ರಜ್ಞಾನ ಹಾಗೂ ವಿಜ್ಞಾನ ಮತ್ತು ತಂತ್ರಜ್ಞಾನ ಇಲಾಖೆ, ಕರ್ನಾಟಕ ಸರ್ಕಾರದ ಸಚಿವಾಲಯ, 7ನೇ ಮಹಡಿ, 4ನೇ ಹಂತ, ಬಹುಮಹಡಿ ಕಟ್ಟಡ, ಡಾಗಿ ಅಂಬೇಡ್ಕರ್ ವೀಧಿ, ಬೆಂಗಳೂರು-560001 ದೂರವಾಣಿ 080-2203-2013, ಇ-ಮೇಲ್: visiongroup, mediate karastaka gov in

	N Strice of the www. vgstost.karnataka.gov.in
ಸಂಖ್ಯೆ: ವಿತಂದಾಸ/ ಜಿ.ಆರ್.ಡಿ ಸಂಖ್ಯೆ: 1150 (202	
ಇವರಿಗೆ,	Di- There Hundard hiceshiology 01 AUG 2024 HOD hiceshiology
The Principal	0 1 AUG 2026 HOD PULL
J N Medical College	HOU LULA ANNI
Belagavi, Nehru Nagar, Belagavi - 590 010	Inward 838
ಮಾನ್ಯರೇ,	Sign.

ವಿಷಯ: K-FIST(L1) ಯೋಜನೆಯಡಿಯಲ್ಲಿ ಆಯ್ಕೆಯಾಗಿರುವ ಫಲಾನುಭವಿ ಸಂಸ್ಥೆಗೆ ಮೊದಲನೇ ಕಂತಿನ ಅನುದಾನದಿಂದ ಉಪಕರಣಗಳ/ವಸ್ತುಗಳ ಖರೀದಿಗೆ (ಜಿ.ಆರ್.ಡಿ-1150) ಅನುಮೋದನೆ ನೀಡುವ ಬಗ್ಗೆ.

ಉಲ್ಲೇಖ: 1. ಸೂಚನೆ ಪತ್ರ ಸಂಖ್ಯೆ: ಕೆಸ್ಟೆಪ್ಸ್/ವಿತಂದಾಸ/K-FIST(L1)/GRD No.1150/2022-23/671 ದಿನಾಂಕ: 05.02.2024

2. ತಮ್ಮ ಸಂಸ್ಥೆಯಿಂದ PART-A ದಾಖಲೆಗಳನ್ನು ಸಲ್ಲಿಸಲಾದ ದಿನಾಂಕ:20.03.2024

3. ಮೊದಲನೇ ಕಂತಿನ ಅನುದಾನ ಬಿಡುಗಡೆಯ ಪತ್ರದ ಸಂಖ್ಯೆ: KSTePS/VGST/2022-23/ K-FIST L1/GRD-1150 /54 /2024-25/56 ದಿನಾಂಕ:10.06.2024

ಮೇಲ್ಕಂಡ ವಿಷಯ ಮತ್ತು ಉಲ್ಲೇಖಗಳಿಗೆ ಸಂಬಂಧಿಸಿದಂತೆ, ವಿಜ್ಞಾನ ಮತ್ತು ತಂತ್ರಜ್ಘಾನ ದಾರ್ಶನಿಕ ಸಮೂಹ (ವಿತಂದಾಸ)ದ ವಿವಿಧ ಯೋಜನೆಗಳಲ್ಲೊಂದಾದ K-FIST(L1) ಕಾರ್ಯಕ್ರಮದಡಿ 2022-23ನೇ ಸಾಲಿನಲ್ಲಿ ಆಯ್ಕೆಯಾಗಿದ್ದ ಡಾ. ಶೀತಲ್ ಯು.ಹರಕುಣಿ, ಪ್ರೊಫೆಸರ್, ಮೈಕ್ರೋಬಯಾಲಜಿ ವಿಭಾಗ, J N ವೈದ್ಯಕೀಯ ಕಾಲೇಜು, ಬೆಳಗಾವಿ, ನೆಹರು ನಗರ, ಬೆಳಗಾವಿ ರವರು ಸಲ್ಲಿಸಿದ್ದ "Evaluation of antibiofilm peptide as an adjunct for better antimicrobial activity among biofilm-forming isolates of infected diabetic foot ulcer" ಶೀರ್ಷಿಕೆಯ ಪ್ರಸ್ತಾವನೆಗೆ (ಜಿ.ಆರ್.ಡಿ-1150) ಮೊದಲನೇ ಕಂತಿನ ಅನುದಾನವಾಗಿ ರೂ. 9,58,000/- ಗಳನ್ನು RTGS ಮೂಲಕ ಬಿಡುಗಡೆ ಮಾಡಲಾಗಿರುವುದು ಸರಿಯಷ್ಠ.

ಈ ನಿಟ್ಟಿನಲ್ಲಿ, ವಿತಂದಾಸ ವಿಮರ್ಶಾ ಸಮಿತಿಯ ಶಿಫಾರಸ್ಸಿನ ಆಧಾರದ ಮೇಲೆ ಮತ್ತು ಯೋಜನಾ ಸಂಯೋಜಕರು ಮೊದಲನೇ ಕಂತಿನ ಅನುದಾನಕ್ಕೆ ಸಲ್ಲಿಸಿದ್ದ PART-A ದಾಖಲೆಗೆ ಅನುಗುಣವಾಗಿ ರೆಕರಿಂಗ್ (Recurring) ಮತ್ತು ನಾನ್-ರೆಕರಿಂಗ್ (Non-recurring) ಉಪಕರಣಗಳ/ವಸ್ತುಗಳ ಖರೀದಿಗೆ ಅನುಮೋದನೆಯನ್ನು ಈ ಕೆಳಕಂಡಂತೆ ನೀಡಲಾಗಿದೆ:

ಕ್ರ. ಸಂ.	ವಿವರಗಳು ನಾನ್- ರೆಕರಿಂಗ್	ಒಟ್ಟು ಪ್ರಮಾಣ	ವಿತಂದಾಸದಿಂದ ಅನುಮೋದನೆ ನೀಡಿದ ಮೊತ್ತ (ರೂ. ಗಳಲ್ಲಿ)
1	Anaerobic Jars (Anaerobic System Mark III)	03	1,74,000.00
2	Eppendorf Research Plus Pippetes	01	1,54,000.00
	ಒಟ್ಟು ನಾನ್- ರೆಕರಿಂಗ್ ಮೊತ್ತ(A)		3,28,000.00
	ರೆಕರಿಂಗ್ ಪಟ್ಟಿ		
1	Chemicals (for 250 sample processing)		2,64,000.00
2	Glassware (250 Units)		56,000.00
3	Plasticware (for 250 sample processing)		3,00,000.00
4	Contingency		10,000.00
	ಒಟ್ಟು ರೆಕರಿಂಗ್ ಪ	ಬೊತ್ತ(B)	6,30,000.00
	ಒಟ್ಟು ನಾನ್- ರೆಕರಿಂಗ್ ಮತ್ತು ರೆಕರಿಂಗ್ ಮೊ	ತ್ತ(A+B)	9,58,000.00

--2

- ಐ) ತಮ್ಮ ಸಂಸ್ಥೆಗೆ ಸದರಿ ಯೋಜನೆ/ಕಾರ್ಯಕ್ರಮದ ಅನುಷ್ಠಾನಕ್ಕೆ ಬಡುಗಡೆ ಮಾಡಿರುವ ಮೊದಲನೇ ಕಂತಿನ ಅನುದಾನದಲ್ಲ ಬಳಕೆಯಾಗದೆ ಉಳಕೆಯಾಗುವ ಮೊತ್ತವನ್ನು ವಿತಂದಾಸದ ವಿಮರ್ಶನಾ ಸಮಿತಿ ಸಭೆಯ ಶಿಫಾರಸ್ಸಿಗನುಗುಣವಾಗಿ ಸದರಿ ಮೊತ್ತವನ್ನು ಮುಂದಿನ ಕಂತಿನ ಅನುದಾನದಲ್ಲ ಕಡಿತಗೊಳಸಿ ಉಳದ ಅನುದಾನವನ್ನು ಮಾತ್ರ ಬಡುಗಡೆ ಮಾಡಲಾಗುವುದು.
- (ಒ) ಉದ್ದೇಶಿತ ಯೋಜನೆಯ ಅನುಷ್ಠಾನಕ್ಕೆ ಸಂಬಂಧಿಸಿದಂತೆ ಪ್ರತ್ಯೇಕವಾದ ದಾಬಲೆ ಪುಸ್ತಕವನ್ನು ನಿರ್ವಹಿಸುವುದು ಹಾಗೂ ಸಂಸ್ಥೆಯ ಮುಖ್ಯಸ್ಥರು ಮತ್ತು ಕಾರ್ಯಕ್ರಮ ಸಂಯೋಜಕರು ಯೋಜನೆಗೆ ಸಂಬಂಧಪಟ್ಟ ಎಲ್ಲಾ ಲೆಕ್ಕಪತ್ರಗಳನ್ನು ಹಾಗೂ ಸಂಬಂಧಪಟ್ಟ ದಾಬಲೆಗಳನ್ನು ಸಂರಕ್ಷಿಸಿಡುವುದು. ಅಲ್ಲದೆ, ಸರ್ಕಾರದ ಮಹಾಲೇಬಪಾಲಕರು ಅಥವಾ ಕೆಸ್ಟೆಪ್ಸ್ ಸಂಸ್ಥೆಯ ಲೆಕ್ಕಪತ್ರ ತಪಾಸಣೆ ಹಾಗೂ ಮೌಲ್ಯಮಾಪನಕ್ಕಾಗಿ ಕೋರಿದಾಗ ಸದರಿ ದಾಬಲೆಗಳನ್ನು ಒದಗಿಸುವುದು.
- (ಓ) ಕೆಸ್ಟೆಪ್ಸ್/ ವಿತಂದಾಸದ ಅಧಿಕಾರಿಗಳು ಕಾರ್ಯಕ್ರಮದ ಅನುಷ್ಠಾನ ಮತ್ತು ಪ್ರಗತಿಯ ಬಗ್ಗೆ ಫಲಾನುಭವಿ ಸಂಸ್ಥೆಗೆ ಭೇಟ ನೀಡಿದಾಗ ಅಗತ್ಯ ದಾಖಲೆಗಳನ್ನು ಮತ್ತು ಭೌತಿಕ ಪ್ರಗತಿಯ ವಿವರಗಳನ್ನು ಒದಗಿಸುವುದು.
- 2) ಉದ್ದೇಶಿತ ಯೋಜನೆಯನ್ನು ವಿತಂದಾಸದ ಮಾರ್ಗಸೂಚಿ ಹಾಗೂ ಮೇಲ್ಕಂಡ ನಿಯಮಗಳು ಮತ್ತು ಷರತ್ತುಗಳನುಸಾರ ಅನುಷ್ಠಾನಗೊಳಸುವುದು.

ಶುಭಾಶಯಗಳೊಂದಿಗೆ,

ವ್ಯವಸ್ಥಾಪಕ ನಿರ್ದೇಶಕರು

ಇವರಿಗೆ,


Dresor

The Principal Jawaharlal Nehru Medical College Nehru Nagar, Belagavi-590 010

ಪ್ರತಿಗಳು:

- 1. Dr. Sheetal U Harakuni, Department of Microbiology, Jawaharlal Nehru Medical College, Nehru Nagar, Belagavi-590 010.
- 2. ವಿಜ್ಞಾನ ಮತ್ತು ತಂತ್ರಜ್ಞಾನ ದಾರ್ಶನಿಕ ಸಮೂಹ ವಿಭಾಗ, 7ನೇ ಮಹಡಿ, 4ನೇ ಹಂತ, ಬಹುಮಹಡಿ ಕಟ್ಟಡ, ಬೆಂಗಳೂರು– 01, ಇವರ ಅವಗಾಹನೆಗೆ ಮತ್ತು ಸೂಕ್ತ ಕ್ರಮಕ್ಕಾಗಿ

-3-



ವಿಷಯ: ವಿಜ್ಞಾನ ಮತ್ತು ತಂತ್ರಜ್ಞಾನ ದಾರ್ಶನಿಕ ಸಮೂಹದ KFIST (L1) ಯೋಜನೆಯಡಿಯಲ್ಲ ಮೊದಲನೇ ಕಂತಿನ ಅನುದಾನ ಜಡುಗಡೆ ಮಾಡಿರುವ ಬಗ್ಗೆ.

ವಿಜ್ಞಾನ ಮತ್ತು ತಂತ್ರಜ್ಞಾನ ಇಲಾಖೆಯು, ಖ್ಯಾತ ವಿಜ್ಞಾನಿ ಭಾರತರತ್ನ ಪ್ರೊಫೆಸರ್ ಸಿ.ಎನ್.ಆರ್. ರಾವ್, F.R.S. ರವರ ಅಧ್ಯಕ್ಷತೆಯಲ್ಲ ವಿಜ್ಞಾನ ಮತ್ತು ತಂತ್ರಜ್ಞಾನ ದಾರ್ಶನಿಕ ಸಮೂಹ (ವಿತಂದಾಸ) ವನ್ನು 2008ರಲ್ಲ ಸ್ಥಾಪಿಸಿದ್ದು. ಈ ಯೋಜನೆಯಡಿ ಹಲವಾರು ವೈಜ್ಞಾನಿಕ ಕಾರ್ಯಕ್ರಮಗಳನ್ನು ಕಳೆದ 16 ವರ್ಷಗಳಂದ ರಾಜ್ಯಾದ್ಯಂತ ಯಶಸ್ವಿಯಾಗಿ ಅನುಷ್ಠಾನಗೊಳಸಿಕೊಂಡು ಬರುತ್ತಿರುವುದು ಸರಿಯಷ್ಠೆ. 2022–23ನೇ ಸಾಅನಲ್ಲ ತಮ್ಮ ಸಂಸ್ಥೆಯಿಂದ ಸಲ್ಲಸಿದ ಪ್ರಸ್ತಾವನೆಯಾದ "Evaluation of antibiofilm peptide as an adjunct for better antimicrobial acitivity among biofilm-forming isolates of infected diabetic foot ulcer" ಅನ್ನು ವಿತಂದಾಸದ ಪ್ರಮುಖ ಕಾರ್ಯಕ್ರಮವಾದ <u>Karnataka Fund for Infrastructure Strengthening in Science and Technology</u> (<u>KFIST (L1))</u> ಅಡಿಯಲ್ಲ ದಾರ್ಶನಿಕ ಸಮೂಹವು ಆಯ್ಕೆ ಮಾಡಿ, ಸರ್ಕಾರ ಆದೇಶ ನೀಡಿರುವುದು ತಮಗೆ ತಿಳಿದ ವಿಷಯವಾಗಿದೆ.

ಆದುದರಿಂದ. ತಮ್ಮ ಸಂಸ್ಥೆಯಿಂದ ಆಯ್ಕೆಗೊಂಡ ಪ್ರಸ್ತಾವನೆಗೆ ಮೊದಲನೇ ಕಂತಿನ ಅನುದಾನವಾಗಿ ರೂ. 9.58.೦೦೦/–ಗಳನ್ನು ಕೆಸ್ಟೆಪ್ಸ್ ನಿಂದ Principal, J N M C, Belgaum ಹೆಸರಿನ ಬ್ಯಾಂಕ್ ಖಾತೆಗೆ (UTR No. SBINR52024052925729876) RTGS ಮೂಲಕ ದಿನಾಂಕ: 29.05.2024 ರಂದು ಐಡುಗಡೆ ಮಾಡಲಾಗಿರುತ್ತದೆ. ಸದರಿ ಅನುದಾನವನ್ನು ಸ್ವೀಕರಿಸಿದ ನಂತರ. ಸ್ವೀಕೃತ ರಶೀದಿ (Acknowledgement) ಯನ್ನು ಕೆಸ್ಟೆಪ್ಸ್ ಸಂಸ್ಥೆಗೆ ಕಳುಹಿಸುವುದು.

ಮುಂದುವರೆದು, ಪ್ರಸ್ತುತ ಚಿಡುಗಡೆ ಮಾಡಿರುವ 1ನೇ ಕಂತಿನ ಅನುದಾನವನ್ನು ಈ ಕೆಳಕಂಡ ಷರತ್ತು ಮತ್ತು ನಿಬಂಧನೆಗಳನ್ವಯ ಉದ್ದೇಶಿತ ಯೋಜನೆಗೆ ಮಾತ್ರ ಬಳಸಿಕೊಳ್ಳುವುದು.

ಷರತ್ತು ಮತ್ತು ನಿಬಂಧನೆಗಳು:

- ಅ) ನಿಗದಿತ ನಮೂನೆಯಲ್ಲರುವಂತೆ ಪ್ರಾಯೋಜಕತ್ವದ ಸಂಸ್ಥೆ/ಇಲಾಖೆಯ ಹೆಸರನ್ನು ಫಲಾನುಭವಿ ಸಂಸ್ಥೆಗಳಲ್ಲ ಸ್ಥಾಪಿಸಲಾಗುವ ವಿತಂದಾಸದ ಸಂಶೋಧನಾ/ಬೋಧನಾ ಕೇಂದ್ರಗಳಲ್ಲ ಕಡ್ಡಾಯವಾಗಿ ಬೋರ್ಡ್ (ಕನ್ನಡ ಮತ್ತು ಆಂಗ್ಲ ಭಾಷೆಯಲ್ಲ) ಅನ್ನು ಅಕವಡಿಸುವುದು.
- ಆ) ಉದ್ದೇಶಿತ ಯೋಜನೆ/ಕಾರ್ಯಕ್ರಮವನ್ನು ತಮ್ಮ ಸಂಸ್ಥೆಯಿಂದಾಗಲೇ ಅಥವಾ ಬೇರೆ ಸಂಸ್ಥೆಗಳ ಮುಖಾಂತರವಾಗಲೇ ಅನುಷ್ಠಾನಗೊಳಸುವಾಗ ಕರ್ನಾಟಕ ಸಾರ್ವಜನಿಕ ಸಂಗ್ರಹಣೆಯಲ್ಲ ಪಾರದರ್ಶಕತೆ ಅಧಿನಿಯಮ –1999 ಮತ್ತು ನಿಯಮಗಳು 2೦೦೦ (KTPP Act-1999 & Rules-2000) ಕರ್ನಾಟಕ ಆರ್ಥಿಕ ಸಂಹಿತೆ (KFC) ಹಾಗೂ ಕರ್ನಾಟಕ ಸರ್ಕಾರದ ಮಾರ್ಗಸೂಚಿಗಳನ್ನು ಕಟ್ಟುನಿಟ್ಟಾಗಿ (Strictly) ಮತ್ತು ಕಡ್ಡಾಯವಾಗಿ (Compulsorily) ಅನುಸರಿಸುವುದು/ಪಾಲಸುವುದು. ಮುಂದುವರಿದು, ಇ–ಟಿಂಡರ್ ನಲ್ಲ ಖರೀದಿಸಲಾಗುವ ಎಲ್ಲಾ ಉಪಕರಣ/ವಸ್ತುಗಳನ್ನು ಕಡ್ಡಾಯವಾಗಿ ಕರ್ನಾಟಕ ಸಾರ್ವಜನಿಕ ಸಂಗ್ರಹಣೆಗಳ ಪೋರ್ಟಲ್ (Karnataka Public Procurement Portal) ಮುಖಾಂತರ ಖರೀದಿಸುವುದು.

- (ಇ) ಪ್ರತಿ ತ್ರೈಮಾಸಿಕವಾಗಿ ಯೋಜನೆಯ ಪ್ರಗತಿಯ ಬಗ್ಗೆ ಪರಿಶೀಲನೆ ಮಾಡಲಾಗುವುದು. ಅದರಂತೆ, ತ್ರೈಮಾಸಿಕವಾಗಿ ಭಿ ಯೋಜನೆಯ ಪ್ರಗತಿಯ ವರದಿಯನ್ನು ವಿತಂದಾಸಕ್ಕೆ ಸಲ್ಲಸುವುದು. ಅಲ್ಲದೇ, ಪ್ರತಿ ವರ್ಷ ಕಡ್ಡಾಯವಾಗಿ ಉದ್ದೇಶಿತ ಯೋಜನೆಯ ಅನುಷ್ಠಾನದ ಪ್ರಗತಿಯ ವರದಿಯನ್ನು ಸೂಕ್ತ ದಾಖಲೆಗಳೊಂದಿಗೆ ವಿತಂದಾಸಕ್ಕೆ ಸ್ಲಜ್ಗಸುವುದು.
- (ಈ) ಉದ್ದೇಶಿತ ಯೋಜನೆಯ ಅನುಷ್ಠಾನಕ್ಕೆ ಚಿಡುಗಡೆಯಾಗುವ ಅನುದಾನದಿಂದ ಅನುಮೋದಿತ **ಪಾರ್ಟ್–ಎ (Part-**A) ನಲ್ಲ ನಮೂದಿತವಾಗಿರುವ ಉಪಕರಣ/ವಸ್ತುಗಳನ್ನು/ಸಲಕರಣಿಗಳನ್ನು ಮಾತ್ರ ಖರೀದಿಸುವುದು ಇದರಲ್ಲ ಯಾವುದೇ ಬದಲಾವಣಿಗೆ ಅವಕಾಶವಿರುವುದಿಲ್ಲ.
- ಉ) ಫಲಾನುಭವಿ ಸಂಸ್ಥೆಗೆ ಜಡುಗಡೆ ಮಾಡುವ ಅನುದಾನವನ್ನು ಉಳತಾಯ ಬ್ಯಾಂಕಿನ ಖಾತೆಯಲ್ಲಟ್ಟು ಅಗತ್ಯಕ್ಕೆ ಅನುಗುಣವಾಗಿ ಅನುಮೋದನೆ ನೀಡಿರುವ ಉದ್ದೇಶಕ್ಕೆ ಮಾತ್ರ ಅನುದಾನವನ್ನು ಬಳಸುವುದು ಹಾಗೂ ಸದರಿ ಅನುದಾನಕ್ಕೆ ಬರುವ ಬ್ಯಾಂಕ್ ಬಡ್ಡಿ ಮೊತ್ತವನ್ನು ಯಾವುದೇ ಕಾರಣಕ್ಕೂ ಉದ್ದೇಶಿತ ಯೋಜನೆಯ ಅನುಷ್ಠಾನಕ್ಕೆ ಬಳಸಿಕೊಳ್ಳಲು ಅನುಮತಿ/ಅವಕಾಶವಿರುವುದಿಲ್ಲ. ಈ ಬಡ್ಡಿಯ ಮೊತ್ತವನ್ನು ಉಪಯೋಗಿತ ಪ್ರಮಾಣ ಪತ್ರದೊಂದಿಗೆ ವ್ಯವಸ್ಥಾಪಕ ನಿರ್ದೇಶಕರು, ಕೆಸ್ಟೆಪ್ಸ್ ಇವರ ಹೆಸರಿನಲ್ಲ ಚೆಕ್/ಡಿ.ಡಿ. ಮೂಲಕ ವಾಪಸ್ ನೀಡುವುದು.
- ಊ) ಫಲಾನುಭವಿ ಸಂಸ್ಥೆಗೆ ಚಿಡುಗಡೆ ಮಾಡುವ ಅನುದಾನಕ್ಕೆ ಬ್ಯಾಂಕಿನಿಂದ ಬರುವ ಕ್ರೋಡೀಕೃತ (Accrued) ಬಡ್ಡಿ ಮೊತ್ತವನ್ನು ಉಪಯೋಗಿತಾ ಪ್ರಮಾಣಪತ್ರದಲ್ಲ ಕಡ್ಡಾಯವಾಗಿ ನಮೂದಿಸುವುದು ಮತ್ತು ಸದರಿ ಬಡ್ಡಿಯ ಮೊತ್ತದ ದೃಢೀಕರಣಕ್ಕೆ ಬ್ಯಾಂಕ್ ಖಾತಾ ಪಾಸ್ ಮಸ್ತಕದ ನೋಂದಣಿಯ ಪ್ರತಿಯನ್ನು (Latest up-to-date bank passbook copy) ಅಥವಾ ಬ್ಯಾಂಕಿನಿಂದ ಪಡೆದ ದೃಢೀಕೃತ ಪತ್ರವನ್ನು ಕಡ್ಡಾಯವಾಗಿ ವಿತಂದಾಸ/ಕೆಸ್ಟೆಪ್ಸ್ ಗೆ ಸ್ಲಳಸುವುದು.
- ಋ) ಸದರಿ ಅನುದಾನದ ಜಡುಗಡೆಯ ದಿನದಿಂದಲೇ ಉದ್ದೇಶಿತ ಕಾರ್ಯಕ್ರಮವನ್ನು ಅನುಷ್ಠಾನಗೊಳಸಲು ಕ್ರಮ ಕೈಗೊಂಡು ಒಂದು ವರ್ಷದ ಕಾಲಮಿತಿಯೊಳಗೆ ಸದರಿ ಅನುದಾನವನ್ನು ಕಡ್ಡಾಯವಾಗಿ ನಿಯಮಾನುಸಾರ ಬಳಸಿಕೊಂಡು ಉದ್ದೇಶಿತ ಕಾರ್ಯಕ್ರಮದ ಧ್ಯೇಯೋದ್ದೇಶಗಳನ್ವಯ ಅನುಷ್ಠಾನಗೊಳಸುವುದು.
- ಎ) ಉದ್ದೇಶಿತ ಯೋಜನೆ/ಕಾರ್ಯಕ್ರಮವನ್ನು ಕ್ರಿಯಾ ಯೋಜನೆಯಲ್ಲ ತಿಳಸಿರುವಂತೆ ಅನುಷ್ಠಾನಗೊಳಸಿ ಆಡಿಬ್ ಮಾಡಿಸಿ ವಿತಂದಾಸ/ಕೆಸ್ಟೆಪ್ಸ್ ನಿಂದ ನಿಗದಿಪಡಿಸಲಾದ ನೋಂದಾಯಿತ ಲೆಕ್ತಪರಿಶೋಧಕರಿಂದ ನಮೂನೆಯಲ್ಲ ಉಪಯೋಗಿತ ಪ್ರಮಾಣಪತ್ರವನ್ನು ಮತ್ತು Annexure D ಅನ್ನು (ದ್ವಿಪ್ರತಿಯಲ್ಲ) ಹಾಗೂ ಯೋಜನಾ ಪ್ರಗತಿಯ ವರದಿಯನ್ನು ಉದ್ದೇಶಿತ ಯೋಜನೆಯ ಅನುಷ್ಠಾನದ ಕಾಲಮಿತಿ ಮುಕ್ತಾಯಗೊಂಡ ಒಂದು ತಿಂಗಳ ಅವಧಿಯೊಳಗೆ ಕೆಸ್ಟೆಪ್ಸ್ ಸಂಸ್ಥೆಯ ವಿತಂದಾಸ ಕಛೇರಿಗೆ ನೀಡುವುದು.
- ಏ) ಸದರಿ ಯೋಜನೆಯಡಿ ಖರೀದಿಸಲಾಗುವ ಎಲ್ಲಾ ಉಪಕರಣ/ವಸ್ತುಗಳ ಜಿ.ಎಸ್.ಟಿ. ತೆರಿಗೆ ಒಳಗೊಂಡ ಜಿಲ್ಲುಗಳನ್ನು (GST Tax Invoice bills) ವರದಿ ಮತ್ತು ಉಪಯೋಗತಾ ಪ್ರಮಾಣಪತ್ರದ ಜೊತೆ ಎರಡನೇ ಕಂತಿನ ಅನುದಾನದ ಬಡುಗಡೆಗೆ ಮುನ್ನ ವಿತಂದಾಸ ಕಛೇರಿಗೆ ತಪ್ಪದೇ ಸಲ್ಲಸುವುದು.

300

..З

છે

4074400 Jacob 1416 1410

ಯೋಜನೆಯ ಅನುಷ್ಠಾನಕ್ಕೆ ಅನುದಾನವನ್ನು ಬಳಸುವಾಗ ಈ ಕೆಳಕಂಡ ಅಂಶಗಳನ್ನು ಕಡ್ಡಾಯವಾಗಿ ಅನುಸರಿಸುವುದು:

- ಉದ್ದೇಶಿತ ಯೋಜನೆ/ಕಾರ್ಯಕ್ರಮವನ್ನು ತಮ್ಮ ಸಂಸ್ಥೆಯಿಂದಾಗಲೀ ಅಥವಾ ಬೇರೆ ಸಂಸ್ಥೆಗಳ ಮುಖಾಂತರವಾಗಲೀ ಅನುಷ್ಠಾನಗೊಳಿಸುವಾಗ ಕರ್ನಾಟಕ ಸಾರ್ವಜನಿಕ ಸಂಗ್ರಹಣೆಯಲ್ಲಿ ಪಾರದರ್ಶಕತೆ ಅಧಿನಿಯರ್ಮ 1999 ಮತ್ತು ನಿಯಮಗಳು 2000 (KTPP Act - 1999 & Rules - 2000), ಕರ್ನಾಟಕ ಆರ್ಥಿಕ ಸಂಹಿತೆ (KFC) ಹಾಗೂ ಕರ್ನಾಟಕ ಸರ್ಕಾರದ ಮಾರ್ಗಸೂಚಿಗಳನ್ನು ಕಟ್ಟುನಿಟ್ಟಾಗಿ (Strictly) ಮತ್ತು ಕಡ್ಡಾಯವಾಗಿ (Compulsorily) ಅನುಸರಿಸುವುದು/ ಪಾಲಿಸುವುದು.
- 2. ಉದ್ದೇಶಿತ ಯೋಜನೆಯ ಅನುಷ್ಠಾನಕ್ಕೆ ಭಿಡುಗಡೆಯಾಗುವ ಅನುದಾನದಿಂದ ಅನುಮೋದಿತ ಪಾರ್ಟ್-ಎ (Part-A) ನಲ್ಲಿ ನಮೂದಿತವಾಗಿರುವ ಉಪಕರಣಗಳು / ವಸ್ತುಗಳನ್ನು ಮಾತ್ರ ಖರೀದಿಸುವುದು. ಇದರಲ್ಲಿ ಯಾವುದೇ ಬದಲಾವಣೆಗೆ ಅವಕಾಶವಿರುವುದಿಲ್ಲ.
- 3. ರೂ.1.00 ಲಕ್ಷ ಮತ್ತು ಅದಕ್ಕಿಂತ ಹೆಚ್ಚಿನ ಬೆಲೆಯ ಉಪಕರಣ/ವಸ್ತುಗಳನ್ನು ಕಡ್ಡಾಯವಾಗಿ (Compulsory) ಇ-ಟೆಂಡರ್ ನಲ್ಲಿ "ಕರ್ನಾಟಕ ಸಾರ್ವಜನಿಕ ಸಂಗ್ರಹಣೆಗಳ ಪೋರ್ಟಲ್" (Karnataka Public Procurement Portal) ಮುಖಾಂತರ ಖರೀದಿಸುವುದು. ರೂ. 1.00 ಲಕ್ಷಕ್ಕಿಂತ ಕಡಿಮೆ ಬೆಲೆಯ ಉಪಕರಣಗಳನ್ನು ಮ್ಯಾನ್ಯುಯಲ್ ಟೆಂಡರ್ (Manual Tender) ಮೂಲಕ ಖರೀದಿಸಬಹುದು.
- 4. ಸದರಿ ಯೋಜನೆಯಡಿ ಖರೀದಿಸಲಾಗುವ ಎಲ್ಲ ಉಪಕರಣ/ವಸ್ತುಗಳ ಜಿ. ಎಸ್. ಟಿ. ತೆರಿಗೆಯನ್ನು ಒಳಗೊಂಡ ಬಿಲ್ಲುಗಳು (GST Tax Invoice bills) ಹಾಗೂ ಟೆಂಡರ್ ಪ್ರಕ್ರಿಯೆಯ ದಾಖಲೆಗಳನ್ನು ವರದಿ ಮತ್ತು ಉಪಯೋಗಿತಾ ಪ್ರಮಾಣಪತ್ರದ ಜೊತೆ ಎರಡನೇ ಕಂತಿನ ಅನುದಾನದ ಬಿಡುಗಡೆಗೆ ಮುನ್ನ ವಿತಂದಾಸ ಕಛೇರಿಗೆ ತಪ್ಪದೆ ಸಲ್ಲಿಸುವುದು.
- 5. ಫಲಾನುಭವಿ ಸಂಸ್ಥೆಗೆ ಬಿಡುಗಡೆ ಮಾಡುವ ಅನುದಾನವನ್ನು ಅಗತ್ಯಕ್ಕೆ ಅನುಗುಣವಾಗಿ ನೀಡಲಾದ ಉದ್ದೇಶಕ್ಕೆ ಮಾತ್ರ ಬಳಸುವುದು ಹಾಗೂ ಸದರಿ ಅನುದಾನಕ್ಕೆ ಬರುವ ಬ್ಯಾಂಕ್ ಬಡ್ಡಿ ಮೊತ್ತವನ್ನು ಯಾವುದೇ ಕಾರಣಕ್ಕೂ ಉದ್ದೇಶಿತ ಯೋಜನೆಯ ಅನುಷ್ಠಾನಕ್ಕೆ ಬಳಸಿಕೊಳ್ಳಲು ಅನುಮತಿ/ ಅವಕಾಶವಿರುವುದಿಲ್ಲ. ಈ ಬಡ್ಡಿಯ ಮೊತ್ತವನ್ನು ಉಪಯೋಗಿತ ಪ್ರಮಾಣಪತ್ರದೊಂದಿಗೆ ವ್ಯವಸ್ಥಾಪಕ ನಿರ್ದೇಶಕರು, ಕೆಸ್ಟೆಪ್ಸ್ ರವರ ಹೆಸರಿನಲ್ಲಿ ಚೆಕ್/ಡಿ.ಡಿ. ಮೂಲಕ ಹಿಂತಿರುಗಿಸುವುದು.
- 6. ತಮ್ಮ ಸಂಸ್ಥೆಗೆ ಸದರಿ ಕಾರ್ಯಕ್ರಮದ ಅನುಷ್ಠಾನಕ್ಕೆ ಬಿಡುಗಡೆಯಾಗಿರುವ ಅನುದಾನದಲ್ಲಿ ಬಳಕೆಯಾಗದೆ ಉಳಿಕೆಯಾಗುವ ಮೊತ್ತವನ್ನು ಮುಂದಿನ ಕಂತಿನ ಅನುದಾನದಲ್ಲಿ ಕಡಿತಗೊಳಿಸಿ ಉಳಿದ ಅನುದಾನವನ್ನು ಬಿಡುಗಡೆ ಮಾಡಲಾಗುವುದು. ಅದರೆ, ಅದು ಯೋಜನೆಯ ಕೊನೆಯ ಕಂತು ಆಗಿದ್ದಲ್ಲಿ ಉಳಿಕೆಯಾಗುವ ಮೊತ್ತವನ್ನು ವಿತಂದಾಸಕ್ಕೆ ಹಿಂತಿರುಗಿಸುವುದು.
- ಯೋಜನೆಯನ್ನು ಕಾರ್ಯಗತಗೊಳಿಸುವಾಗ ಸರ್ಕಾರದ ಎಲ್ಲಾ ಮಾರ್ಗಸೂಚಿಗಳು, ನಿಯಮಗಳು ಮತ್ತು ಷರತ್ತುಗಳನ್ನು ತಪ್ಪದೇ ಕಟ್ಟುನಿಟ್ಟಾಗಿ ಅನುಸರಿಸತಕ್ಕದ್ದು.
- 8. ಯೋಜನೆಯ ಅನುಷ್ಠಾನದ ಯಾವುದೇ ಹಂತದಲ್ಲಿ ಯಾವುದೇ ಮಾಹಿತಿಯ ಅಗತ್ಯವಿದ್ದಲ್ಲಿ, ವಿತಂದಾಸ ಕಛೇರಿಯನ್ನು ಸಂಪರ್ಕಿಸಬಹುದು.

ತಮ್ಮ ವಿಶ್ವಾಸಿ, Rhut terha 26/07/202 ಆರ್.ಟಿ. ವೆಂಕಟೇಶ ವಿಜ್ಞಾನಿ-ಎಸ್.ಇ, ಕೆಸೈಪ್ಸ್ /ಸಂಯೋಜಕರು, ವಿತಂದಾಸ

ಪ್ರತಿ: Dr. Sheetal U Harakuni, Professor, Department of Microbiology, J N Medical College, Belagavi, Nehru Nagar, Belagavi - 590 010

movie and state from the section of THE PARTY STATION WATER PARTY IN THE PARTY IS Web-rate science or minimum ina contraction of the second of the भारतीय आयुर्विज्ञान अनुसंधान परिषद INDIAN COUNCIL OF MEDICAL RESEARCH वो रामलिगगवामां भवनः अन्यांगे नगरः योग्रह योकम् ४९।।, मई डिल्लो -(10.029 V.RAMAUNGASWAMI BILAWAN, ANSARI NAGAR, POST BOX 4911, NEW DELHI - 110 029 File No. 5/7/1727/NTF/2020-RBMCH Dated: 01.09.2021 Subject: ICMR Task Force study entitled: "India Pediatric HIV Cohort" Dear Dr. Dorle & Mubashir, As you are aware, under the initiative on Pediatric HIV, the Project Advisory Group Meeting on 11.10 2018, approved a proposal entitled: "India Pediatric HIV Cohort' for a 3 years duration. As per 0 recommendation of PAG, ICMR has approved a task force study entitled: India Pediatric HIV Cohort with total budget of Rs 1.36.12.769- in FY 2020-2021. As a study of National importance and that coordinated by ICMR. This project is implemented at SNMC, Bagalkot under Dr. Ashok Dorle and INMC (K MIER) Belgaum under Dr. Mubashir Angolkar as Pla. Total 3rd year 2nd year 1st year 42.71,227/-Siles Name SI.No. 15.77.776/-4.51.402/-22.42.049/-SNMC. Bagalkot 48,84,102/-9.17.891/-19,77,418/-19.88.793/-INMC 2. (KAHER). 44,57,440/-Belgaum 16.94.360/-14,02,480/-13.60.600/-Hqrs. ICMR 3 Coordinating site 1,36,12,769/-**Lotal Sanctioned amount** ICMR has already released the first year grant to both implementing sites which was transferred in FY 2021-2022. This is for your kind information. Yours sincerely,

(Dr. Anju Sinha) Consultant (Scientist) For Director General

TO.

- 1. Dr. Ashok S. Dorle, Professor and Head, Dept. of Community Medicine, S. Nijalingappa Medical College and H.S.K Hospital and Research Centre, Navanagar, Bagalkot 587102
- 2. Dr. Mubashir Angolkar, Head, Dept. of Public Health, Jawaharlal Nehru Medical College, KAHER, Nehru Nagar, Belagavi - 590010

.*





भारतीय आयुर्विज्ञान अनुसंधान परिषद स्वाख्थ्य अनुसंधान विभाग, स्वाख्थ्य और परिवार कल्याण मंत्रालय, भारत सरकार

Indian Council of Medical Research

Department of Health Research, Ministry of Health and Family Welfare, Government of India

Dated: 27, 8,

No-HRD-Head/PGthesis-program/2023-24 (47)

To,

Dr. Sruthi Krishna Jumbugolum, Department of Community Medicine, Jawaharlal Nehru Medical College, Belagavi-590010 MDMS23DEC-0480

Subject:- Award of ICMR Financial Support for the ICMR MD/MS/DM/MCH/DNB/Dr.NB/MDS thesis for the 2023 batch- reg.

Dear Dr. Sruthi Krishna Jumbugolum,

This is in reference to your application seeking financial assistance from the ICMR-DHR under PG Medical and Dental Thesis Program, for the study entitled "Assessment of risk factors for hypertensive disorders of pregnancy among women delivering at tertiary care facility : A case-control study" at JNMC Belagavi under the guidance of Dr. Avinash Kavi, Department of Community Medicine.

On behalf of Secretary DHR and DG, ICMR, We are pleased to inform you that, ICMR-DHR is awarding stipend of Rs. 1,00,000/- (one lakh only) as a financial support for your PG thesis. The amount will be disbursed in two installments. The first installment that is amount of Rs. 25,000/- will be released after receipt of the undertaking duly forwarded through the guide as per the existing guidelines and the 2nd installment that is amount of Rs. 75,000/- will be released on receipt of the following documents as mentioned below, duly approved and forwarded by the competent authority of the Host Institute:

- 1. Forwarding PG Thesis submission certificate duly signed by the competent authority of the host Institute.
- 2. Summary of thesis work done though the guide.
- 3. Copy of the publication(s) only related to the PG thesis highlighting the due acknowledgement for funding support from ICMR-DHR.

You are also required to submit the a/m undertaking, along with the duly filled and signed mandate form (format available on ICMR website), a photocopy of the cancelled cheque within two weeks of the receipt of this letter, for the purpose of verification of the bank account where the stipend is to be remitted. This will enable the release of the 1st installment of the grant (please ignore, if both the documents are already submitted).

Yours faithfully

Administrative Officer-HRD (For Director General, ICMR)

Copy to:

1. Guide: Dr.Avinash Kavi, Department of Community Medicine, Jawaharlal Nehru Medical College, Belagavi-590010.

वी. रामलिंगस्वामी भवन, पोस्ट बॉक्स नं. 4911, अंसारी नगर, नई दिल्ली - 110 029, भारत

V. Ramalingaswami Bhawan, P.O. Box No. 4911, Ansari Nagar, New Delhi - 110 029, India Tel: +91-11-26588895 / 26588980 / 26589794 +91-11-26589336 / 26588707 Fax: +91-11-26588662 | icmr.nic.in



आई सी एम आर - राष्ट्रीय रोग सूचना विज्ञान एवं अनुसंधान केंद्र स्वास्थ्य अनुसंधान विभाग, स्वास्थ्य एवं परिवार कल्याण मंत्रालय, भारत सरकार ICMR - National Centre for Disease Informatics and Research Department of Health Research, Ministry of Health and Family Welfare, Government of India

Dated: 05.09.2024

NCDIR/DHR/1002/2022[E-file No. 164968] /8157-

Dr. Kumar Vinchurkar, Chief Consultant, Surgical Oncology, KLES Dr Prabhakar Kore Hospital & Medical Research Centre, Belagavi, Karnataka – 590 010

Sir,

Sub: Project entitled "A Situational analysis of cancer care services in India" at KLES Dr Prabhakar Kore Hospital & Medical Research Centre, Belagavi, Karnataka.

Thank you for submitting the duly signed Memorandum of Understanding (MoU) and other related documents pertaining to the above-mentioned project.

Please find enclosed one copy of the MoU duly signed by Director, ICMR-NCDIR, Bengaluru.

भवदीय /Yours faithfully,

finisz (रमेशा एन.एम /Ramesha N.M.)

वरिष्ठ प्रशासनिक अधिकारी /Sr. Administrative Officer

निर्मल भवन, आई सी एम आर कॉप्लेक्स, पूजनहद्वी रोड, कन्नमंगला पोस्ट, बेंगलुरु - 562 110. कर्नाटक (भारत)



NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH, Bengaluru (INDIAN COUNCIL OF MEDICAL RESEARCH)

Memorandum of Understanding

<u>between</u>

<u>The National Centre for Disease Informatics and Research (NCDIR), Bengaluru</u> <u>and</u> <u>KLES Dr Prabhakar Kore Hospital & Medical Research Centre, Belagavi,</u> Karnataka (Nodal Institution)

Project entitled 'A SITUATIONAL ANALYSIS OF CANCER CARE SERVICES IN INDIA' UNDER INDIAN COUNCIL OF MEDICAL RESEARCH: NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH (NCDIR), BENGALURU.

- 1. The broad and overall objective of National Centre for Disease Informatics and Research (NCDIR), Bengaluru is to sustain and develop a national research data-base on cancer, diabetes, CVD, stroke, other NCDs and their risk factors through recent advances in electronic information technology with a national collaborative network, so as to undertake etiological, epidemiological, clinical and control research in these areas.
- 2. The project entitled "A SITUATIONAL ANALYSIS OF CANCER CARE SERVICES IN INDIA" is being funded by Department of Health Research, (Ministry of Health and Family Welfare, Government of India, New Delhi) through the <u>ICMR- National Centre for Disease</u> <u>Informatics and Research, Bengaluru, Karnataka (Central Coordinating Institution) at KLES</u> <u>Dr Prabhakar Kore Hospital & Medical Research Centre, Belagavi, Karnataka (Nodal</u> institution) with the following objectives:

Primary objectives

(i) To assess the availability and distribution of cancer care services according to geographic location.

Secondary objectives

- (i) To identify disparities in the availability of cancer care services
- (ii) To propose a framework for strengthening cancer care provision in India.

The study encompasses a situational analysis of the status of cancer care services in terms of physical infrastructure, human resources, referral links and care coordination at cancer diagnosing and treating facilities in the given state/UT of <u>Karnataka</u> covering the following districts <u>Belagavi</u>, <u>Bagalkote</u>, <u>Raichur</u>, <u>Bijapura</u>, <u>Yadgir</u>, <u>Kalaburagi</u>, <u>Bidar</u>, <u>Dharwad</u>, <u>Gadag</u>, <u>Koppal</u>.

The study is being conducted in a phase wise manner covering all the states and Union Territories throughout the country through a network of Nodal Institutions. Each Nodal Institution is expected to cover a pre-determined number of cancer treating health facilities in a selected number of districts and complete the survey within duration of three months

- 3. The nodal hospital is responsible for the following:
- Identifying all tertiary (including your institution), secondary-level cancer treatment hospitals, and Primary Health Centres (PHCs) in the specified districts with support of ICMR-NCDIR
- Establishing contact with a nodal person at each of these institutions.
- Facilitating data collection through a user-friendly online portal from all these hospitals. This will include information on the availability of cancer diagnosis and treatment facilities, human resources, infrastructure, and cancer screening facilities at the PHCs.
- Check for any data errors/ missing values in the data that is compiled from the identified participating institutions.
- Submit the compiled data through a survey portal provided by ICMR-NCDIR.
- Ensure proactive communication and coordination with ICMR-NCDIR

4. Data ownership, sharing and preparation of reports/publications

The ICMR-NCDIR will serve as the primary custodian of the data. After collecting and receiving complete data from all the identified nodal hospitals in this study, the NCDIR study team will execute the entire analysis plan, including data cleaning and seeking clarifications from the participating centers. A consolidated report will be prepared between June and August 2026, acknowledging the involvement of the participating nodal officers and hospitals. The ICMR-NCDIR will collaboratively prepare manuscripts with the nodal hospitals for publication in peer-reviewed journals, based on suitable research questions and data availability. If a nodal officer wishes to conduct any further analysis, anonymized data without health facility identifiers will be made available for the preparation of scientific publications.

5. Cost to NCDIR:

- Funds are being provided to cover costs related to communication and incentives for any hospital staff who may be involved in communicating and coordinating with cancer treating hospitals in the selected districts.
- The funds should be spent for the purpose for which it has been sanctioned.
- A separate bank account (Current/ Savings) for the grants received and expenditure incurred shall be maintained. The accounts will be subjected to audit by the authorized auditors of the centre and ICMR-NCDIR.

• The nodal officer agrees to send the statement of expenditure and utilization certificates duly verified and signed by the Accounts Officer/ Drawing and Disbursing Officer. The same has to be done under each budgetary head

6. The project sanction is for <u>three months</u>, and it is effective from 01.09.2024. The funds will be released on an instalment basis based on performance.

In consideration of the above, a budget of **Rs. 19,000/-** is provided and will be released as a contingency amount after receiving the duly completed MoU and mandate form and completion of the required formalities

The undersigned parties hereby agree and conclude the present agreement:

Signature:

Ante Nate

Dr. Anita Nath Principal Investigator NCDIR, Bengaluru Email ID: anita.nath@icmr.gov.in Date: जिन्हींग तीनक - ई/Scientist - EF (जिई सी का 1927), बेंगलुरु Wational Centre for Disease Informatice

and Research (ICMR), Bengaluru

Signature: Dr. Kumar Vinchurkar Professor & VC HOD Surgical Oncology Nodal Officer College, BELAGAVI

Name: D.R. KUMAR VINCHURKAR Designation: PROF & HERD, SURG.ONCO Email: VKUMAR_007@YAHOD. COM

Date:

Head of the institution Jawaharlel Nehru Medical College BELAGAVI

Name:

Designation:

Full Postal address: Institutional website:

Date:

PRINCIPAL	Office of the J. N. MEDICAL COLLEGE BELAGAVI
From: Sent: To:	STO Karnataka <stoka@rntcp.org> Wednesday, March 6, 2024 2:11 PM Director cum Dean BMCRI; M S Ramaiah rajarajeswarimedicalcollege@yahoo.com principal@mvjmc.edu.in; Chandra shekar drbramc@yahoo.co.in; principal.epcms@eastpoint.ac.in; principal.tomch@theoxford.edu; bgsprincipal@gmail.com; Dr. M E MOHAN; Esi</stoka@rntcp.org>
	Pgimsr; Dean Principal; dean.sjmc@stjohns.in; tbchest_alamelu104@vimsmail.com;
	principalmedical@vimsmail.com;
	principal@ssmctumkur.org; shridevimedical@gmail.com; info@smcri.edu.in; principal@ssmcri.edu.in; director@smcri.edu.in; dean@ajims.edu.in; dean fmmc; kimsrntcpdkn@gmail.com; dean@kanachur.edu.in; dean.kmcmlr@manipal.edu; dean.kshema@nitte.edu.in; KVG MEDICAL COLLEGE; deanmedical@srinivasgroup.com; principalymc@yenepoya.edu.in; Dean KMCMpl [MAHE-KMC]; office.kmc@manipal.edu; Director Krwr; principalgrmc@gmail.com;
	MIMS Mandva; iss mc; mmcrimysore@yahoo.com; DIRECTOR CIMS;
	directorhims@yahoo.com; Director Kodagu; aims@bgsaims.edu.in; directorcims202 @gmail.com; info@scmch.org; principal@scmch.org; snmcmedbgk@yahoo.co.in; Director Gims; commedgimsgulbarga@gmail.com; deanesicdcglb@yahoo.com; Lavanya SP; dean.medicine@kbn.university; Dr. K. Monappa; Principal Navodaya; info@rims-raichur.com; msrimsthr@gmail.com; alameenbijapur@yahoo.com; Dean Faculty of Medicine and Principal Shri B M Patil Medical College Hospital and RC,
	Vijayapur; directoryimsyadgir@gmail.com; director@brims-bidar.in;
	principalbrims@gmail.com; Director KIMS,KOPPAL; Director Vims;
	imsballaridirector@karnataka.gov.in; director@sims-shimoga.com; dir sims; smcshimoga@yahoo.co.in; himshvr@gmail.com; gimsgadag@gmail.com; principaljgmm2021@gmail.com; Ramalingappa Antaratani; Principal Hubli; Dr. S. K. Joshi SDM; principal@jjmmc.org; principalssimsrc@gmail.com; bmc_h@hotmail.cor deancmcri@gmail.com; Director BIMS; principal@jnmc.edu; jyothihattiholi
•	Mission Director, NHM; ZTF South Zone 1; Naghabhushan - SAPTHAGIRI; Mamatha V; Ramachandra Kamath; akshay k m; Balu Palicheralu; Sharath BN; STF Karnataka; o anil; Bharathraj.B.S Davangere; Pratham A S; drshivappahkt1969@gmail.com; kaconsultants; jdtb lwstc
bject:	Re: Proceedings of the State Task Force Meeting held on 8th Dec 2023
achments:	Annexure 1.pdf

Please find the attached list of PG thesis to be approved for funding during the year 2023-24.

On Fri, 12 Jan 2024 at 19:44, STO Karnataka <<u>stoka@rntcp.org</u>> wrote: Dear Sir/Madam,

Please find attached the proceeding of the State Task Force (STF) meeting held on 8th Dec 2023 .

Cortes of the i heroical societ creation societ

Regards, Dr. Shivayogappa.U MBBS, D.ORTHO Joint Director (TB), STO – Karnataka, LWSTC, 2nd Floor, Arogya Soudha, Magadi Road, Bengaluru-23, Karnataka. Contact No.9449843405



Regards, Dr. Shivayogappa.U MBBS, D.ORTHO Joint Director (TB), STO – Karnataka, LWSTC, 2nd Floor, Arogya Soudha, Magadi Road, Bengaluru-23, Karnataka. Contact No.9449843405

SI. Name of Course and No. Applicant Institution Subject Title of study Dr. Amaal Kareen MD Community Sri Siddhartha Medical A study to Assess Challenges in Implementation of Medicine College, 1. Tuberculosis Preventive Treatment and Factors Influencing Tumkur. Karnataka TPT among House hold contacts of TB patients in Tumkur city, Karnataka Mr. Amrut PhD Scholar. Yenepoya School of Psychological stress and health-related quality of life among 2. Hondappagol Department of Allied Health Sciences, Tuberculosis patients in Dakshina Kannada: A prospective Public Health Mangaluru cohort study Dr. Ankit Dua **MD** Community Jawaharlal Nehru Awareness and Utilisation of 'patient support systems' 3. Medicine Medical College. among patients diagnosed with Tuberculosis in an urban KAHER, Belagavi area: A Descriptive study Dr. Aparna S Nair MD Community ESIC Medical College Tuberculosis preventive therapy and its adherence among 4. Medicine and household contacts of Pulmonary TB patients in selected TB PGIMSR. Bengaluru, Karnataka Units of Bengaluru Urban District Dr. Dev Rishi MD Respiratory KAHERS Jawaharlal Comparative Study To Find Sensitivity And Specificity Of Medicine Nehru Medical College, Bronchoalveolar Aspirate CBNAAT For Mycobacterium Belagavi Tuberculosis And Induced Sputum CBNAAT For 5. Mycobacterium Tuberculosis In Diagnosis Of Sputum Negative Pulmonary Tuberculosis - A One Year Tertiary Hospital Based Study Dr. Hariprasad K **MD** Respiratory Shridevi Institute A study on clinical, radiological, microbiological outcome in of Medicine Medical Sciences and MDR-TB patient receiving Bedaquiline containing anti-6. Research Hospital, tubercular regimen, after six months of initiation of Tumkur treatment MD Respiratory Karnataka Institute of Study of clinical profile, microbiological, radiological Dr. Impa M R Medicine Medical Sciences. features of Pulmonary Tuberculosis and its treatment 7. Hubballi, Karnataka response, outcome in geriatric patients at a tertiary care 21. Huy Autoint Unector hospital

Magaal Real

Annexure 1: List of PG thesis/ dissertations to be approved for funding during 2023-24

8.	Dr. Merlyn Mony Vadakkan	MD Respiratory Medicine	Sri Siddhartha Medical College, Tumkur, Karnataka	effect on the outcome of tuberculosis. A prosperior
9.	Dr. Monisha Mary P	MD Community Medicine	K Ş Hegde Medical Academy, Deralakatte, Mangalore	for Tuberculosis among diabetes menitus patiente menitus community in Karnataka
10.	Dr. Monisha MN	MD Microbiology	Bangalore Medical College and Research Institute, Bangalore, Karnataka	antibiotic susceptibility pattern in a tertiary care nospital
11.	Dr. Mridul M	MD Community Medicine	Yenepoya Medical College, Deralakatte, Mangalore	sensitive Tuberculosis: A Cross- sectional study from Dakshina Kannada, Karnataka
12.	Dr. Narendra B C	MD Psychiatry	KVG Medical College and Hospital, Sullia	Impact of alcohol use disorder on tuberculosis treatment outcome in Sullia taluk
13.՝	Dr. Pooja B Hebballi	MD Community Medicine	JJM Medical College, Davangere	household contacts of Tuberculosis patients- A community based cohort study from central Karnataka
14.	Ms. Rajashree V Hosamani	МРН	KAHERs Jawaharlal Nehru Medical College, Belagavi	Exploring the chalenges regarding HIV and TB co-infected
15.	Dr. Ruthvik B S	MD Respiratory Medicine	JJM Medical College, Davangere	Study on Pattern of Lung USG Findings and Co-Morbidities in Newly Detected Pulmonary Tuberculosis Cases
16.	Dr. Shaiby M O	MD Community Medicine	St. John's Medical College, Bengaluru	Latent Tuberculosis Infection in people with and without Diabetes Mellitus, registered at an Urban Health Training Center, in Bengaluru City-A Cross Sectional Comparative Study
17.	Dr. Shreyas Shastry C S	MD Respiratory Medicine	JJM Medical College, Davangere	Comparison of clinical profile and quality of life in patients with post tuberculosis obstructive airway disease with patients of chronic obstructive airway disease

18.	Ms. Shruti Zadbuke	MPH	KAHERs Jawaharləl Nahru Medical College, Beləgəvi	Assessment of Quality of Sleep Among Tuberculosis Patients Registered with District TB Centre Belagavi: A community based cross sectional study An Observational Cross-Sectional Study Of "Pattern Of
19.	Dr. Siddhartha S Chikkeri	MD Respiratory Medicine	The Oxford Medical College Hospital and Research Center, Bengaluru	Pulmonary Dysfunction Among Treatment Complete Pulmonary Tuberculosis Patients
20.	Mr.Srinivas M	Ph.D. Scholar	Sri Devaraj Urs Academy of Higher Education and Research, Kolar	Effect of Integrated Yoga as an adjuvant therapy to standard care in Pulmonary Tuberculosis- A Randomized Control Trial
21.	Dr. Supreetha	MD Respiratory Medicine	KVG Medical College, Sullia	Comprison of clinico-radiological features between alcoholics and non-alcoholic in microbiologically confirmed Pulmonary Tuberculosis diagnosed in Sullia Taluk
22.	Dr. Ullas Sathya Babu	MD Community Medicine	Yenepoya Medical College, Deralakatte, Mangalore	A Stakeholder Analysis on Stigma Among People with Tuberculosis and its Influencing Factors - Mixed Method Study from Mangalore Taluka
23.	Ms. Umme Zainab I Todewale	MPH	KAHERs Jawaharlal Nghru Medical College, Belagavi	Assessment of Knowledge, Attitude, and Practice on Tuberculosis among School Teachers in Belagavi- A cross sectional study

21. Sugan

Joint Director (TB) Lady Willingdon State TC, Centre Arogya Soudha, 2nd Florir, 1st Cross. Magadi Road, Bengeluru - 500 023.





भारतीय आयुर्विज्ञान अनुसंधान परिवद स्वास्थ्य अनुसंधान विनाग, स्वास्थ्य एव परिवार कल्पाण नवालय, नारत सरकार

Date: 29/0//2024

Indian Council of Medical Research Department of Health Research, Ministry of Health and Family Welfare, Government of India

File No. EM/Dev/SG/161/7380/2023 (E-Office-173937)

Subject: Payment of Full Instalment of 1st Year grant in aid for the research scheme entitled "Development of non-invasive Point of Care Testing Device to Screen Oral Potentially Malignant Disorders at all Levels of Health Care." under Dr Ashwini Narasannavar Basagouda Narasannavar, Associate Professor Jawaharlal Nehru Medical College, Belagavi-590010.

MEMORANDUM

The Director General, ICMR sanction the payment of **Rs. 84,11,105/- (Rupees Eighty Four Lakh Eleven Thousand One Hundred Five Only)** as the full instalment of 1st Year grant for incurring expenditure in connection with the above mentioned research scheme. The amount of Rs. 84,11,105/- may be debited in the provision of Rs. 84,11,105/- made for the above research scheme for the current Financial Year 2023-24.

A formal bill for <u>Rs. 84,11,105/-</u> is sent herewith for payment to Principal J.N. Medical College, <u>Belagavi</u> through RTGS BANK ACCOUNT NUMBER: 05042160000052, MICR CODE of bank 590015019, IFSC Code CNRB0010504.

> (Harjeet Kaur Bajaj) Administrative Officer

Accounts Section- V, ICMR

(This issue with the concurrence of Finance Section vide E-office No. 173937 dated 24.01.2024)

Copy to:

- 1. The Principal, Jawaharlal Nehru Medical College, Belagavi-590010
- 2. Dr Ashwini Narasannavar Basagouda Narasannavar, Associate Professor Jawaharlal Nehru Medical College, Belagavi-590010
- 3. IIRP Section Number (2023-7380)
- 4. Mr. Rohitash, Budget Coordinator, Division of Development Research.





भारतीय आयुविज्ञान अनुसंधान धारेषद स्यास्थ्य अनुसंधान विभाग, स्वास्थ्य एवं धारेवार कल्याण मंत्रालय, भारत सरकार

Date: 29/0//2024

Indian Council of Medical Research Department of Health Research, Ministry of Health and Family Welfare, Government of India

File No. EM/Dev/SG/161/7380/2023 (E-Office-173937)

To,

The Principal Jawaharlal Nehru Medical College Belagavi-590010

Subject: Sanction & budget allotment of new Extramural Research (small-grants) Projects "Development of non-invasive Point of Care Testing Device to Screen Oral Potentially Malignant Disorders at all Levels of Health Care." under Dr Ashwini Narasannavar Basagouda Narasannavar, Associate Professor Jawaharlal Nehru Medical College, Belagavi-590010.

Sir/Madam,

The Director General of the Council sanction the above mentioned research scheme initially for a period of One Year from 15.02.2024 to 14.02.2025 subject to extension up to the total duration as mentioned below.

The Director General of the Council also sanctions the budget allotment of **Rs. 84,11,105**/- (Rupees Eighty Four Lakh Eleven Thousand One Hundred Five Only) as detailed in the attachment statement for the year 2023-24.

The grant in aid will be given subject to the following conditions:

- 1. The payment of the grant will be release in instalments to the Head of the Institute. The First instalment of the grant will be paid generally as soon as report regarding the commencement of the project and appointment of the staff is received by the Council.
- 2. The Staff appointed on the project should be paid as indicated in the budget statement attached.
- 3. The approved duration of the research scheme <u>2 (Two) years</u>. The annual extension will be given after review of the work done on the research scheme during the previous years.
- 4. The annual progress report along with Protocol of work done be submitted to the Council every year after completion of ten months of the project. Failure to submit the report in time may lead to termination of the project.

- 5. The Institute will maintain a separate saving account of the receipts and expenditure incurred on the research scheme and will furnish a utilization certificate and an audited statement of the accounts pertaining to the grant along with interest thereon.
- 6. The host institute shall utilize the grant after following provision as laid down in GFR-2017 and TA rules.
- 7. The other terms & condition are available on ICMR website.

The receipt of this letter may please be acknowledged.

Yours faithfully,

(Harjeet Kaur Bajaj) Administrative Officer

Copy to:

- 1. Accounts Section- V, ICMR
- 2. Dr Ashwini Narasannavar Basagouda Narasannavar, Associate Professor Jawaharlal Nehru Medical College, Belagavi-590010
- 3. IIRP Section Number:- (2023-7390)
- 4. Mr. Rohitash, Budget Coordinator, Division of Development Research.

(This issue with the concurrence of Finance Section vide E-office No. 173937 dated 24.01.2024)

Administrative Officer

INDIAN COUNCIL OF MEDICAL RESEARCH ANSARI NAGAR, NEW DELHI-110029

Budget Statement for the 1st year duration (From 15.02.2024 to 24.02.2025)

Sub:- New Extramural (small-grants) Projects entitled:- "Development of non-invasive Point of Care Testing Device to Screen Oral Potentially Malignant Disorders at all Levels of Health Care." under Dr Ashwini Narasannavar Basagouda Narasannavar, Associate Professor Jawaharlal Nehru Medical College, Belagavi-590010.

	Jawaharlal Nehru Medical College, Vel	lagavi
Sl.No.	Budget Heads	1 st year
Ι	Manpower	
a)	Project Research Scientist-III (One) @ Rs. 78,000/- + 18% HRA of Rs. 14,040/- Total Rs. 92,040/- per month	11,04,480
b)	Project Technician-I (One) @ Rs. 18,000/- + 18% HRA of Rs. 3,240/- Total Rs. 21,240/- per month	0
II	Recurring	
b)	Consumables	0
c)	Contingencies	2,00,000
	Total (I+II)	13,04,480
	Overhead @ 3%	39,134
III	Non-Recurring	
	Equipment	70,67,491
VI	Travel	0
	Grand Total	84,11,105

Rs. 84,11,105/- (Rupees Eighty Four Lakh Eleven Thousand One Hundred Five Only) File No. EM/Dev/SG/161/7380/2023 (E-Office-173937)

Administrative Officer



KLE ACADEMY OF HIGHER EDUCATION AND RESEARCH (DEEMED TO BE UNIVERSITY) KAHER'S KLE VISHWANATH KATTI INSTITUTE OF DENTAL SCIENCES, BELGAVI



CONGRATULATIONS

Research Grant sanctioned for Short Term Studentship (STS-2022) from Indian Council for Medical Research (ICMR) For the topic entitled

"ASSESSMENT OF PERCEPTION ABOUT CHALLENGES FACED BY UNDERGRADUATE DENTAL STUDENTS DUE TO COVID -19 PANDEMIC- A CROSS SECTIONAL STUDY"

ICMR Ref No- 2022-08569

Sanctioned Amount - Rs 50000/- Dated 27/09/2023



PRIMARY INVESTIGATOR DR VIVEKA SHAMRAO PATIL Intem 100

GUIDE DR RAMESH P NAYAKAR PROFESSOR Department of Prosthodontics and Crown and Bridge



Dear Customer,

Thank you for banking with State Bank of India.

Your account has been credited for NEFT received as per the details given below

Credited to Your A/c: XX7462 Amount: INR 50,000.00 UTR No.: RBI2712392832510 Date: 27/09/2023 Sent by: ICMR NEW DELHI Sender Bank IFSC: RBIS0PFMS01


This is an auto generated mail. Please do not reply to this message or on this email address. For any query, please contact our toll-free numbers 1800-1234, 1800-2100 & 1800 112211.

Do not disclose any confidential information such as Username,Password,OTP etc. to anyone.

Sincerely, SBI NEFT Team



KLE ACADEMY OF HIGHER EDUCATION AND RESEARCH (DEEMED TO BE UNIVERSITY) KAHER'S KLE VISHWANATH KATTI INSTITUTE OF DENTAL SCIENCES, BELGAVI



CONGRATULATIONS

Research Grant Sanctioned for Short Term Studentship (STS-2022) From Indian Council Of Medical Research (ICMR) For The Topic Entitled

"Knowledge, Attitude and Practice of Biosafety guidelines among Dental Undergraduates During COVID-19 pandemic in a Dental Institution in North Karnataka- An Institutional based crosssectional study"

ICMR Ref No. - 2022-00811

Sanctioned Amount - Rs. 50,000/- Dated - 27/09/2023



PRIMARY INVESTIGATOR Dr. VAISHNAVI ASHOK NIDARKAR **GUIDE** Dr. ZAMEERA NAIK PROFESSOR



Dear Customer,

Thank you for banking with State Bank of India.

Your account has been credited for NEFT received as per the details given below

Credited to Your A/c:	XX4521
Amount:	INR 50,000.00
UTR No.:	RBI2702392052865
Date:	27/09/2023
Sent by:	ICMR NEW DELHI
Sender Bank IFSC:	RBIS0PFMS01

This is an auto generated mail. Please do not reply to this message or on this email address. For any query, please contact our toll-free numbers 1800-1234, 1800-2100 & 1800 112211.

Do not disclose any confidential information such as Username, Password, OTP etc. to anyone.

Sincerely, SBI NEFT Team





भारतीय आयुर्विज्ञान अनुसंधान परिषद स्वास्थ्य अनुसंधान विभाग, स्वास्थ्य एवं परिवार कल्याण मंत्रालय, भारत सरकार

Indian Council of Medical Research Department of Health Research, Ministry of Health and Family Welfare, Government of India

File No. EM/Dev/SG/157/5805/2023 (E-Office-178529)

Date: 16.02.2024

To,

The Principal KLE Vishwanath Katti Institute of Dental Sciences Belgavi-590010

Subject: Sanction & budget allotment of new Extramural Research (small-grants) Projects "In situ formation of injectable thermoreversible silk protein hydrogel for guided bone tissue Engineering." under Dr Santosh Yamanappa Nelogi, Assistant Professor, KLE Vishwanath Katti Institute of Dental Sciences, Belagavi.

Sir/Madam,

The Director General of the Council sanction the above mentioned research scheme initially for a period of One Year from **25.02.2024 to 24.02.2025** subject to extension up to the total duration as mentioned below.

The Director General of the Council also sanctions the budget allotment of **Rs.36,40,749/- (Rupees Thirty Six Lakh Forty Thousand Seven Hundred Forty Nine Only)** as detailed in the attachment statement for the year 2023-24.

The grant in aid will be given subject to the following conditions:

- 1. The payment of the grant will be release in instalments to the Head of the Institute. The First instalment of the grant will be paid generally as soon as report regarding the commencement of the project and appointment of the staff is received by the Council.
- 2. The Staff appointed on the project should be paid as indicated in the budget statement attached.
- 3. The approved duration of the research scheme <u>3 (Three) years</u>. The annual extension will be given after review of the work done on the research scheme during the previous years.
- 4. The annual progress report along with Protocol of work done be submitted to the Council every year after completion of ten months of the project. Failure to submit the report in time may lead to termination of the project.
- 5. The Institute will maintain a separate saving account of the receipts and expenditure incurred on the research scheme and will furnish a utilization certificate and an audited statement of the accounts pertaining to the grant along with interest thereon.

- 6. The host institute shall utilize the grant after following provision as laid down in GFR-2017 and TA rules.
- 7. The other terms & condition are available on ICMR website.

The receipt of this letter may please be acknowledged.

Yours faithfully,

(Harjeet Kaur Bajaj) Administrative Officer

Copy to:

- 1. Accounts Section- V, ICMR
- 2. The Principal, KLE Vishwanath Katti Institute of Dental Sciences, Belgavi-590010.
- 3. PI-Dr Santosh Yamanappa Nelogi, Assistant Professor, KLE Vishwanath Katti Institute of Dental Sciences, Belagavi
- 4. Co-PI- Dr Vijay Mahadev Kumbar, Scientist-I, KLE Academy of Higher Education and Research
- 5. Co-PI- Dr Manju S, Scientist-E, Sree Chitra Tirunal Institute for Medical Sciences and Technology
- 6. IIRP Section Number (2023-5805)
- 7. Mr. Rohitash, Budget Coordinator, Division of Development Research.

(This issue with the concurrence of Finance Section vide E-office No. 178529 dated 15.02.2024)

Administrative Officer

INDIAN COUNCIL OF MEDICAL RESEARCH ANSARI NAGAR, NEW DELHI-110029

Budget Statement for the 1st year duration (From 25.02.2024 to 24.02.2025)

Sub:-New Extramural (small-grants) Projects entitled:- "In situ formation of injectable thermoreversible silk protein hydrogel for guided bone tissue Engineering." under Dr Santosh Yamanappa Nelogi, Assistant Professor, KLE Vishwanath Katti Institute of Dental Sciences, Belagavi.

Sl.No.	Budget Heads	1 st year
Ι	Manpower	
	Project Research Scientist-I (Non-Medical) (one) @ Rs. 56,000/- + 18% HRA of Rs. 10,080/- Total Rs. 66,080/- per month	0
II	Recurring (Consumables/Contingencies)	14
a)	Consumables	0
b)	Contingencies	0
	Total (I+II)	0
	Overhead @ 3%	0
III	Non-Recurring	
	Equipment	0
IV	Travel	1,00,000
	Grand Total	1,00,000
1.	B- KLE Academy of Higher Education and Research	ch Centre
Sl.No.	Budget Heads	1 st year
Ι	Manpower	
a)	Project Research Scientist-I (Non-Medical) (one) @ Rs. 56,000/- + 18% HRA of Rs. 10,080/- Total Rs. 66,080/- per month	0
II	Recurring (Consumables/Contingencies)	
a)	Consumables	0
b)	Contingencies	0
	Total (I+II)	0
	Overhead @ 3%	0
III	Non-Recurring	
	Equipment	8,00,000
a)	Equipment	0,00,000
a) IV	Travel	1,00,000

Cont..02

Sl.No.	Budget Heads	1 st year		
Ι	Manpower			
a)	Project Research Scientist-I (Non-Medical) (one) @ Rs. 56,000/- + 18% HRA of Rs. 10,080/- Total Rs. 66,080/- per month	7,92,960		
II Recurring (Consumables/Contingencies)				
a)	Consumables	7,50,000		
b)	Contingencies	50,000		
	Total (I+II)	15,92,960		
III	Overhead @ 3%	47,789		
IV	Non-Recurring			
a)	Equipment	8,00,000		
b)	Travel	2,00,000		
	Grand Total	26,40,749		
	Total A+B+C	36,40,749		

Rs.36,40,749/- (Rupees Thirty Six Lakh Forty Thousand Seven Hundred Forty Nine Only) File No. EM/Dev/SG/157/5805/2023 (E-Office-178529)

Administrative Officer

Ţ.





भारतीय आयुर्विज्ञान अनुसंधान परिषद स्वास्थ्य अनुसंधान विमाग, स्वास्थ्य एवं परिवार कल्याण मंत्रालय, मारत सरकार

Indian Council of Medical Research Department of Health Research, Ministry of Health and Family Welfare, Government of India

File No. EM/Dev/SG/157/5805/2023 (E-Office-178529)

Date: 16.02.2024

Subject: Payment of Full Instalment of 1st Year grant in aid for the research scheme entitled "In situ formation of injectable thermoreversible silk protein hydrogel for guided bone tissue Engineering." under Dr Santosh Yamanappa Nelogi, Assistant Professor, KLE Vishwanath Katti Institute of Dental Sciences, Belagavi.

MEMORANDUM

The Director General, ICMR sanction the payment of Rs.36,40,749/- (Rupees Thirty Six Lakh Forty Thousand Seven Hundred Forty Nine Only) as the full instalment of 1st Year grant for incurring expenditure in connection with the above mentioned research scheme. The amount of Rs. 36,40,749/- may be debited in the provision of Rs. 36,40,749/- made for the above research scheme for the current Financial Year 2023-24.

A formal bill for <u>Rs. 36,40,749/-</u> is sent herewith for payment to Principal Klevk Institute of Dental Science through RTGS BANK ACCOUNT NUMBER: 05042010105534, MICR CODE of bank 590015019, IFSC Code CNRB0010504.

(Harjeet Kaur Bajaj) Administrative Officer

Accounts Section- V, ICMR (This issue with the concurrence of Finance Section vide E-office No. 178529 dated 15.02.2024)

Copy to:

- 1. The Principal, KLE Vishwanath Katti Institute of Dental Sciences, Belgavi-590010.
- 2. PI-Dr Santosh Yamanappa Nelogi, Assistant Professor, KLE Vishwanath Katti Institute of Dental Sciences, Belagavi
- 3. Co-PI- Dr Vijay Mahadev Kumbar, Scientist-I, KLE Academy of Higher Education and Research
- 4. Co-PI- Dr Manju S, Scientist-E, Sree Chitra Tirunal Institute for Medical Sciences and Technology
- 5. IIRP Section Number (2023-5805)
- 6. Mr. Rohitash, Budget Coordinator, Division of Development Research.

पी.ए.वी.एक्स./PABX : +91-11-26588980, 26588707, 26589336, 26589745, 26589873, 26589414 फैक्स,/FAX : +91-11-26588662, 26589791, 26589258 तार/GRAM: विज्ञानी /SCIENTIFIC वेनसाइट/Website: www.icmr.nic.in ईमेल/Email: icmrhqds@sansad.nic.in

भारतीय आयुर्विज्ञान अनुसंधान परिषद INDIAN COUNCIL OF MEDICAL RESEARCH

वी. रामलिंगस्वामी भवन, अंसारी नगर, पोंस्ट बॉक्स 4911, नई दिल्ली – 110029 V. RAMALINGASWAMI BHAWAN, ANSARI NAGAR, POST BOX 4911, NEW DELHI - 110029

No. BMI/014(03)/TF/2023 ID No. 2023-20012

Dated: 8 02 2024

The Principal, KLE VK Institute of Dental Sciences, JNMC Campus, Nehru Nagar, Belagavi, Karnataka-590010

Sub: - Sanction and budget allotment for the New Schemes Entitled, "Generate medical imaging datasets (MIDAS) for tobacco induced oral lesions to enhance research in health in India" under Dr. Punnya V Angadi, Professor & Head, Department of Oral Pathology & Microbiology, KLE VK Institute of Dental Sciences, JNMC Campus, Nehru Nagar, Belgaum, Karnataka-590010

Sir,

To,

- 1. The Director General of the Council sanctions the above-mentioned research scheme initially for a period of One year from 01.03.2024 to 28.02.2025 subject to extension up to the total duration specified in para 3(c) below.
- 2. The Director General of the Council also sanctions the budget allotment of Rs.29,33,124/- (Rupees Twenty Nine Lakh Thirty Three Thousand One Hundred Twenty Four Only) as detailed in the attached statement for the year 2023-24 subject to the condition that the grant will be utilized after following the provisions laid down in the GFRs-2017 & TA Rules. Please keep the fund in a separate Saving Bank account opened for ICMR funded Research Projects so that interest earned thereon is credited into this account.
- 3. The grant-in-aid will be given subject to the following conditions:
- a) The payment of the grant will be made in lump-sum to the Head of the Institution. The first installment of the grant will be paid generally as soon as a report regarding the commencement of the project and appointment of the staff is received by the Council.
- b) The staff appointed on the project should be paid as indicated in the budget statement attached.
- c) The approved duration of the scheme is for 3 Years. The annual extension will be given after a review of the work done on the scheme during the previous year.

Contd.....2

- d) **Two copies of the annual progress report (with a soft copy also)** of work done be submitted to the Council every year **after completion of ten months** of the project, failure of submit the report in time may lead to termination of the project.
- e) The institute will maintain a separate account of the receipts and the expenditure incurred on the scheme and will furnish a utilization certificate and an audited statement of account pertaining to the grant may be furnished to ICMR for the period of 01.03.2024 to 28.02.2025.
- f) The next year grant will only be released after receipt of the Progress Report along with Utilization Certificate and Statement of Expenditure.
- g) The other terms and conditions are indicated in Annexure I. The receipt of this letter may please be acknowledged.

Yours faithfully,

(Jaibir Singh) Sr.Admn. Officer for Director General.

RFC No. BMI/NTF/01/2023-24 dated. 17/07/2023

Copy together with a copy of the budget statement forwarded for information to: -

- 1. Dr. Punnya V Angadi, Professor & Head, Department of Oral Pathology & Microbiology, KLE VK Institute of Dental Sciences, JNMC Campus, Nehru Nagar, Belgaum, Karnataka-590010
- 2. Copy together with two copies of the budget statement forwarded to the <u>Accounts</u> <u>Section, ICMR</u> for information and necessary action.
- 3. RFC No. BMI/NTF/01/2023-24 dated. 17/07/2023
- 4. IRIS ID No. 2023-20012

Sr. Admn. Officer for Director General.

Sanction and budget allotment for the New Schemes Entitled, "Generate medical imaging datasets (MIDAS) for tobacco induced oral lesions to enhance research in health in India" under Dr. Punnya V Angadi, Professor & Head, Department of Oral Pathology & Microbiology, KLE VK Institute of Dental Sciences, JNMC Campus, Nehru Nagar, Belgaum, Karnataka-590010

S No.	Head	1st Year
1	Project Technical Support III (2) @ 28,000/- + 18% HRA=Rs.33,040/- p.m.	3,96,480
	Consultant (Medical) – (1) @ Rs. 1,00,000/- p.m.	12,00,000
2	Contingencies	25,000
-	Non-Recurring (Equipment)	I hter million
	Imaging Equipment	10,00,000
41	Computer Desktop and Printer – 1	60,000
3	Recurring (consumables)	1,00,000
4	Travel	1,00,000
5	Overhead Charges @ 3%	51,644
	Total	29,33,124

Budget Statement (01.03.2024 to 28.02.2025)

(Rupees Twenty Nine Lakh Thirty Three Thousand One Hundred Twenty Four Only) RFC No. BMI/NTF/01/2023-24 dated. 17/07/2023 DOS: 01.03.2024 Duration: Three years

J' 912124

Sr. Admn. Officer for Director General.

INDIAN COUNCIL OF MEDICAL RESEARCH ANSARI NAGAR, NEW DELHI-110 029

No BMI/014(03)/TF/2023

Dated: 8 2 2024

Sub: - Payment of 1st installment of 1st year grant-in-aid for the research scheme entitled, "Generate medical imaging datasets (MIDAS) for tobacco induced oral lesions to enhance research in health in India" under Dr. Punnya V Angadi, Professor & Head, Department of Oral Pathology & Microbiology, KLE VK Institute of Dental Sciences, JNMC Campus, Nehru Nagar, Belgaum, Karnataka-590010.

MEMORANDUM

Reference this office letter No BMI/014(03)/TF/2023dated.....

The Director-General, ICMR sanction the payment of Rs.29,33,124/- (Rupees Twenty Nine Lakh Thirty Three Thousand One Hundred Twenty Four Only) as the Ist installment of 1st year the grant for the period from 01.03.2024 to 28.02.2025 for incurring expenditure in connection with the above mentioned research scheme. The amount of Rs.29,33,124/- may be debited out of the funds allocated to the division BMI for the above mentioned research scheme for the year 2023-24.

A formal bill for Rs.29,33,124/- is sent herewith for payment by RTGS to Principal, KLE VK Institute of Dental Sciences.

Jag 1214

(Jaibir Singh) Sr. Admn. Officer for Director General.

Accounts Section-V, ICMR.

RFC No.BMI/NTF/01/2023-24 dated. 17/07/2023 along with formal bill of Rs.29,33,124/- for necessary payment (Mandate from/ Cancelled cheque/ and PFMS form are enclosed).

Copy to:

- 1. The Principal, KLE VK Institute of Dental Sciences, JNMC Campus, Nehru Nagar, Belgaum, Karnataka-540010.
- 2. Dr. Punnya V Angadi, Professor & Head, Department of Oral Pathology & Microbiology, KLE VK Institute of Dental Sciences, JNMC Campus, Nehru Nagar, Belgaum, Karnataka-590010.

Sr.Admn. Officer for Director General.



ಕರ್ನಾಟಕ ವಿಜ್ಞಾನ ಮತ್ತು ತಂತ್ರಜ್ಞಾನ ಪ್ರೋತ್ಸಾಹಕ ಸೊಸೈಟಿ

ವಿದ್ಯುನ್ಮಾನ, ಮಾಹಿತಿ ತಂತ್ರಜ್ಞಾನ, ಜೈವಿಕ ತಂತ್ರಜ್ಞಾನ ಹಾಗೂ ವಿಜ್ಞಾನ ಮತ್ತು ತಂತ್ರಜ್ಞಾನ ಇಲಾಖೆ, ಕರ್ನಾಟಕ ಸರ್ಕಾರ ವಿಜ್ಞಾನ ಭವನ' ನಂ: 24/2, 3ನೇ ಮಹಡಿ, 21ನೇ ಮುಖ್ಯ ರಸ್ತೆ, ಬನಶಂಕರಿ 2ನೇ ಹಂತ, ಬೆಂಗಳೂರು-560070 ದೂರವಾಣಿ-080-2671116 ಇ-ಮೇಲ್: ksteps.dst@gmail.com

ಸಂಖ್ಯೆ: ಕೆಸ್ಟೆಪ್ಸ್/ ವಿತಂದಾಸ /ECRA/GRD No.1175/2022-23/ 696

ದಿನಾಂಕ: 05ನೇ ಫೆಬ್ರವರಿ, 2024

ಇವರಿಗೆ:

Dr. Snehalata Narvekar Lecturer Department of Oral and Maxillofacial Surgery KLE Deemed University JNMC Campus, Nehru Nagar, Belagavi - 590 010

ಮಾನ್ಯರೇ,

ವಿಷಯ: 2022-23ನೇ ಸಾಲಿನ ವಿತಂದಾಸದ ECRA ಯೋಜನೆಯಡಿ ತಮ್ಮ ಪ್ರಸ್ತಾವನೆ ಆಯ್ಕೆಯಾಗಿರುವ ಬಗ್ಗೆ ಉಲ್ಲೇಖ: 1. ವಿತಂದಾಸ ಅರ್ಜಿ ಆಹ್ವಾನ ಜಾಹೀರಾತು ಸಂಖ್ಯೆ: DST/KSTePS/VGST/2022-23 ದಿನಾಂಕ: 25.03.2023

2. ಸರ್ಕಾರಿ ಆದೇಶ ಸಂಖ್ಯೆ: ಐಟಿಬಿಟಿ 10 ಎಸ್ ಟಿ ಎಸ್ 2023, ಬೆಂಗಳೂರು, ದಿನಾಂಕ: 03.01.2024

ಮೇಲ್ಕಂಡ ವಿಷಯ ಮತ್ತು ಉಲ್ಲೇಖಗಳಿಗೆ ಸಂಬಂಧಿಸಿದಂತೆ, ಭಾರತ ರತ್ನ ಪ್ರೊ|| ಸಿ.ಎನ್.ಆರ್. ರಾವ್, ಎಫ್.ಆರ್.ಎಸ್., ರವರ ಅಧ್ಯಕ್ಷತೆಯಡಿ ರಚಿಸಲಾಗಿರುವ ವಿಜ್ಞಾನ ಮತ್ತು ತಂತ್ರಜ್ಞಾನ ದಾರ್ಶನಿಕ ಸಮೂಹದ (ವಿತಂದಾಸ) ಶಿಫಾರಸ್ಸಿನ ಆಧಾರದ ಮೇಲೆ 2022-23ನೇ ಸಾಲಿನ ವಿತಂದಾಸದ ಆರಂಭಿಕ ವೃತ್ತಿ ಸಂಶೋಧನಾ ಪ್ರಶಸ್ತಿ (ECRA) ಯೋಜನೆಯಡಿ ತಾವು ಸಲ್ಲಿಸಿದ್ದ "Evaluation of Efficacy of Exosomes Loaded Hydrogel for Targeted Delivery of Dental pulp Stem cells derived Therapeutics in Diabetic Wound Healing: *In Vitro* study" ಶೀರ್ಷಿಕೆಯ ಪ್ರಸ್ತಾವನೆಯು ಆಯ್ಕೆಗೊಂಡು ಸರ್ಕಾರದಿಂದ ಅನುಮೋದನೆಗೊಂಡಿರುತ್ತದೆ ಎಂದು ತಿಳಿಸಲು ಹರ್ಷಿಸುತ್ತೇನೆ.

ವಿವಿಧ ಯೋಜನೆಗಳಡಿ ಆಯ್ಕೆಯಾದ ಪ್ರಸ್ತಾವನೆಗೆ ಸರ್ಕಾರದಿಂದ ಒದಗಿಸಲಾಗುವ ಅನುದಾನದ ವಿವರವನ್ನು ಅನುಬಂಧ-1 ರಲ್ಲಿ ಲಗತ್ತಿಸಿದೆ.

ಈ ನಿಟ್ಟಿನಲ್ಲಿ, ಈ ಕೆಳಕಂಡ ದಾಖಲೆಗಳನ್ನು ವಿತಂದಾಸ ಕಛೇರಿಗೆ (ನಂ: 702, 7ನೇ ಮಹಡಿ, 4ನೇ ಹಂತ, ಬಹುಮಹಡಿ ಕಟ್ಟಡ, ಅಂಬೇಡ್ಕರ್ ವೀದಿ, ಬೆಂಗಳೂರು-560001) ಸಲ್ಲಿಸಲು ಸೂಚಿಸಿದೆ:

- PPMS ನಲ್ಲಿ ಪ್ರಸ್ತಾವನೆಯೊಂದಿಗೆ ಸಲ್ಲಿಸಲಾಗಿರುವ ಸಂಬಂಧಪಟ್ಟ ಪ್ರಾಧಿಕಾರದ ಸಹಿಯಿರುವ ಕೆಳಕಂಡ ದಾಖಲೆಗಳು:
 - ಪ್ರಸ್ತಾವನೆಯ ಮೂಲ ಪ್ರತಿ 2 ಪ್ರತಿಗಳು
 - Part-A ದಾಖಲೆಯ ಮೂಲ ಪ್ರತಿ (ಅನುಬಂಧ-1 ರಲ್ಲಿ ನೀಡಲಾಗಿರುವ ಅನುದಾನದ ವಿವರಕ್ಕೆ ಹೊಂದುವಂತೆ ಇರತಕ್ಕದ್ದು)
 - Undertaking letter ಮತ್ತು ಸಂಸ್ಥೆಯಿಂದ ನೀಡಲಾಗಿರುವ Endorsement Letter ನ ಮೂಲ ಪ್ರತಿಗಳು ಮತ್ತು ನಕಲು ಪ್ರತಿ
 - ಸಂಸ್ಥೆಯಿಂದ ಹಣಕಾಸು ಬೆಂಬಲವಿದ್ದಲ್ಲಿ ಬೆಂಬಲ ಪತ್ರ (Institutional Financial Support letter) - ಪ್ರಸ್ತಾವನೆಯಲ್ಲಿ ನಮೂದಿಸಿರುವಂತೆ
 - ಸಹಯೋಗದ ಪತ್ರ (Letter of Collaboration) ಪ್ರಸ್ತಾವನೆಯಲ್ಲಿ ನಮೂದಿಸಿದ್ದಲ್ಲಿ
 - ಸಂಶೋಧನಾ ಲೇಖನಗಳ (Publications) ಪ್ರತಿ, CV, ಅನುಭವ ಪ್ರಮಾಣ ಪತ್ರ, ಎಂ.ಟೆಕ್./ಎಮ್.ಇ, ಪಿ.ಹೆಚ್.ಡಿ. ಪ್ರಮಾಣ ಪತ್ರ, ಪ್ಯಾನ್ ಕಾರ್ಡ್ ನಕಲು ಪ್ರತಿ, ಮತ್ತು ಇತರೆ ಸಂಬಂಧಪಟ್ಟ ದಾಖಲೆಗಳು (Both PI and Co-PI)

- ಅಫಿಡವಿಟ್ ನಲ್ಲಿ (ಅನುಬಂಧ-2) ನೀಡಲಾಗಿರುವ ನಮೂನೆಯಲ್ಲಿ ರೂ. 100/- ರ ಛಾಪಾ ಕಾಗದದ ಮೇಲೆ ನೀಡತಕ್ಕದ್ದು.
- 3. ಸಂಸ್ಥೆಯ ಮುಖ್ಯಸ್ಥರ ಲೆಟರ್ ಹೆಡ್ ನಲ್ಲಿ ಅನುದಾನ ಬಿಡುಗಡೆಗೆ ಸಂಸ್ಥೆಯ ಬ್ಯಾಂಕ್ ನ ಉಳಿತಾಯ ಖಾತೆಯ ಕೆಳಕಂಡ ವಿವರ ಹಾಗೂ ಪಾಸ್ ಪುಸ್ತಕದ ಸದರಿ ವಿವರವುಳ್ಳ ಪುಟದ ನಕಲು ಪ್ರತಿ (ಸಂಸ್ಥೆಯ ಮುಖ್ಯಸ್ಥರ ಖಾತೆಯ ವಿವರವನ್ನು ಮಾತ್ರ ನೀಡತಕ್ಕದ್ದು):

ಖಾತೆಯ ಹೆಸರು: ಖಾತೆಯ ಸಂಖ್ಯೆ: ಬ್ಯಾಂಕ್ ನ ಹೆಸರು ಮತ್ತು ಶಾಖೆ: IFSC ಸಂಖ್ಯೆ:

ಮುಂದುವರಿದು, ತಮ್ಮ ಯೋಜನೆಯ ಅನುದಾನ ಸಂಬಂಧಿತ ದಾಖಲೆ (Grant Related Document) ಜಿ. ಆರ್. ಡಿ. ಸಂಖ್ಯೆ.1175 ಆಗಿದ್ದು, ವಿತಂದಾಸ/ಕೆಸ್ಟೆಪ್ಸ್ ಜೊತೆ ನಡೆಸಲಾಗಿರುವ ಮುಂದಿನ ಎಲ್ಲಾ ಪತ್ರ ವ್ಯವಹಾರಗಳಿಗೆ ಈ ಸಂಖ್ಯೆಯನ್ನು ತಪ್ಪದೇ ನಮೂದಿಸಲು ಸೂಚಿಸಿದೆ.

ಈ ಎಲ್ಲಾ ದಾಖಲೆಗಳನ್ನು ದಿನಾಂಕ: 20ನೇ ಫೆಬ್ರವರಿ, 2024 ರೊಳಗಾಗಿ ವಿತಂದಾಸ ಕಛೇರಿಗೆ ಸಲ್ಲಿಸಲು ಕೋರಿದೆ. ಹೆಚ್ಚಿನ ಮಾಹಿತಿಗಾಗಿ ದೂರವಾಣಿ ಸಂಖ್ಯೆ: 080-2203-2013/ ಇಮೇಲ್: visiongroup.st@gmail.com ಅನ್ನು ಸಂಪರ್ಕಿಸಬಹುದಾಗಿದೆ.

ಧನ್ಯವಾದಗಳೊಂದಿಗೆ,

ನಿರ್ದೇಶಕರು (ತಾಂತ್ರಿಕ) ವಿದ್ಯುನ್ಮಾನ, ಮಾತಂ, ಜೈತಂ ಹಾಗೂ ವಿಜ್ಞಾನ ಮತ್ತು ತಂತ್ರಜ್ಞಾನ ಇಲಾಖೆ/ ವ್ಯವಸ್ಥಾಪಕ ನಿರ್ದೇಶಕರು, ಕೆಸ್ಟೆಪ್ಸ್

ಪ್ರತಿ:

- 1. The Registrar, KLE Deemed University, JNMC Campus, Nehru Nagar, Belagavi 590 010
- Dr. Punnya Rao, Professor and Head, Department of Oral Pathology and Microbiology (Co-PI), KLE Vishwanatha Katti Institute of Dental Sciences, Deemed University, JNMC Campus, Nehru Nagar, Belagavi - 590 010
- 3. ಸರ್ಕಾರದ ಜಂಟಿ ಕಾರ್ಯದರ್ಶಿಗಳು, ವಿಜ್ಞಾನ ಮತ್ತು ತಂತ್ರಜ್ಞಾನ ಇಲಾಖೆ, ಕೊಠಡಿ ಸಂಖ್ಯೆ: 305, 5ನೇ ಮಹಡಿ, 5ನೇ ಹಂತ, ಬಹುಮಹಡಿ ಕಟ್ಟಡ, ಡಾ|| ಅಂಬೇಡ್ಕರ್ ವೀದಿ, ಬೆಂಗಳೂರು – 560 001.
- 4. ಕಛೇರಿ ಪ್ರತಿ.



ಕರ್ನಾಟಕ ವಿಜ್ಞಾನ ಮತ್ತು ತಂತ್ರಜ್ಞಾನ ಪ್ರೋತ್ಸಾಹಕ ಸೊಸೈಟಿ

ವಿದ್ಯುನ್ಮಾನ, ಮಾಹಿತಿ ತಂತ್ರಜ್ಞಾನ, ಜೈವಿಕ ತಂತ್ರಜ್ಞಾನ ಹಾಗೂ ವಿಜ್ಞಾನ ಮತ್ತು ತಂತ್ರಜ್ಘಾನ ಇಲಾಖೆ, ಕರ್ನಾಟಕ ಸರ್ಕಾರ ವಿಜ್ಞಾನ ಭವನ' ನಂ: 24/2, 3ನೇ ಮಹಡಿ, 21ನೇ ಮುಖ್ಯ ರಸ್ತೆ, ಬನಶಂಕರಿ 2ನೇ ಹಂತ, ಬೆಂಗಳೂರು-560070 ದೂರವಾಣಿ-080-2671116 ಇ-ಮೇಲ್: ksteps.dst@gmail.com

ಸಂಖ್ಯೆ: ಕೆಸ್ಟೆಪ್ಸ್/ ವಿತಂದಾಸ /AORP-14/2022-23/ 724

ದಿನಾಂಕ: 05ನೇ ಫೆಬ್ರವರಿ, 2024

ಇವರಿಗೆ:

Dr. Punnya V Angadi Professor and Head Department of Oral and Maxillofacial Pathology KLE Vishwanath Katti Institute of Dental Sciences and Hospital Nehrunagar, Belagavi - 590 010

ಮಾನ್ಯರೇ,

ವಿಷಯ: 2022-23ನೇ ಸಾಲಿನ ವಿತಂದಾಸದ AORP ಯೋಜನೆಯಡಿ ತಮ್ಮ ಪ್ರಸ್ತಾವನೆ ಆಯ್ಕೆಯಾಗಿರುವ ಬಗ್ಗೆ

ಉಲ್ಲೇಖ: 1. ವಿತಂದಾಸ ಅರ್ಜಿ ಆಹ್ವಾನ ಜಾಹೀರಾತು ಸಂಖ್ಯೆ: DST/KSTePS/VGST/2022-23 ದಿನಾಂಕ: 25.03.2023

2. ಸರ್ಕಾರಿ ಆದೇಶ ಸಂಖ್ಯೆ ಐಟಿಬಿಟಿ 10 ಎಸ್ ಟಿ ಎಸ್ 2023, ಬೆಂಗಳೂರು, ದಿನಾಂಕ: 03.01.2024

ಮೇಲ್ಕಂಡ ವಿಷಯ ಮತ್ತು ಉಲ್ಲೇಖಗಳಿಗೆ ಸಂಬಂಧಿಸಿದಂತೆ, ಭಾರತ ರತ್ನ ಪ್ರೊ॥ ಸಿ.ಎನ್.ಆರ್. ರಾವ್, ಎಫ್.ಆರ್.ಎಸ್., ರವರ ಅಧ್ಯಕ್ಷತೆಯಡಿ ರಚಿಸಲಾಗಿರುವ ವಿಜ್ಞಾನ ಮತ್ತು ತಂತ್ರಜ್ಞಾನ ದಾರ್ಶನಿಕ ಸಮೂಹದ (ವಿತಂದಾಸ) ಶಿಫಾರಸ್ಸಿನ ಆಧಾರದ ಮೇಲೆ 2022-23ನೇ ಸಾಲಿನ ವಿತಂದಾಸದ **ಅತ್ಯುತ್ತಮ ಸಂಶೋಧನಾ** ಪ್ರಕಟಣೆಗಾಗಿ ಪ್ರಶಸ್ತಿ (AORP) ಯೋಜನೆಯಡಿ ತಾವು ಸಲ್ಲಿಸಿದ್ದ ಪ್ರಸ್ತಾವನೆಯು ಆಯ್ಕೆಗೊಂಡು ಸರ್ಕಾರದಿಂದ ಅನುಮೋದನೆಗೊಂಡಿರುತ್ತದೆ ಎಂದು ತಿಳಿಸಲು ಹರ್ಷಿಸುತ್ತೇನೆ.

ವಿವಿಧ ಯೋಜನೆಗಳಡಿ ಆಯ್ಕೆಯಾದ ಪ್ರಸ್ತಾವನೆಗಳಿಗೆ ಸರ್ಕಾರದಿಂದ ಒದಗಿಸಲಾಗುವ ಅನುದಾನದ ವಿವರವನ್ನು ಅನುಬಂಧ-1 ರಲ್ಲಿ ಲಗತ್ತಿಸಿದೆ.

ಈ ನಿಟ್ಟಿನಲ್ಲಿ, ಈ ಕೆಳಕಂಡ ದಾಖಲೆಗಳನ್ನು ವಿತಂದಾಸ ಕಛೇರಿಗೆ (ನಂ: 702, 7ನೇ ಮಹಡಿ, 4ನೇ ಹಂತ, ಬಹುಮಹಡಿ ಕಟ್ಟಡ, ಅಂಬೇಡ್ಕರ್ ವೀದಿ, ಬೆಂಗಳೂರು-560001) ಸಲ್ಲಿಸಲು ಸೂಚಿಸಿದೆ:

- 1. PPMS ನಲ್ಲಿ ಅರ್ಜಿಯೊಂದಿಗೆ ಸಲ್ಲಿ ಸಲಾಗಿರುವ ಸಂಬಂಧಪಟ್ಟ ಪ್ರಾಧಿಕಾರದ ಸಹಿಯಿರುವ ಕೆಳಕಂಡ ದಾಖಲೆಗಳು:
 - ಪ್ರಸ್ತಾವನೆಯ ಮೂಲ ಪ್ರತಿ 2 ಪ್ರತಿಗಳು
 - ಸಂಶೋಧನಾ ಲೇಖನಗಳ (Publications) ಪ್ರತಿ, CV, ಅನುಭವ ಪ್ರಮಾಣ ಪತ್ರ, ಪಿ.ಹೆಚ್.ಡಿ. ಪ್ರಮಾಣ ಪತ್ರ, ಪ್ಯಾನ್ ಕಾರ್ಡ್ ನಕಲು ಪ್ರತಿ, ಮತ್ತು ಇತರೆ ಸಂಬಂಧಪಟ್ಟ ದಾಖಲೆಗಳು
- ಅನುದಾನ ಬಿಡುಗಡೆಗೆ ತಮ್ಮ ಬ್ಯಾಂಕ್ ಖಾತೆಯ ಕೆಳಕಂಡ ವಿವರ ಹಾಗೂ ಪಾಸ್ ಪುಸ್ತಕದ ಸದರಿ ವಿವರವುಳ್ಳ ಪುಟದ ನಕಲು ಪ್ರತಿ (ತಮ್ಮ ಸ್ವಂತ ಖಾತೆಯ ವಿವರವನ್ನು ಮಾತ್ರ ನೀಡತಕ್ಕದ್ದು):

ಖಾತೆಯ ಹೆಸರು: ಖಾತೆಯ ಸಂಖ್ಯೆ: ಬ್ಯಾಂಕ್ ನ ಹೆಸರು ಮತ್ತು ಶಾಖೆ: IFSC ಸಂಖ್ಯೆ: ಧನ್ಯವಾದಗಳೊಂದಿಗೆ,

ನಿರ್ದೇಶಕರು (ತಾಂತ್ರಿಕ)

ವಿದ್ಯುನ್ಮಾನ, ಮಾತಂ, ಜೈತಂ ಹಾಗೂ ವಿಜ್ಞಾನ ಮತ್ತು ತಂತ್ರಜ್ಞಾನ ಇಲಾಖೆ/ ವ್ಯವಸ್ಥಾಪಕ ನಿರ್ದೇಶಕರು, ಕೆಸ್ಟೆಪ್ಸ್

ಪ್ರತಿ:

- 1. The Principal, KLE Vishwanath Katti Institute of Dental Sciences and Hospital, Nehrunagar, Belagavi 590 010
- 2. ಸರ್ಕಾರದ ಜಂಟಿ ಕಾರ್ಯದರ್ಶಿಗಳು, ವಿಜ್ಞಾನ ಮತ್ತು ತಂತ್ರಜ್ಞಾನ ಇಲಾಖೆ, ಕೊಠಡಿ ಸಂಖ್ಯೆ: 305, 5ನೇ ಮಹಡಿ, 5ನೇ ಹಂತ, ಬಹುಮಹಡಿ ಕಟ್ಟಡ, ಡಾ|| ಅಂಬೇಡ್ಕರ್ ವೀದಿ, ಬೆಂಗಳೂರು – 560 001
- 3. ಕಛೇರಿ ಪ್ರತಿ



the set is a set of the set of th

Dated: 06 .2024 F. No. HQ-PROJ011/184/2022-PROJ 1446 10 JUN 2024 ORDER

Sanction of the Director-General, CCRAS, New Delhi is hereby conveyed in exercise of the powers conferred upon him under item No.51 of the schedule-f of Rule 04 of the Rules, Regulations and Bye-laws of the Central Council for Research in Ayurvedic Sciences, New Delhi to release 1st quarter budget of Rs.18,09,217/- (Rupees Eighteen Lakh Nine Thousand Two Hundred Seventeen only) as contingent advance to the Assistant Director Incharge, CARI, Bengaluru to execute the collaborative project entitled "Evaluation of Hepatoprotective activity of PTK as an add on therapy in the patients of Tuberculosis on ATT - A double blind Randemized control clinical study". Terms & conditions contained in the Council even order No. 1096/2020-21 dated 25:03:2021 needs to be complied.

The expenditure is debitable to the Grant-in-Aid Budget of HQs for the year 2024-25 under sub-head "Research Activities".

> (Renu Rajan) Administrative Officer (Project) For Director General

To.

The Administrative Officer (Account), CCRAS, New Delhi with the request to release an amount of Rs.18,09,217/- (Rupees Eighteen Lakh Nine Thousand Two Hundred Seventeen only) as contingent advance to the Assistant Director Incharge, CARI, Bengaluru. A photocopy of the approved note is enclosed. .

Copy to:-

Signed by Renu Rajan Date: 07-06-2024 17:41:14

1. The Assistant Director Incharge, CARI, Bengaluru with the request to keep Rs.3,96,000/with the institute and for onward transmission of Rs.14,13,2177- to BMK, Belagavi. 2. Dr. BCS Rao, AD (Ay.), Program Officer, CCRAS, New Delhi for information.

- 3. Dr. Ashok Patil, Professor and Head/Principal Investigator, BMK Ayurveda Mahavidyalaya, Shahapur, Belagavi-590003, Karnataka for Information.
- Dr. Shruti Khanduri, RO (Ay.), Coordinating Officer, CCRAS, New Delbi for 4. Information.
- Dr. Sophia Jameela, RO (Ay.), Nodal Officer, CCRAS, New Delhi for information. 5.

1101 Ayurvada Resur



For Director General

#ApprovedBv#

PRINC Shri B. M. Kankanawadi Ayurved Mahavidyalaya A Constituent Unit of KAHE Shahapur, BELAGAVI-03.

Approval date in PFMS: 14-Aug-2024 DSC Signing Date in PFMS: 14-Aug-2024 Amount (in Rs.) : 1,413,217.00 (Amount in words : Fourteen Lakhs Thirteen Thousand Two Hundred No. Of Beneficiaries: 1 Not to be used by bank for making any payments Debit Payment Advice No.: C082422234416 5.N **Beneficiary Name** PFMS 0. Account IFSC Code Aadhaar Transaction ID Amount In Number 1 PRINCIPAL KLE No. (Rs.) C082420102800 DOMARY SALAND LINIVER SIT Y SBMK CNR80010 1,413,217.0 538 AYURVEDA 0 Total Amount(Rs): 1,413,217.0 0 Clonen (Sign by Authorized Signatory) Name - Doz S.H. Doddaman (Sign by Authorized Signatory) Name -Designation - Research De Designation -Mobile No Mobile No -Public Financial Management Page No:1/1 16/08/24 12:45



PRINCIPAL Shri B. M. Kankanawadi Ayurved Mahavidyalaya A Constituent Unit of KAHER Shahapur, BELAGAVI-03.





केंद्रीय आयुर्वेद अनुसंधान संस्थान भारत सरकार, अगुपर मंत्रालय, केन्द्रीय आयुर्तेदीत विज्ञान त्रतुनंधान गण्पियथ #12, उत्तरहरूवी मयवलेकावल, कत्रकपुर मेत रोज, तथ्यधद्रपूरा धोग्ध, वंदशाहरू -560109

Central Ayurveda Research Institute

Govt. of India, Ministry of AYUSH, Central Council for Research in Ayurvedic Sciences # 12, Uthershalli Manavathe Kaval, Kanakapisa Main Road, Thalaghaitapura post, Bengaluru-560109 Centre of Excellence awarded by Ministry of AYUSH, Govt. of India Ph. No. 080-29535034, 29635035, 'B-mail: <u>andri-benzalturidzav in</u>, <u>Badri-benzalturi @arnati.com</u> Website: <u>http://www.csri.gov.in</u>

Date:11-08-2024

सेवा में,

The Principal, KAHER's, BMK Ayurveda Mahavidyalaya, Shahapur, Belagavi - 590003.

F.No. 6-101/2021/CARI/BNG/Tech/ATT/11/54

विषय: श्री बी.एम.के आयुर्वेद महाविद्यालय, बेलगावी में संचालित ए.टी.टी परियोजना के लिए राशि

रूपए 14,13,217/- स्थानान्तरण करने के संबंध में।

Transferring an amount of Rs. 14,13,217/- towards the Tuberculosis on ATT project being conducted at KAHER's Shri BMK Ayurveda Mahavidyalaya, Belagavi - reg.

सन्दर्भ: 1) Council's sanctioned Office Order No. 1096/2020-21, dated 25-03-2021 (F.No. 3-30/2021-CCRAS/Admn.JMR/Coll.) (copy enclosed).

2) CCRAS Order No. HQ-PROJ011/184/2022-PROJ/1446, dated 10-06-2024 (Amount released letter).

महोदय,

उपर्युक्त सन्दर्भ में, मैं यह सुचित करना चाहती हूँ कि हमने आपके संस्थान में परियोजना शीर्षक ए.टी.टी के निष्पादन के लिए प्रिंसिपल, के.एल.इ. यूनिवसिंटी के पक्ष में खाता संख्या 05382150000029 आईएफएससी संख्या CNRB0010538 को RTGS/NEFT द्वारा श्री बी.एम.के आयुर्वेद महादिद्यालय, बेलगावी को राशि 14,13,217/- दिनांक 14.08.2024 (ट्रांसाकशन पावती इसके साथ संलग्नित है) को स्थानोतरण किया गया है।

एशि को शीर्षत्रार आवंटन को पार किए दिना और जीएफआर 2017 और सीसीआरएएस अनुसंघात नीति (गरिपव पत्र की प्रति इसके साथ संलग्न है) के अनुसार सीसीआरएएस मंजूरी आदेश में उल्लिखित झेकअप के अनुसार सखती से खर्च करना चाहिए।


With reference to the above, I am to inform that we have transferred an amount of Rs. 14,13,217/- (Rupees Fourteen lakh thirteen thousand two hundred and seventeen only) through RTGS/NEFT to your Account No. 05382150000029, IFSC code, CNRB0010538 in favour of The Principal KLE University's A/C on 14-08-2024 (A copy of transaction receipt is enclosed), towards the project amount for the project entitled "Evaluation of Hepatoprotective activity of PTK as an add on therapy in the patients of Tuberculosis on ATT - A Double blind Randomized control clinical study" for execution of the project at your centre.

The amount has to be spent strictly in accordance with the breakup mentioned in CCRAS Sanction order referred above without crossing the head wise allocation and in accordance with GFR 2017 & CCRAS Research Policy (Copy of the Council's letter enclosed herewith).

मबदीय 1918124 526

संलग्न: as above प्रतिनिधिः 1) The Director General CCRAS, New Delhi for information के आ अ सं, बेल्यूड - 500109 2) Project file 3) Pl of the Project 4) Cash Section 5) Technical file

URVED MAHA



Shri B. M. Kankanawadi Ayurved Mahavidyalaya **Constituent Unit of KAHER** Shahapur, BELAGAVI-03.

रेषद् TH. HA Breat

IL FOR RESEARCH IN AYURVEDIC SCIENCES 2 5 MAR 2021 Ministry of AYUSci, Covil of India

अनस

Poplathy Anusamilhan Bhawan Aitun F No. 61-65, Institutional Area. Opp. D. Block, Janakpuri, Now Dolhi-110058

F. No. 3-30/2021-CCRAS/Adma/IMR/Coll.

Dated: 25.03.2021

Office Order No. 1096 12020-21

In pursuance of F. No.27-11/2017-CCRAS/Tech/HQ. the sanction of the Director General, CCRAS. New Delhi is hereby conveyed in exercise of the powers conferred upon him under schedule - 1 of Rule 04 of the Rules, Regulations and Bye-laws of the Central Council for Research in Ayurvedic Sciences, New Delhi for the collaborative clinical research project entitled "Evaluation of Hepatoprotective activity of PTK as an add on therapy in the patients of Tuberculosis on ATT - A Double Blind Randomized controlled clinical study" to Assistant Director In-charge, CARI, Bengaluru to execute the above mentioned project at KAHER's BMK Belagavi, Bengaluru with the total cost of Rs.66,89,830/- (Rupces Sixty-six Lakh Eighty-nine Thousand Eight Hundred Thirty only) as per budget break up given in the tables (i to iii) subject to terms and conditions mentioned in para 3 below.

Table-I: Budget required at KAHER's Shri BMK Ayurveda Mahavidyalaya, Belagavi

S. No.	Details	Preparatory Phase	1" year	2 nd year	3rd year	Total
1. 111	Salary			5.04.000/-1	5.64.000/	15,12,000/
1	01 SRF (Ay.) @35.000 + HRA (20%) = 42.000/-		5.04.000/-		0/- 5.04.000/- 0/- 1.92.000/- 0/- 4.00.320/- 0/- 20.000/- 0/- 1.000/- 0/- 1.00.000/-	5,76,000/
	01 DEO 16,0004-		1,92,000/-	1,92,000/-		5,76,000
	Recurring expenditure	- Andrew Andrew	1 10 00 000 I	6,00,480/-	5.04.000/- 1.92.000/- 5. 4.00.320/- 20.090/- 21.000/- 1.50.000/- 1.50.000/- 1.3.87.320/- 54. 22. 54. 55. 55. 55. 55. 55. 55. 55	20,01,600%
2	1.(ab investigation)		10,00,800/-	0,00,480-1	4,00,3207	4.50,000/
-	2 Triel Drug(ATT regimen)	4,50,000/-			5.04.000/- 1.92.000/- 4.00.320/- 20.000/- 21.000/- 1.50.000/- 1.00.000/-	60,000
3	Travel Expenses		20,000/-	20,000/-		the dates of the states and the
4	Incidental support for travelling expenses of		52,500/-	31,500/-	21.000/-	1,05.000/
	periscipents	1,00,000/-	1.00,000/-1	50,000/-	1,50,000/-	4,00,000/
	1. Contingency/Miscellancous Expenditure	1,00,000	1.00.000/-	1.00.000/-	1.00,000/-	3,00,0084
	2 Insurance	4 80 000/	19.69.300/-	14.97.980/-	13.87.320/-	54,04,600/
	Sub Total	3.30,004	17,07,300	1 1,2		2,35,230/
6	Institutional Overnesd charges @ 5%			the states of	and the second	56,19,8304
Grand			ا ا ا	المستجمع بيديني		

Table -II: Budget required at Central Ayurveda Research Institute, Bengaluru

fin Ra.)

S. No.	Details	Preparatory Phase	1 st year	2 nd year	3rd year	Total
	Recurriag expenditures (Ayurveda Irial Imig + placeho)	4,00,000/-		2.00,000/-		6.00,000/
	Prevering expenditors: (A/DA for the members of DSMB and Travel expenses: (I A/DA for the members of DSMB and Monitoring committee) Setting up of DSMB, Sitting fee for	$\mathbf{x}_{i} = \left\{ \mathbf{x}_{i} \in \operatorname{supp}(i) \in \operatorname{supp}(i) \right\}$	2,00,000/-	1,00,000/-	1,00,0007-	4,00,000/
	Members.		50,000/-	_		\$0,000/
3	Contingency/Miscellaneous Expenditure	-4,00,000/-	and the same I wanted the same	3,00,000/-	1,00,000/-	10,50,000/

Table-III: Total Budget required under this study is as follows

No. Institute	
the barrier of the barrier along the lagery	56,39,830
KAHER's Shri BMK Ayurveda Mahavidyalaya, Belagavi KAHER's Shri BMK Ayurveda Mahavidyalaya, Belagavi	10,50,000
Central Ayurveda Research Institute (CARI), Bengaluru	Rs. 66.89.830/-

The Approval of Competent Authority is also conveyed to release 1^{ii} instalment of Rs.9,50,000/- (Rupces Nine Lakhs Fifty Thousand Only) as a contingent advance to Assistant Director In-charge, CARI, Bengaluru for execution of the above mentioned project in collaboration with KAHER's Shri BMK Ayurveda Mahavidvalava, Belagavi.

8 31

1216

Shri B. M. Kankanawadi Ayurved Mahavidyalaya A Constituent Unit of KAHER Shahapur, BELAGAVI-03.

3. Terms & Conditions:

1. The project will be executed in accordance with CCRAS Research Policy. The Fund provided to the institute will be spent strictly on the project components in the mechanism followed by the Council normally and Head/In-charge will provide the fund as per requirement from the PI from time to time. No diversion of funds from one component to another be done without the prior approval of the competent authority.

2

- 2. The progress of this project should be reported on monthly, quarterly and annual basis in the prescribed format (Annexure -6 of CCRAS Research Policy).
- The final report of this project should be sent in the prescribed format (Annexure -7 of CCRAS Research Policy) within two weeks from the date of completion of the project.
 Release of funds and funds and funds are shown in the date of completion of the project.
- 4. Release of funds and operation of accounts shall be as per clause no.1.5.11 (iii) of CCRAS Research Policy. Second Instalment will be released after submission of interim progress report, statement of expenditure of 1st instalment by Institute In-charge.
- 5. The institute will submit quarterly expenditure statement along with the progress reports regularly as per format (Please refer clause no. 16.3 of CCRAS Research Policy) for midterm evaluation.
- 6. The final utilisation certificate for the project along with expenditure details may be furnished to the Council immediately after completing the project work. The unspent balance should be refunded to Council's specific account within one month of completion of project.
- The Institute/Principal Investigator/Co-Investigator shall maintain separate register to record all the expenses related to the project along with interest for audit purpose.
- The expenditure for the project is to be incurred as per the principles in General Financial Rules 2017 under "Procurement of Goods and Services".
- 9. Original bills/vouchers/registers etc should be kept at the institute in safe custody for audit purpose.
- 10. Except in exceptional cases, the tenure of a project will normally be as indicated in the research protocol.
- 11. The project should be executed after fulfilling all ethical/statutory/regulatory requirements.
- 12. The observations derived from these studies will not be communicated to any other partywithout Council's permission.
- 13. The study results will be published by the Head Quarters (not by individual investigators) after completion of the study and all the Investigators/Nodal Officer/Programme Officer will be given the credit of authorship.
- 14. The Council reserves full right to issue guidelines/to terminate the project during the course of the study (Please refer clause no. 1.9 of CCRAS research policy).
- 15. Duration of the project will be three and half year. (42 months)
- 16. Ceiling of each head may be changed as per need with prior approval of DG, CCRAS.
- 17. Assets acquired on the basis of the project should be properly accounted in asset register. On completion of the project, the same may be entered in the stock register of the institute referring as "Acquired under specific project".
- 18. Publication will be done for future reference and the budget for the same may be met from Contingency/Miscellaneous 'head at KAHER's Shri BMK Ayurveda Mahavidyalaya, Belagavi separately after the completion of the project and submission of the article and final report.

The expenditure is debitable to the Grant-in-Aid Budget of HQs for the year 2020-21 under sub-bcad "Research Activities".

/

e.

(Dilip Jain) Administrative Officer (P&V) For Director General



PRINCIPAL Shri B. M. Kankanawadi Ayurved Mahavidyalaya A Constituent Unit of KAHER Shahapur, BELAGAVI-03

The Administrative officer (Account), CCRAS, New Delhi with the requested that the amount of Rs.9,50,000/- (Rupces Nine Lakhs Fifty Thousand Only) as a contingent advance to Assistant Director In-charge, CARI, Bengaluru. Copy of the approved note is enclosed.

Copy to:-


- The Assistant Director In-charge, CARI, Bengaluru with the request that the amount of Rs.4.00,000/- kccp at the institute for drug procurement and Rs.5.50,000/- (as 1st instalment for procurement of allopathic drug and contingency) onward transmission to JNMC &KAHER's BMK, Bengaluru, The budget may be transferred only after getting IEC approval and signing of MoU between Central Ayurveda Research Institute, Bengaluru and JNMC &KAHER's BMK, Bengaluru.
- 2. Dr. Ashok Patil, Professor and Head/Principal Investigator, BMK Ayurveda Mahavidyala, Belagavi for information.
- 3. Dr. Bhagyashri Patil, Co-Investigator, Associate Professor, Department of Respiratory Medicine, JN Medical College Belagavi for information.
- Dr. Shashidhar Doddamani, RO (Ay.)/Co-Investigator, CARI, Bengaluru for information.
- Dr. Shashidhar Doddamani, RO (Ay.)/Co-Investigator, CARI, Bengaruta for information.
 Dr. BCS Rao, AD (Ay.)/Programme Officers, CCRAS HQ., New Delhi for information.
- 6. Dr. Babita Yadav, RO (Ay.)/Nodal Officer, CCRAS HQ., New Delhi for information.
- 7. Co-Nodal Officer's Dr. Rinky Thakur, RO (Ay.) and Dr. Sophia Jameela, RO (Ay.), CCRAS, New Delhi for information.
- 8. Sr. P.S to D.G/P.S to DDG/P.A. to DDA, CCRAS, New Delhi.

For Director



Shri B. M. Kankanawadi Ayurved Mahavidyalaya A Constituent Unit of KAHER Shahapur, BELAGAVI-03,







. भारत सरकार, आयुप मंत्रालय, केन्द्रीय आयुर्वेदीय विज्ञान अनुसंधान परिषद #12, उत्तरहल्ली मनवर्तेकावल, कनकपुर मेन रोड, तलघट्टपुरा पीस्ट, वंगलुरु -560109

Central Ayurveda Research Institute

Govt. of India, Ministry of AYUSH, Central Council for Research in Ayurvedic Sciences # 12, Uttarahalli Manavarthe Kaval, Kanakapura Main Road, Thalaghattapura post, Bengaluru-560109 Centre of Excellence awarded by Ministry of AYUSH, Govt. of India Ph. No. 080-29535034, 29635035, E-mail: nadri-bengaluru@gov.in, nadri.bengaluru1@gmail.com

Website: http://www.cari.gov.in

F.6-75/2019/CARI/BNG/AYUSH GMH NAFLD/ 14 59

Date: 17-08-2024

सेवा में.

The Director, The National Institute of Traditional Medicine-ICMR. Nehru Nagar, National Highway No.4, Belagavi- 590010.

विषय: आयुष जीएमएच - एनएएफएलडी परियोजना के लिए राशि रूपए 11,44,448/- स्थानान्तरण करने के संबंध में।

Transferring an amount of Rs. 11,44,448/- towards the project "Evaluation of AYUSH GMH in the subjects of mild to moderate non-alcoholic fatty liver disease (NAFLD) - A Double blind Randomized control clinical study" -reg.

सन्दर्भ: 1) CCRAS Sanction Order No. F.No: 3-6/2019-CCRAS/Admn./F.L/5730, dated 18th March 2019.

2) CCRAS Order ref. No. F.No.HQ-PROJ011/109/2023-PROJ/1759 dated 21.06.2024. महोदय.

उपर्यक्त उदधत पत्रों के सन्दर्भ में, आपके संस्थान में निदेशक, आईसीएमआर, एनआईटीएम, बेलगावी के पक्ष में खाता संख्या 0505101051605 आईएफएससी संख्या CNRB0000505 को RTGS/NEFT द्वारा राशि रूपए 11,44,448/- दिनांक 14-08-2024 (ट्रांसाकशन पावती इसके साथ संलग्नित है) को स्थानांतरण किया गया है। आपसे अनुरोध है कि इस संस्थान को सूचित करते हुए श्री बी.एम.के आयुर्वेद महाविद्यालय, बेलगावी को रूपए 10,33,612/- स्थानांतरण कर सकते हैं।

राशि को शीर्षवार आवंटन को पार किए बिना और जीएफआर 2017 और सीसीआरएएस अनुसंधान नीति (परिषद पत्र की प्रति इसके साथ संलग्न है) के अनुसार सीसीआरएएस मंजूरी आदेश में उल्लिखित ब्रेकअप के अनुसार सख्ती से खर्च करना चाहिए।

As per above cited letters an amount of Rs. 11,44,448/- (Rupees Eleven lakh forty four thousand four hundred and forty eight only) has been transferred to Account No. 0505101051605 IFSC No. CNRB0000505 in favour of Director, ICMR, NITM, Belagavi on 14-08-2024 (A copy of transaction receipt is enclosed). It is requested that an amount of Rs. 10,33,6127- (Rs. Ten lakh thirty three thousand six hundred and twelve only) may be transferred to BMK Ayurveda Mahavidyalaya, Belagavi under intimation to this Institute.

The amount has to be spent strictly in accordance with the breakup mentioned in CCRAS Sanction order referred above without crossing the head wise allocation and in accordance with GFR 2017 & CCRAS Research Policy (Copy of the Council's letter

enclosed herewith Pyro सलग्न: as aboy

मारी सहयक निदेशक प्रभारी सहायके निदेशक (आय.)

प्रतिलिपि: 1) The Director General CCRAS, New Delhi for information के आ अ स, बेगलूरु - 560109 2) Project file 3) PI of the Project 4) Cash Section 5) Technical file

केन्द्रीय आयुर्वेदीय विज्ञान अनुसंधान परिषद (आयुष्ट गंत्रालय, भारत सरकार) जवाहर लाल लेहरू भारतीय चिकित्सा एवं होम्योपैथी अनुसंधान भवन न. 61–65, संस्थागत क्षेत्र, सम्नुख 'डी' ब्लाक, जनकपुरी, नई दिल्ली - 110058

फा. न. 3-6/2019-सीसीआएएस/प्रशा./एफ.एल/ 5730

दिनांक

1 8 MAR 2019

आदेश

केन्द्रीय आयुर्वेदीय विज्ञान अनुसंघान परिषद्र, नई दिल्ली के नियम एवं विनियम की अनुसूची—1 के नियम 50 में दिए गए अधिकारों के अतर्गत महानिदेशक. केन्द्रीय आयुर्वेदीय विज्ञान अनुसंघान परिषद, नई दिल्ली के अनुमोदन से इस परियोजना कि कुल लागत रू 55,32,925/- (रू पचपन लाख बतीस हजार नौ सौ पचीस मात्र) A.D I/c, RARIMD, Bengaluru को परियोजना – Institute responsible for the research project : National Institute of Traditional Medicine – ICMR Belagavi and KAHER Shri BMK Ayurveda Mahavidyalaya and Hospital, Belagavi को "Evaluation of AYUSH GMH in the subjects of mild to moderate non-alcoholic fatty liver disease (NAFLD) – A Double Blind Randomized control clinical study" के निषपादन के लिए पैरा तीन में नीचे वर्णित निबंघन और शतों के अध्यधीन उक्त राशि को निम्नलिखित तालिका मे दिये गए बजट ब्रेक अप के अनुसार देने की रवीकृति प्रदान की जाती है।

S. No	Institution	1 Year	2Year	3Year	Total
A.	BMK Ayurveda Mahavidyalaya	20,13,200	1323200	1152100	44,88,500/-
B.	Institutional overhead charges@5%=		Alt of the line of the	2,24,425	2,24,425
C.	ICMR-NITM Belagavi	2,90,000	2,65,000	2,65,000	8,20,000
	Total	2303200	1588200	1641525	55,32,925
	Grand Total	S MARKING AN ANY	55,3	32,925	

Budget required for BMK Ayurveda Mahavidyalaya, Belagavi

SI. No		Year 1	Year 2	Year 3	Total
1.	Manpower * (SRF) Rs.28,000+20% HRA= @33,600/ month x36 Project assistant- @20000/month x36	6,43,200	6,43,200	6,43,200	19,29,600
2.	Trial Drug Ayush-GH* (for 50 pts) matching placebo(n=50) softules of Vitamin E (400mg)** for 100 pts	600000	-		600000
3.	Investigations charges (n=100)	300000	300000	98900	6,98,900
4.	Contingencies	270000	200000	250000	700000
5.	Miscellaneous	150000	150000		720000
-		150000	130000	150000	450000
6.	Incidental support for 100 patients@ 100 x 7 visits Ethics committee	30000	30000	10000	70000
		20,000			20,000
7.	Total	20,13,200	1323200	1152100	and the second
8.	Institutional Over head Charges (5%)		2,24,4		44,88,500/-
	Grand total	47,12,925/-			



Shri B. M. Kankanawadi Ayurved Mahavidyalaya **Constituent Unit of KAHER** Shahapur, BELAGAVLO3.

Budget required for ICMR-NITM Belagavi

SI. No.	ltem	Year I(N=35)	Year 2 (N=35)	Year 3 (N=30)	Total
1.	Staff (DEO)	240000	240000	240000	720000
2.	2. Contingencies- Miscellaneous	50000	25000	25000	100000
	Total	290000	265000	265000	8,20,000/-

 सक्षम अधिकारी ने आकस्मिक अग्निम के रूप में RARIMD, Bengaluru को प्रथम वर्ष के लिए रू 23.03.200 / - (रूपये तेईस लाख तीन हजार दो सौं मात्र) को जारी करने का भी अनुमोदन किया है।

3 नियम एवं शर्ते:-

परियोजना सीसीआरएएस रिसेंच पोलोसी का अनुसरण करने हुए पूर्ण की जाएगी।

Institute responsible for the research project : National Institute of Traditional Medicine – ICMR Belagavi and KAHER Shri BMK Ayurveda Mahavidyalaya and Hospital, Belagavi के प्रधम वर्ष के व्यय हेतु ICMR-NITM, Belagavi को स्वीकृति आदेश सीसीआरएएस रिसंच पोलोसी के अनुसार जारी किया जाएगा एवं बजट विवरण के अनुसार आकस्मिक अग्रिम राशि को हस्तांतरण किया जाएगा।

- 3. The progress of project in accordance with approved timeline and deliverable should be submitted to the Council Hqrs on monthly basis in the prescribed format (Annexure-6 to CCRAS Research Policy). The final report should be sent in the prescribed format (Annexure-7 to CCRAS Research Policy) within two months from the date of completion of the project. उक्त तीन participating institutes अध्ययन प्रारंभ करने के बाद मासिक. तिमाही एवं वार्षिक प्रगति रिपोर्ट RARIMD, Bengaluru को प्रस्तुत करेंगे तथा RARIMD, Bengaluru उक्त प्रतिभागी संस्थानों की मासिक तिमाही एवं वार्षिक प्रगति रिपोर्ट परिषद मुख्यालय को यथासमय प्रेषित करेंगे।
- 4. परियोजना के लिए किये जाने वाले खर्च को principles laid down in Chapter 6 of the General Financial Rules 2017 titled "Procurement of Goods and Services" का अनुसरण करने हुए किया जाएगा।

 Separate account will be maintained for the project by all the participating institutes and RARIMD, Bangalore. Record of expenditure may be kept separately by respective Pls for the audit purpose.

- इस परियोजना की प्रगति मासिक, तिमाही आधार पर विनिर्दिष्ट प्रारूप् में दी जानी चाहिए। सीसीआरएएस अनुसंधान नीति का अनुलग्नक–6।
- इस परियोजना की अंतिम रिपोर्ट परियोजना के पूर्ण होने के दो हफतो के भीतर विनिर्दिष्ट प्रारूप अनुसंधान नीति का अनुलग्नक–7 मे भेजी जानी चाहिए।
- सीसीआरएएस अनुसंधान नीति के खंड सं0 1.5.11 iii के अनुसार निधि जारी होगी और खातों का संचालन होगा।
- संस्थान प्रारूप सीसीआरएएस अनुसंधान नीति की खंड संo 16.3 को संदर्भ के लिए देखे के अनुसार मध्यायिधि मूल्याकन के लिए नियमित प्रगति रिपोर्ट के साथ तिमाही व्यय विवरण प्रस्तुत करेगा।
- 10. परियोजना काये के पूर्ण होने पर परियोजना के लिए अंतिम उपयोगिता प्रमाण पत्र के साथ व्यय का विवरण शीघ ही परिषद को प्रदान किया जाए। परियोजना के पूर्ण होने के एक माह के भीतर अव्ययित राशि को परिषद के विनिर्दिष्ट खाते मे वापस कर दिया जाए।.
- 11. लेखा के उद्देशय के लिए परियोजना से संबंधित सभी खर्चों के लिए संस्थान मुख्य अन्वेषक सह अन्वेषक एक अलग पंजिका का रख रखाव करेगा।

- 1... परियोजना के लिए व्यय सामान्य वित्तीय नियमावली 2017 के अंतर्गत यस्तु और सेवा संबंधित नियमों के अनुसार किया जाए।
- 13. लेखा के उद्देश्य से मूल बिलों/वाउचरों/पंजिकाओं आदि को संस्थान मे सुरक्षित रखा जाए।
- 14 अपवादस्वरूप कुछ मामलो को छोडकर परियोजना की अवधि सामान्यता अनुसंघान नयाचार मे इगित अवधि ही रहेगी।
- 15 सभी नीतिपरक सांविधिक विनियमन आवश्यकताओं का पूर्ण करने के पश्चात परियोजना का निष्पादन किया जाना चाहिए।
- 16. इस अध्ययन से प्राप्त निष्कर्षों को परिषद् की अनुमति के बिना किसी अन्य को बताया या साझा नही जा सकता।
- 17. अध्ययन की पूर्ण होने पर मुख्यालय अध्ययन परिणामों को प्रकाशित करेगा और सभी अन्वेषको नोडल अधिकारियों कार्यक्रम अधिकारियों को इसकी रचना का श्रेय दिया जाएगा।
- 18 अध्ययन की अवधि के दौरान परिषद के पास परियोजना के लिए मार्गनिर्देश जारी करने रद करने का पूर्ण अधिकार है। सदर्भ के लिए सीसीआरएएस अनुसंधान नीति का खंड संठ 1.9 को देखें।
- 19. यदि जरूरत हो तो परियोजना के बजट की शीर्षनुसार अधिकतम सीमा में परिवर्तन करने के लिए प्रस्ताव RARIMD, Bengaluru द्वारा परिषद को भेजा जा सकता है।
- 20 The funds released and spent will be subject to audit by sponsoring authority and Govt Audit System. On completion of the project, the investigator from ICMR-NITM, Belagavi should submit the audited utilization certificate (UC) and audited statement of expenditure alongwith unspent balance (if any) through DD to the funding authority through RARIMD, Bangalore.
- 21. परिषद परियोजना के दौरान दिशा-निर्देश जारी करने का अधिकार सुरक्षित रखती है।
- 22 परियोजना के तहत अध्ययनों से निकाली गई टिप्पणियों को परिषद की अनुमति के बिना किसी अन्य पार्टी को नहीं भेजा जाएगा। इन अध्ययनों से निकाले गए किसी भी शोध पत्र/किसी भी अन्य संचार को परिषद की पूर्व अनुमति के बिना प्रकाशित नहीं किया जाएगा। संबंधित शोध पत्र/किसी भी अन्य संचार को संयुक्त रूप से परिषद् द्वारा प्रकाशित किया जाएगा।
- 23. इस परियोजना के तहत सहायता के लिए मंजूर की गई जनशक्ति किसी भी तरह से आगे अवशोषण के लिए परिषद की जिम्मेदारी नहीं होगी। जनशक्ति की सेवा को परियोजना के पूरा होने के तुरंत बाद समाप्त किया जा सकता है।
- 24. संविदात्मक कर्मचारियों को अनुबंध के आधार पर नियोजित किया जा सकता है। इनमें से किसी भी कर्मचारी को किसी भी तरीके से सीसीआरएएस का कर्मचारी नहीं माना जाएगा।
- 25. परियोजना का कार्यकाल 03 (तीन) वर्ष के लिए है।
- 26. चिकित्सीय परीक्षण को आंरम करने से पूर्व इसका ICMR-NITM, Belagavi के तहत पंजीकरण National Institute of Traditional Medicine – ICMR Belagavi and KAHER Shri BMK Ayurveda Mahavidyalaya and Hospital, Belagavi द्वारा किया जाएगा।
- 27. भविष्य में सदर्भ के लिए प्रकाशन किया जाए और इसके लिए बजट दस्तावेजों को पूर्ण और जमा करने के पश्चात् सीसीआरएएस मुख्यालय से अलग से लिया जा सकता है।
- 28. महानिदेशक सीसीआरएएस के पूर्व अनुमोदन से ही आवश्यकतानुसार प्रत्येक शीर्ष की अधिकतम सीमा में परिवर्तन किया जा सकता है।
- 29. परियोजना के अर्जित की गई परिसंपपित्तियों की परिसंपति पंजिका में उचित प्रकार से गणना की जाए। परियोजना के पूर्ण होने पर, संस्थान के विनिर्दिष्ट परियोजना के अंतर्गत प्राप्त नामक स्टॉक पंजिका में इसकी प्रविध्टि की जाए।

परियोजना के लिए व्यय, परिषद गुरस्यालय कार्यालय के बजट से अनुसंधान गतिविधियों के तहत वित्तीय वर्ष 18-19 थे किया जन्मा है।

(एस.बी मि प्रशासनिक अधिकारी (परियोजना) कृते महानिदेश्वक 158-4

सेवा में.

प्रशासनिक अधिकारी (लेखा अधिकारी) केन्द्रीय आयुर्वेदीय विज्ञान अनुसंधान परिषद, नई दिल्ली को अनुमोदित नाट को कायाप्रति संग्रित A.D I/c. RARIMD, Bengaluru को रू 23,03,200 / - (रू तंईस लाख तीन हजार दो सौ नाठों को आकरिसक अग्निम सांशे का रिलीज करने की कृपा करें।

प्रतिलिपिः-

- A.D I/c, RARIMD, Bengaluru से अनुरोध है कि व ICMR, NITM Belagavi को स्वीकृती आदेश जारी करने एवं प्रथम वर्ष के बजट विभाजन के अनुसार आकरिमक अग्रिम राशि विमोचन करने की कृपा करें।
- 2. साख्यिकीय अधिकारी, सीसीआरएएस, नई दिल्ली।
- 3. डॉ चेतन ए.सी. Scientist B मुख्य अन्येषक National Institute of Traditional Medicine ICMR Belagavi.
- डॉ एस.एल होटी, निर्देशक, समन्वयक, National Institute of Traditional Medicine ICMR Belagavi.
- 5. Dr. S.N. Gaidhani, A.D (P), CCRAS, New Delhi for information.
- 6. Dr. BCS Rao. A.D (Ay.) Programming Officer for information.
- 7. Dr. Babita Yadav, R.O (Ay.) Nodal Officer for F. No. 27-5/2018-CCRAS/Tech/Hq for record.
- 8. Dr. Sophia, R.O (Ay.) Co-Nodal Officer for information.
- भहानिदेशक के वरिष्ठ निजी सचिव एवं उप महानिदेशक के निजी सचिव।
- 10. कार्यालय आदेश फाईल ।



PRINCIPAL Shri B. M. Kankanawadi Ayurved Mahavidyalaya A Constituent Unit of KAHER Shahapur, BELAGAVI-03.

HIE NO.HQ-EST1012/59/2022-EST1



केन्द्रीय आयुर्वेदीय विज्ञान अनुसंधान परिषद्)) प्राप्त समानव, माग्त संस्थान अवाहर लाव केटरू वार्ट्साव विदिस्ता एवं होग्वेलीकी अनुसंसाल संवत १९७5, हास्वानिक सेव, सम्पूछ 'ही' ब्लार, अध्यसुध, वई हिन्दी 110058

25052, 28520501 22524, 28525831 25862, 2852583

61-85. Intentione 114, Intel 121 Mere, Stricht, of test 110035 CENTRAL COUNCIL FOR RESEARCH IN AVURVEDIC SCIENCES Menistry of AVUSH, Govt of India Jawahar Lai Nehru Bhariya Chèrisa Evam Homoeopathy Anusandhan Briawan 61-65, Institutional Area, Opp. D. Block, Janakpuri, New Delte-110058

E-F. No. 11Q-ESTT012/59/2022-ESTT/S/64

ORDER

Dated 3 0 0CT 2023

Sanction of the Director General, CCRAS is hereby accorded for the award of grant for the research proposals/approved MD/MS (Ayu) synopsis received from the students studying at Karnataka Liberal Education University, Shri B.M. Kankanadi Ayurveda Mahavidyalaya, Shahapur, Belgaum- 590003, Karnataka under Scheme for Training in Ayurveda Research for PG Scholars (PG-STAR) 2023-24 session as per following details:-

SI. No	PG STAR Id	Name of the student	PG discipline	Title of the research proposal	Sanctioned budget (1 st	First installment
1	STAR/627/135	Dr. Ujjwal Gupta	Shalya	Development Of Dhoopan Yantra with Evaluation of Srivasadi Dhoopana Karma in The Management of Dustavrana - A Randomized	+2 nd inst.)	70,000/-
2	STAR/594/131	Dr. Raktimabha Jena	Swasthavritta	Controlled Clinical Trial Development of Ashtaguna manda Ready-To-Eat (RTE) therapeutic food	1,00,000/-	70,000/-
3	STAR/722/169	Dr. Keerthi S. V.	Rasa Shastra evam Bhaishajya Kalpana	Comparative Analytical and Antimicrobial Study of Yashada Bhasma and Green Synthesized Zinc Oxide Nano Particles using Aloc Vera Leaf Extract	1,00,000/-	70,000/-
4	STAR/595/148	Dr. Harsha Chuttani	Panchakarma	Evaluation of Complete Protocol of Samsarjana Krama on Intestinal Gut Flora w.s.r. to Hydrogen Breath Test – An Open Observational Clinical Study''	1,00,000/-	70,000/-

File No.HQ-EST1012/59/2022-EST1

E File. No. 11Q-ESTT012/59/2022-ESTT

11211

2. The total grant sanctioned by the competent authority is Rs. 4,00,000/- (Rupees Four lakh only). Total amount of first installment to be released is Rs. 2,80,000/- (Rupees Two lakh eighty thousand only) to the above stated college for the student named as above as per the following account details submitted by the college authority through electronic transfer from the Research Activity head of GIA General budget of CCRAS Hqrs. for the financial year 2023-24:

Name of the Concerned College / Institution	Karnataka Liberal Education University, Shri B.M. Kankanadi Ayurveda Mahavidyalaya, Shahapur, Belgaum- 590003, Kamataka	
Account No.	05382150000029	
Турс	Savings Account	
Bank Name & Branch Name with address	Canara Bank Goaves, Belgaum - 590011	
Account holder name	The Principal KLE University's Shri B.M. Ayurveda Mahavidyalaya, Shahapur, Belgaum	
IFSC Code	CNRB0010538	
MICR Code	590015029	
Phone	0831-2486286, 9449603234	

3. All selected students under PG-STAR 2023-24 shall follow the timeline available at the "PG-STAR" website (i.e. <u>http://pgstar.hopto.org:443/</u>) and shall have to submit their interim progress report after every six months in the prescribed format (Annexure IV of the PG-STAR scheme) through e-mail (<u>pgstar.ayu@ccras.nic.in</u>) followed by the final report on the completion of research work within stipulated period.


4. CCRAS institutes may be approached by the guide/student for any technical guidance in formulation, amendment and execution of research proposals.

5. The first installment i.e., 70% of the total sanctioned amount will vary from case-to-case basis as per the submitted financial proposal. The grant is applicable for the individual student during his/her PG tenure for maximum of two years or till the completion of project and the first installment will be released at the beginning of the project. The second installment will be released only after completion of research work, publication of research outcome (at least acceptance/preprint in minimum UGC care listed journal) and approval of final report on submission to CCRAS at given e-mail (pgstar.ayu@ccras.nic.in).

6. On satisfactory completion of the project and acceptance and approval of the final report by the competent authority, a certificate will be issued and posted to the office of the concerned Principal/ Director/ Dean/ Registrar.

(Renu Rajan)

(Renu Rajañ) Administrative Officer (Proj.) For Director General



Ajit Lingayat <ajitlingayat26@gmail.com>

Establishment of Herbal Garden in Residential Schools working under KREIS – Reg

medplantconsult.kampa <medplantconsult.kampa@karnataka.gov.in>

Fri, May 19, 2023 at 1:31

To: "bmkprincipal.kaher@kleayurworld.edu.in" <bmkprincipal.kaher@kleayurworld.edu.in>, "ajitlingayat26@gmail.com" <a href="mailto:<a href="mailto:<t



81544 Karnataka State Medicinal Plants Authority(KaMPA)

TCH-1/SHG/BMK-BLG- 2023-24

Date:18.05.2023

To,

The Principal Shri B M Kankanwadi Ayurveda Mahavidyalaya, Shahpur, Belagavi – 590003, Karnataka. **bmkprincipal.kaher@kleayurworld.edu.in**

Sir,

Sub:

Establishment of Herbal Garden in Residential Schools working under KREIS – Reg

Ref:

1. Your office email dated 24.04.2023

2. This office email dated 24th April, 2023

Kindly refer to our earlier communication regarding "Project proposal on establishment of School Herbal Garden in residential schools of KRESIS".


Thank for showing interest to collaborate with us for establishing school herbal gardens in Karnataka. The proposal for establishment and maintenance of four School Herbal Garden submitted vide letter under ref (1) has been considered and approved. Approved school list is as given below.

https://mail.google.com/mail/u/0/?ik=c?eead3e58&view=nt&search=all&nermmsgid=msg-f:1766308756917779070&simpl=msg-f:1766308756917

1. Morarji Desai Residential School, Mandoli, Belagavi Taluk

2. MDRS Halabhavi, Belagavi Taluk

Lope ne per-



CFFICE OF THE PRINCIPAL SHRI B. M. KANKANAWADI AYURVED MAHAVIDYALAYA A CONSTITUENT UNIT OF RAHER SHAHAPUR, BELGAUM 03. DATE: 426 2028 IMWARD NO.: 456 3000

1/3

Gmail - Establishment of Herbal Garden in Residential Schools working under KREIS - Reg

4. Morarji Desai Residential School, Hidakal Dam, Hukkeri Taluk

5. Morarji Desai Residential School, Nidasosi, Hukkeri Taluk

Information, Education and Capacity Building (IEC) material will be provided by KaMPA.

A guideline along with approved financial break is enclosed to facilitate implementation of the project. An amount of Rs 2,40,000/- has been approved for establishment and maintenance of herbal garden.

Instalments will be released as below:

Instalments	Unit Cost (in Rs)	For 5 SHG Amount (in Rs.)
1 st instalment	20,000	1,00,000
2 nd instalment	7,000	35,000
3 rd instalment	7,000	35,000
4 th instalment	7,000	35,000
5 th instalment	7,000	35,000
Total	48,000	2,40,000

It is requested to submit Utilisation Certificate, Statement of Expenditure and progress report along with photographs year wise after accomplishment of activities.

For any clarification, please contact Dr.M.J.Prabhu Medicinal Plants Consultant, Karnataka State Medicinal Plants Authority, 080-23464089 ' Mob: 9886780258 E-mail: medplantconsult.kampa@karnataka.gov.in.

1st installment will be released shortly.

Thank you,

sincerely

Yours

Principal Chief Conservator of Forests and

Chief Executive Officer

Dr. M J Prabhu

Medicinal Plants Consultant

2/3

T

080 - 23464089 | +91-9886780258

medplantconsult.kampa@karnataka.gov.in

https://kampa.karnataka.gov.in

4th Floor, 'Vanavikas',, 18th Cross Malleshwaram,, Bangalore - 560 003.

DISCLAIMER:

This e-mail communication and any attachments may be privileged and confidential to Government Of Karnataka., and are intended only for the use of the recipients named above If you are not the addressee you may not copy, forward, disclose or use any part of it. If you have received this message in error, please delete it and all copies from your system and notify the sender immediately by return e-mail. Internet communications cannot be guaranteed to be timely, secure, error or virus-free. The sender does not accept liability for any errors or omissions



Karnataka Science and Technology Promotion Society Dept. of Information Technology, Bio Technology and Science & Technology, GoK "Vijnana Bhavan", 3rd Floor, #24/2, 21st Main Road, Banashankari 2nd Stage, Bangalore-70 Ph/fax: 080-26711166, E-mail: ksteps.dst@gmail.com

Dr. H. Honne Gowda Special Secretary (Technical), Dept. of IT, BT and S&T, Gok/ Managing Director, KSTePS

No. KSTePS/VGST-CISEE/2018-19/GRD No.747]315

Date: 17.07.2019

Dear Sir/Madam,

Sub: Intimation of selection of the project under the VGST scheme of CISEE – reg.

Greetings from the Department of Science and Technology, GoK & KSTePS. We are pleased to inform you that the project titled "Development of Bio adhesive nanoparticles for vaginal delivery of a selected antiretrovirals" submitted under the VGST scheme of CISEE for the financial year 2018-'19 has been approved by the Government based on the recommendations of Vision Group on Science and Technology under the Chairmanship of Bharat Ratna Prof. CNR Rao, Honorary President, JNCASR.

The total project grant award for a period of 3 years is Rs. 30.00 lakh, which will be released annually @ Rs. 10.00 lakh based on the progress of work. You are requested to take an immediate action to initiate the project at the earliest and to be completed within 3 years after receiving the grant of 1st installment from our office.

The grant will be paid to the Head of the institution, under whose supervision the Principal Investigator shall be responsible for completion of the stated objectives of the project. The Principal Investigator through the Institution Head shall have to submit the progress report in soft copy once in 6 months without fail. The grants shall be used only for the purposes described in the grant application by following due procedures of KTPP Act. Any deviation from the scheduled plan must have a prior approval from the VGST.

Future release of grants will be based on satisfactory project performance and review. The funding agency has the right to terminate the project, if it is found to be not satisfactorily pursuing and fulfilling the stated project goals and objectives. The whole amount sanctioned or any unspent balance must be returned back to the funding agency within 60 days following the final report of the project. Any publications or other dissemination arising from research supported by VGST grants should be acknowledged.

Dr. S. G. Sreekanteswara Swamy, Consultant, VGST will be the nodal officer for all future correspondences related to the project. His contact details are given below:



...2

Principal KLE College of Pharmacy Bengaluru-560 010

Scanned with CamScanner

Vision Group on Science and Technology, Department of IT, BT and S & T, Room No. 702, 7th Floor, 4th Gate, M.S. Building, Dr. Ambedkar Veedhi, Bengaluru – 560 001. Phone : 080-2203 2013 Email : <u>visiongroup.st@gmail.com</u> Website : <u>www.vgst.in</u>

The sanctioned grant will be sent through NEFT/RTGS to your institution. Hence, it is requested to send the following bank details on your intuitional letter head, sealed and signed by the head of the institution, by post. A scanned copy of the same may be sent through E-mail: <u>ksteps.dst@gmail.com</u> & <u>visiongroup.st@gmail.com</u> for swift process.

- 1. Account Name
- 2. Account Number
- 3. IFSC Number
- 4. Name of the Bank
- 5. Branch

After receiving the grant to the institute, you are suppose to open an new saving bank account in the name of VGST scheme & get the grant transferred from the institution's main account. I would like to personally thank and greet you for being selected as one of the VGST program members and we wish you a great success in the implementation of the project.

Thanking you,

Yours sincerely,

H. Honne Gowda)

To,

Dr. H.N Shivakumar, Professor & Head, Department of Pharmaceutics, KLE College of Pharmacy, 2nd Block, Rajajinagar, Bengaluru - 560 010.

CC:

- 1) The Principal, KLE College of Pharmacy, 2nd Block, Rajajinagar, Bengaluru 560 010.
- Deputy Secretary to Govt., Dept. of Science and Technology, Room No. 305, 5th Floor, 5th Stage, M.S. Building, Dr. Ambedkar Veedhi, Bengaluru -560 001.
- 3) Dr. S. G. Sreekanteswara Swamy, Consultant, Vision Group on Science and Technology, Department of IT, BT and S & T, Room No. 702, 7th Floor, 4th Gate, M.S. Building, Dr. Ambedkar Veedhi, Bengaluru -560 001.





-2-